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SIX 
 
 
Assessment of Gene-Rave identified genes as 
biomarkers for the classification of three clinical 
and pathological classes of parathyroid 
tumours 
 
 
6 .1  INTRODUCT ION 
6.1.1 Overview 
Chapter 5 of this thesis reports analysis using Gene-Rave that identified nine genes 
from the microarray data able to discriminate between the clinical and pathological 
groups of adenoma, hyperplasia, combined carcinoma and HPT-JT-associated 
tumours, and MEN 1-associated tumours. In this chapter, the assessment of 4 of these 
genes as putative biomarkers of different classes of parathyroid disease, is described. 
Accurate quantitation of transcript levels of these 4 genes in addition to calcium-
sensing receptor (CaSR) and HRPT2 was undertaken. Protein expression of the 4 
Gene-Rave identified genes was also assessed by immunohistochemistry. 
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Immunohistochemical studies of CaSR had previously been reported (reviewed in 
section 1.4.5) and at the time of this study, no parafibromin antibody (the protein 
encoded by HRPT2) was available.  
 
Transcript levels were accurately quantitated by real-time 5′nuclease assays (qPCR) 
incorporating specific dual labelled probes (TaqMan® probes). This is an established 
and highly specific technique for accurate transcript quantitation (reviewed by Bustin 
2002). Protein expression was assessed visually by immunohistochemical (IHC) 
staining of appropriately prepared tissue sections. Histopathology is the most common 
method of diagnostic assessment of parathyroid tumours (reviewed in section 1.3) and 
thus an amenable technique to transfer from a research to a diagnostic application in 
the event that discriminatory biomarkers were found. 
 
6.1.2 Parathyroid tissue and tumour classes for investigation 
Specimens from three tumour classes or subtypes as well as normal tissue were 
chosen for assessment of putative biomarkers identified by microarray analysis: 
1. Sporadic adenoma. These are primary, sporadic (idiopathic) benign neoplasms 
(reviewed in sections 1.3.2.1 and 1.4.1); 
2. Hyperplasia. Primary hyperplasia is sporadic (reviewed in sections 1.3.2.1 and 
1.4.2). Secondary hyperplasia develops in response to biochemical imbalances 
generally due to chronic renal failure (reviewed in section 1.3.3). Tertiary 
hyperplasia develops from the transition of secondary hyperplasia to autonomous 
or unresponsive hyperplasia (reviewed in section 1.3.4). 
3. HRPT2 mutation positive. This class includes familial HPT-JT-associated 
tumours, both benign and malignant (reviewed in section 3.1.2), as well as 
sporadic carcinomas (reviewed in sections 1.3.2.1 and 1.4.3). These tumours have 
been found to harbour somatic HRPT2 mutations (chapter 3 of this thesis).  
4. Pooled normal tissue.  
 
Ideally, for robust assessment, different sets of specimens should be used for the 
microarray and follow-up testing. The rarity of HRPT2-associated tumours, and small 
size of parathyroid tumours in general, made acquisition of a second set of specimens 
in the given timeframe unattainable.  
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6.1.3 Putative biomarkers for investigation 
Gene-Rave analysis identified Ubiquitin carboxyl-terminal esterase L1 (UCHL1) to 
be the most highly discriminatory gene between the HRPT2 mutation positive 
tumours and sporadic adenomas (section 5.3.3.4). Cell surface antigen CD24 was also 
highly discriminatory between these two tumour classes. In addition, Gene-Rave 
found that Vascular Adhesion Molecule 1 (VCAM1) and Parvalbumin together were 
able to discriminate between these 2 tumour classes. A commercial qPCR (TaqMan®) 
probe was not available for CD24. Parvalbumin has been assessed previously by 
immunohistochemistry, showing co-localisation with PTH secreting cells with 
predominant nuclear localisation in adenoma and predominantly cytoplasmic 
localisation in hyperplastic and normal glands (Pauls et al. 2000). Therefore, UCHL1 
(encoding the protein PGP9.5) and VCAM1 were chosen for further investigation. 
 
Gene-Rave analysis found only two genes which together were able to discriminate 
between parathyroid adenoma and hyperplasia (section 5.3.3.2) These two genes, 
Retinaldehyde dehydrogenase 2 (also known as aldehyde dehydrogenase 1 family, 
member A2) (RALDH2 or ALDH1A2) and antigen identified by monoclonal antibody 
MRC OX-2 (MOX2 now also known as CD200) have been investigated further. 
 
VCAM1, UCHL1, RALDH2 and MOX2 have not previously been assessed in the 
context of parathyroid tumours. However, UCHL1 and RALDH2 have been reported 
to be expressed during embryonic development of the parathyroid glands in rodents, 
and intriguingly, the loss of expression of RALDH2 at this time has been shown to be 
associated with lack of development of the parathyroid glands (Luts and Sundler 
1997; Niederreither et al. 2003).  
 
6.1.4 Established immunohistochemical markers of 
parathyroid tissue 
The expression levels of a number of molecules have been characterised in 
parathyroid tissue however none have been found to be effective discriminators of the 
different pathological classes of hyperparathyroidism. Two of these are PTH and 
chromogranin A. Deposition of PTH is found in the secretory granules within the 
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cytoplasm of parathyroid chief cells (Futrell et al. 1979). Chromogranin A or 
“parathyroid secretory protein I” is an acidic glycoprotein and one of the most 
abundant components of secretory granules (Deftos 1991). It co-localises with PTH in 
chief cells and has been suggested as a neuroendocrine tumour marker (Deftos 1991). 
Variable co-expression of chromogranin A and PTH in secondary hyperplasia has 
been reported (Tanaka et al. 2003). However, the usefulness of both PTH and 
chromogranin A appear to be limited to assessment of secretory activity of chief cells 
and the confirmation of the presence of parathyroid tissue (by PTH), rather than as 
discriminant markers of neoplasia and hyperplasia. Other molecules that have been 
considered as biomarkers for parathyroid tumours are reviewed in section 1.4 of this 
thesis. 
 
6.1.5 Aims   
The first aim of the work described in this chapter was to confirm the mRNA 
differential expression trends identified by microarray transcript profiling of 
parathyroid tumour classes or subtypes. In the development of the qPCR assays for 
the confirmation of these mRNA expression trends, genes suitable for normalisation 
of the qPCR assays were sought. Therefore the second aim was to identify putative 
“housekeeping genes” specific for parathyroid tissue. The third aim was to determine 
the protein expression patterns of genes identified by Gene-Rave analysis in the 
different classes of parathyroid tumours, with the goal of identifying which of these 
putative biomarkers showed potential in their ability to discriminate between these 
tumour classes.  
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6 .2  Methods 
6.2.1 Specimens  
Different specimen preservation conditions were required for the different assays 
undertaken. Fresh frozen tissue stored at -80oC was required for qPCR and cryostat 
sections for IHC assessment of CD200 (the protein encoded by MOX2) (NB: The 
requirement for cryostat sections for CD200 IHC was not known prospectively and 
was determined only after extensive assessment of paraffin embedded sections.) 
Formalin fixed paraffin embedded sections were required for IHC assessment of 
PGP9.5 (the protein encoded by gene UCHL1), VCAM1 and RALDH2. 
 
The tumour groups for qPCR consisted of ten sporadic adenomas, ten secondary 
hyperplasia, seven carcinoma / HPT-JT specimens and a pool of 5 normal parathyroid 
tissues. Universal Human Reference RNA (Stratagene, La Jolla, CA, USA) used as 
the reference RNA for all the microarrays was also assessed by qPCR. Up to 10 
specimens from each tumour group underwent IHC analysis. Where possible, the 
same tumour specimens were used for the RNA samples, formalin fixed paraffin 
embedded and fresh frozen tissues prepared for cryostat sections. Different pools of 4-
8 anonymised frozen normal parathyroid tissue from excess cell washings after 
routine parathyroid autotransplantation during thyroidectomy were used for the 3 
different normal specimens preparations required. The specimens are listed in Table 
6.1. The collection and histological assessment of these specimens, as well as the 
collaborative sources from which these specimens were obtained are detailed in 
sections 2.3 and 2.4.1 and Table 2.1.  
 
Classification ID qPCR ID
Paraf 
IHC
Cryo 
IHC
HRPT2 sequencing 
status 
(polymorphism)
LOH1q LOH11q MA
Adenoma 9A 1 Y Y NMD LOH R Y*
Adenoma 14A 2 Y Y (p1) R LOH --
Adenoma 82A 3 Y Y (p1) R R --
Adenoma 100A 4 Y Y -- -- -- --
Adenoma 89A 5 Y Y NMD R R --
Adenoma 99A 6 Y -- NMD R R Y
Adenoma 88A 7 Y -- (p1) R -- Y
Adenoma 93A 8 Y -- (p1) R LOH --
Adenoma 101A 9 Y Y NMD LOH LOH --
Adenoma 78A 10 -- Y (p1) R LOH --
Adenoma T32B6 -- -- Y -- -- -- --
Adenoma T31I4 -- -- Y -- -- -- --
2_Hyperplasia 95A 11 Y Y (p1) R R Y
2_Hyperplasia 1293G 12 Y -- (p1) R R --
2_Hyperplasia 2082G 13 Y -- -- -- -- --
2_Hyperplasia 1749G 14 Y -- NMD R R --
2_Hyperplasia 866G 15 Y -- NMD R R --
2_Hyperplasia 2358G 16 Y -- -- -- -- --
2_Hyperplasia 1363G 17 Y -- -- -- -- --
2_Hyperplasia 2636G 18 Y -- -- -- -- --
2_Hyperplasia 1417G 19 Y -- -- -- -- --
2_Hyperplasia 2356G 20 Y -- -- -- -- --
2_Hyperplasia 17A -- -- Y NMD R R Y
2_Hyperplasia 8A -- -- Y -- -- -- --
3_Hyperplasia 34A -- -- Y NMD R R Y
1_Hyperplasia 20A -- -- Y -- -- -- --
3_Hyperplasia 87A -- -- Y (p1) R R Y
2_Hyperplasia 86A -- -- Y (p2) R -- Y
3_Hyperplasia P915 Y
NORMAL 21 Y Y -- -- -- Y
UHR UHR 22 -- -- -- -- -- Y
HRPT2  (FIHP) 54A 23 Y -- L64P LOH -- Y*
HRPT2  (FIHP) 4A 24 Y Y L64P LOH -- Y
HRPT2 (Carc) 78G 26 Y -- -- -- -- --
HRPT2 ( HPTJT) 1765G 27 Y -- 76delA LOH R Y*
HRPT2 ( HPTJT) 1613G 28 Y -- 76delA/686del4 R R Y*
HRPT2 (Carc) 2077G 29 -- -- IVS6-1delG/Y55X R LOH Y*
HRPT2 (Carc) 2119G 30 Y -- Y54X R -- Y*
Table 6.1 Details of parathyroid specimens for Quantitiative PCR and Immunohistochemical studies, 
including the classification of the tumours, results of HRPT2 sequencing and loss of heterozygosity studies
(LOH) (from Appendix 3.4). Specimens included in the microarray analysis (Chapter 5 of this thesis) are
noted, and quantitiative PCR (qPCR) and immunohistochemical testing (IHC) performed is highlighted in
yellow. Different pools of normal parathyroid tissue were used for the different techniques performed.
Legend: “ID” is the specimen identifier. “MA” denotes microarray testing described in Chapter 5 of this
thesis. “qPCR” denotes the quantitiative real-time PCR specimen identifier for the results described in this
chapter. ”Paraf IHC” denotes immunohistochemical studies using paraffin embedded tissue, and “Cryo
IHC” denotes immunohistochemical studies performed using cryostat sections. Hyperplasia specimens are
designated as primary (“1-“), secondary (“2-“) or tertiary (“3-“). HRPT2 sequencing status “NMD” denotes
that no mutation was detected (taken from Appendix 3.4). Heterozygosity for HRPT2 common 
polymorphisms (but with no mutation detected) are designated as "p1 " for IVS2+28C→T and "p2 " for
IVS2+28del4. "R" denotes retention of heterozygosity at the specified locus. Testing performed is
designated “Y” (or by ID for qPCR). Testing not performed due to unavailability of suitable or sufficient
tissue is designated “—”. * denotes that different pieces of tumour tissue were used for microarray and
realtime PCR analysis. “UHR” is commercial Universal Human Reference RNA.
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6.2.2 Quantitative PCR (qPCR) 
6.2.2.1 Preparation of RNA samples 
Total RNA was extracted from fresh frozen parathyroid tissue using TRI REAGENT 
and purified by precipitation with lithium chloride as described in section 2.4.2.  
 
6.2.2.2 Preparation of cDNA 
cDNA was synthesised from 5µg of total RNA using the Superscript III First-Strand 
Synthesis System for RT-PCR (Invitrogen Corporation, Carlsbad, CA, USA) and 
random hexamers as described in section 2.4.4. Random hexamers were used rather 
than Oligo(dT)20 to enable synthesis of cDNA from ribosomal 18s which does not 
have a poly A tail. The cDNA was assessed for DNA contamination and integrity by 
PCR amplification of GUSB as described in section 2.4.4. The resulting cDNA was 
diluted to 40µL with RNase-free H2O.  
 
Initially one sample from each tumour group with excess RNA was tested in each 
qPCR assay in various dilutions to determine the distribution of results, optimal 
dilution for all assays, as well as the reaction efficiencies. A 1/10 dilution was chosen 
as the majority of results for the majority of assays fell between 15 and 35 cycles at 
this dilution. All cDNA samples (except the aliquots used for the standards) were 
diluted 1/10 with RNase-free H2O (Sigma Aldrich, St. Louis, MO, USA), and 2µL of 
this dilution was used for each assay. This equated to 25ng of initial total RNA per 
reaction. 
 
6.2.2.3 Quantitative PCR Protocol 
All qPCR were performed using a 5′nuclease technique with specific TaqMan® Gene 
Expression Assays (Applied Biosystems (ABI), Foster City, CA, USA) and 
TaqMan® Universal PCR Master Mix, NO AmpErase UNG (Applied Biosystems, 
Foster City, CA, USA). The assays incorporate primer and probe sets in a 20x mix 
with two unlabelled primers (900nM final reaction concentration) and one FAM dye-
labelled TaqMan® MGB (Minor groove binder) probe (250nM final reaction 
concentration). The Universal Master Mix contains all other PCR components 
including Taq GOLD DNA Polymerase. 
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All qPCR were performed on a Rotorgene 3000 (Corbett Research, Mortlake, NSW, 
Australia). The ABI Identifiers for the assays performed are listed in Table 6.2. Three 
repeat runs were performed for each assay. Within each run, all samples, including 
specimens of interest and  4 or 5 serial dilutions of the standard (prepared as described 
in section 6.2.2.4 below) as well as a no template (negative) control were set up in 
duplicate. A master mix was prepared for each run as set out in Table 6.3. The master 
mix was shielded from light as much as possible. Eighteen microliter aliquots of this 
master mix were dispensed into 100µL strip tubes (Corbett Research, Mortlake, NSW, 
Australia) designed for use in the Rotorgene 3000, and 2µL of the appropriate cDNA 
was added to each tube. The prepared tubes were placed in the 72-well rotor of the 
Rotorgene 3000 and cycled using the ABI recommended cycling conditions detailed 
in Table 6.4. 
 
Table 6.2 ABI Assay identifiers, locations of the TaqMan® probes, and standard 
concentration series for each assay. The location information for each probe within the target 
transcript is available at http://www.appliedbiosystems.com/. 
Assay ID Gene Name Probe  location Concentration series for the 
standard 
Hs00363810_m1 C1orf28 / HRPT2 Exon 2 – 3 5, 2, 1, 0.5, 0.25 
Hs00173436_m1 CASR Exon 1 – 2 10, 1, 0.1, 0.01 
Hs00174239_m1 VCAM1 Exon 5 – 6 10, 1, 0.1, 0.01 
Hs00188233_m1 UCHL1 Exon 8 - 9 10, 1, 0.1, 0.01 
Hs00180254_m1 ALDH1A2 [RALDH2] Exon 3 – 4 10, 1, 0.1, 0.01 
Hs00245978_m1 MOX2 [CD200] Exon 1 – 2 5, 2, 1, 0.5, 0.25 
Hs99999901_s1 18s [ABI Control] c608 5, 2, 1, 0.5, 0.25 
Hs00606481_m1 SSR3 Exon 1 – 2 5, 2, 1, 0.5, 0.25 
 
Table 6.3 Quantitative real-time PCR components  
Component x 1 (µL) x 77-full run (µL)  
H20 7 539 
2 x Taqman Universal Master Mix 10 770 
20 x specific Assay-on-demand 1 77 
Sub-total  18 1386 
Aliquot 18 18 
add 2 µL cDNA 2 2 
Total 20 20 
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Table 6.4 Thermal cycling conditions for quantitative Real-time PCR using the 
Rotorgene 3000  
Step Temp Time Data Acquisition Cycles 
Initial Denaturation 95oC 10 minutes  x 1 
Denaturation 95oC 15 seconds   
Annealing 60oC 1 minute Acquire to cycling A on CH1 [FAM] x 40 
Legend: “CH1” is channel 1, “FAM” is the fluorophore. 
 
6.2.2.4 Preparation of standards 
Results from the initial assessment of representative tumour class samples confirmed 
that the hyperplasia and HRPT2 tumour classes would, between them, have the 
highest expression levels for the majority of assays. Two samples, one from each of 
these two groups (95A and 4A), were combined in equal quantities before dilution. 
This combined sample became the “standard” for all assays for the comparison of 
relative abundance of the transcripts. As the samples for testing were diluted 1/10 for 
use (as described in section 6.2.2.2 above), the undiluted “standard” was designated as 
a 10x [concentration] standard. Additional standards of lower concentrations were 
prepared by two-fold, five-fold and ten-fold serial dilutions of this standard. These 
were tested along side representative tumour group samples for each assay to 
determine the appropriate concentration series of standards for each qPCR assay. A 
set of four or five different concentrations of the standards which encompassed the 
expected range of results were chosen for each assay and are listed in Table 6.2. 
These were aliquoted for each run of each assay and stored at -20oC until required. 
 
6.2.2.5 Genes for Normalisation 
Guidelines for real-time quantitation recommend normalisation using rRNA or total 
RNA for in vivo samples (Bustin 2002). The use of 28s is preferable to 18s because of 
the extremely high expression levels of 18s. However, 28s was not available as an 
optimised TaqMan® probe, and therefore 18s was chosen as the active reference or 
endogenous control for normalisation. The use of 18s for normalisation of parathyroid 
samples has not been reported.  
 
A gene from the microarray data showing specific uniformity of expression for all 
parathyroid tumour subtypes, as well as normal parathyroid tissue, was sought to act 
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as a putative housekeeping gene, in addition to 18s, for normalisation of qPCR results. 
The initial selection from the possible 20,000 candidate genes was made using the 
following criteria: 
• Intensity range of 1,000 – 10,000 for both Cy3 and Cy5 to ensure adequate 
expression for real-time assessment,  
• No contamination or ambiguity recorded for the microarray clone, 
• Expression results obtained by microarray analysis for the majority of tumour 
specimens (> 80%) and the pooled normal to ensure the results are 
representative,  
• A relatively central location on the array to minimise artefacts due to edge 
effects,  
• Low Variance and low Maximum Absolute Deviation,  
• No apparent tumour class bias. 
 
This selection was performed with the assistance of Dr Rob Dunne, CSIRO 
Bioinformatics. 
 
6.2.2.6 Quantitation and Statistical Analyses 
A relative rather than absolute method of quantitation was chosen for quantitation for 
the real-time assays as absolute quantitation would have necessitated the generation of 
a different set of standards for each assay. Quantitation using two standard curves (ie. 
standard curves for both the gene of interest and the gene used for normalisation) 
rather than comparative threshold cycle (Ct) was chosen to overcome possible 
problems due to differing assay efficiencies between the genes of interest and the 
genes used for normalisation (Kaiser 2004). 
 
The on-board Rotorgene software (version 5.0) calculated the curve of best fit for 
each run using the standards in that run and set the threshold accordingly. 
Representative standard curves for each gene are shown in Figure 6.1. The calculated 
results for the samples were then exported into Excel.  
 
Results for the normalisation genes, from triplicate experiments, were averaged, and 
these means used for subsequent analysis. For the genes of interest, the duplicate 
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results within each of the three runs were averaged. Each result was then divided by 
the corresponding mean for the normalisation gene (either 18s or SSR3). 
 
The resulting three ratios for each sample were then entered into SPSS version 12.0.1 
(SPSS Inc., Chicago, IL, USA) for the generation of the mean, standard deviation, 
standard error and minimum and maximum results and the generation of 
scattergraphs. The means were grouped according to tumour subtype, and again 
entered into SPSS for the generation of the group means, medians and variance data 
as well as the generation of box plots and scattergraphs. Histograms were generated 
by Deltagraph version 4 (SPSS Inc., Chicago, IL, USA). 
 
Differences between classes were assessed statistically using REST-XL© - version 2 
(Relative Expression Software Tool) software (Pfaffl et al. 2002) (http://www.gene-
quantification.info/). This software enables pairwise comparison of groups with up to 
16 data points in each group. Relative expression ratios are computed based on the 
PCR efficiency and crossing point differences. A Pair Wise Fixed Reallocation 
Randomisation Test© (permutation testing using 2000 randomisations) is used to 
calculate the p-values. Two-sided testing is performed with no assumptions made 
regarding the distribution of the data (Hauton et al. 2005).  
 
Figure 6.1 Standard curves for qPCR for A: CaSR, B: HRPT2, C: MOX2/CD200, D: RALDH2, E: UCHL1, 
F: VCAM1, G: 18S and H: Signal Sequence Receptor, gamma (SSR3) generated by Rotorgene Software 
Version 5. These are graphed as Threshold cycle (Ct) vs Concentration of the standard. Blue dots represent 
the standards, and red dots the samples. In some cases the standards have been overlaid with samples and 
are thus not visible. R^2 is the correlation coefficient (optimal is 1), M is the slope and B is the y intercept 
for the curve (y=Mx+B).  The reaction Efficiency is also shown (optimal is 1).
A B
C D
E F
G H
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6.2.3 Immunohistochemistry 
6.2.3.1 Preparation and assessment of formalin-fixed sections 
Frozen specimens of 8 normal parathyroid tissues were thawed and fixed overnight in 
10% phosphate buffered formalin (pH 7) at room temperature, processed and paraffin 
embedded. These were used for VCAM1, PGP9.5 and RALDH2 immunostaining.  
 
Frozen fragments of hyperplasia specimen 95A and a de-identified lymph node were 
thawed, fixed overnight in Histochoice® (Amresco, Solon, Ohio, USA) at room 
temperature, processed and then embedded in paraffin. Histochoice® is a proprietary 
non-crosslinking fixative that may be used as an alternative to formalin, especially in 
cases where the target epitope is masked or destroyed by the formation of 
crosslinkages (eg by aldehydes such as formalin). This was used for initial 
optimisation of CD200 staining. 
 
Processing of the above sections was carried out by Ms Sue Smith (Institute of Bone 
and Joint Research, RNSH). All other sections were obtained from pathology 
departments in Australia and Martin Luther University (Halle, Germany). 
Anonymised sections of control tissue for antibody optimisation were obtained from 
PaLMS (RNSH).  
 
Consecutive 4µm sections were cut from the formalin fixed paraffin embedded blocks 
by either Ms Sue Smith or technicians at PaLMS (RNSH) and placed onto 
SuperFrost®Plus Microscope slides (#041300, Menzel-Glaser, Germany). One 
section from each block was then stained with Haematoxylin and Eosin (H&E) 
(Bancroft 1996) according to the standard protocol of the laboratory in which the 
section was cut. These sections underwent histopathological assessment by a 
histopathologist (Associate Clinical Professor Jeanette Philips). Each section was 
confirmed as parathyroid tumour tissue, the presence of normal parathyroid tissue was 
noted, and where more than 1 block was available from a particular patient, the best 
morphologically preserved and representative block for immunohistochemistry was 
identified. Sections of poor quality were removed from the study. Cut sections were 
stored at room temperature until staining. 
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6.2.3.2 Preparation of Tissue Arrays 
Tissue arrays were prepared in the Histology Department, Van Andel Research 
Institute (VARI), with the assistance of laboratory technician, Mr Brandon Lesser. 
Initially, one 4µm section from each block was cut and stained with H&E. These 
sections were then assessed with histologist Dr James Resau, VARI, and the best 
regions for punches marked on the stained slide. An asymmetrical grid with a 
minimum spacing between punches of 1.2mm was devised in a spreadsheet, and all 
anticipated punches mapped and recorded on this grid. The punches were placed in a 
relatively random manner to prevent possible positional artefacts during staining. A 
faced (microtome-levelled) blank paraffin recipient block was prepared. Using an 
MTA1 tissue arrayer (Beecher Instruments Inc., Sun Prairie, WI, USA) and a 0.6mm 
punch set (MP06, Beecher Instruments Inc.) the recipient block was aligned according 
to the prepared grid and a core removed and discarded.  While the recipient block was 
still aligned, the donor block (as designated on the grid) was aligned according to the 
markings on the corresponding H&E slide, a punch core taken and placed in the core 
hole made in the recipient block. Between 1 and 3 punches were taken from each 
block. Once all the cores had been placed in the recipient block, it was incubated at 
37oC for 30 minutes to soften the paraffin in order to meld the cores to the block and 
then stored at room temperature. Tissue array P2, contained 88 punches from various 
parathyroid adenoma, hyperplasia and carcinoma / HPT-JT blocks. In preparation for 
the work described in this chapter, consecutive 4µm sections were cut by Ms Sue 
Smith, placed onto SuperFrost®Plus Microscope slides and 1 section was stained with 
H&E to facilitate histological assessment. The tissue array sections were used for 
optimisation of the immunostaining, however full sections were used for the IHC 
grading performed in this study. 
 
6.2.3.3 Preparation of Cryostat Sections 
Cryostat sections from frozen tissue that had been stored at -80oC were prepared in 
the Histology Section, Pathology Department, University of Sydney with the guidance 
of the Laboratory Manager, Dr Jane Radford. A flexible plastic beaker was half-filled 
with hexane and cooled to a gel consistency by floating in the top of a dewer 
containing liquid nitrogen. Each tissue section was embedded into a small amount of 
embedding medium for frozen tissue (OCT, Tissue-Tek, ProSciTech, Thuringowa, 
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QLD, Australia) and placed on a 2cm square piece of cork (gasket cork, Repco 
Australia, Camperdown, NSW Australia). Using large plastic forceps, the cork was 
submerged into the pre-cooled hexane for 15 seconds. The OCT embedded section 
was checked visually to ensure complete freezing, before wrapping in pre-cooled and 
labelled foil. The foil-wrapped sections were immediately re-stored in dry ice or 
transferred to a cryostat. Consecutive 7µm sections were cut from the frozen blocks 
by Jane Radford and placed onto SuperFrost®Plus microscope slides. The cut 
sections were air-dried for at least 1 hour. One section from each block was stained 
with regressive H&E by immersing in Harris’s Haematoxylin (Fronine Pty Ltd, 
Riverstone, NSW, Australia) for 3 minutes; washing in tap water for 30 seconds; 
differentiating by dipping 3 times into acid alcohol (1% Hydrochloric acid in 70% 
alcohol) and then washing in tap water; blueing in Scott’s Blueing Solution (2% 
magnesium sulphate, 0.35% sodium hydrogen carbonate) for 30 seconds and then 
washing in water for at least 2 minutes. Slides were checked for differential staining, 
then dipped briefly into 70% ethanol and counter-stained in alcoholic Eosin (Bancroft 
1996) for 30 seconds each.  The stained sections were then rapidly dehydrated 
(approximately 5 seconds per alcohol change) through 2 changes each of 70%, 95% 
and 100% ethanol, and then 2 changes of  Histo-clear (National Diagnostics, 
Manville, NJ) (5 minutes each), mounted in DPX (BDH Chemicals Ltd, Toronto, 
Ontario, Canada), and coverslipped (Menzel-Glaser, Germany). Unstained sections 
were stored at -20oC until required. In preparation for IHC staining, sections were 
brought to room temperature, fixed in acetone for 2 minutes, and then air dried. 
 
6.2.3.4 Overview of Immunohistochemical staining  
IHC staining was performed for 4 antibodies, RALDH2, PGP9.5, VCAM1 and 
CD200. Staining conditions were optimised with the guidance of Dr Lawrence Young 
(Queen Elizabeth II Research Institute, University of Sydney) and involved staining 
of control sections and tissue arrays with antibodies at different dilutions with and 
without antigen retrieval. Formalin-fixed paraffin embedded sections were used for 
RALDH2, PGP9.5 and VCAM1; cryostat sections were used for CD200. This work 
was performed in two different histology laboratories. Tissue array results of different 
antibody dilutions during optimisation are shown in Figure 6.2. The detection system 
used for all antibodies was the Envision+ Dual link System Peroxidase 
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(DakoCytomation Inc., CA, USA) and the substrate chromogen was 3,3’-
diaminobenzidine (DAB+) (DakoCytomation Inc., CA, USA). The Dual Link system 
was chosen over other detection system as it is suitable for both mouse and rabbit 
antibodies. 
 
6.2.3.5 Deparaffinisation 
All paraffin embedded sections underwent deparaffinisation prior to staining. This 
entailed immersion in 2 changes of xylene for a minimum of 5 minutes each, followed 
by 1 minute immersions in 100%, 100%, 95% and 70% ethanol and then tap water 
until antigen retrieval or loading onto the autostainer. 
 
6.2.3.6 Antigen Retrieval 
Antigen retrieval in 1xTris/EDTA Buffer pH9 (DakoCytomation Inc., CA, USA) was 
required for PGP9.5 and VCAM1. This was performed either by heating the sections 
in 500 mL of the Tris/EDTA buffer in a 1000 watt microwave for 12 minutes on high, 
or for approximately 25 minutes in a container of pre-heated buffer in a boiling 
waterbath. Following antigen retrieval, the solution and sections were allowed to cool 
for a minimum of 20 minutes by placing the container in running tap water. 
 
6.2.3.7 Immunostaining Protocol for paraffin-embedded sections for VCAM1, 
PGP9.5 and RALDH2 
Staining of paraffin embedded sections for VCAM1, PGP9.5 and RALDH2 was 
performed on an autostainer (Autostainer Plus, DakoCytomation Inc., CA, USA). 
Following deparaffinisation and antigen retrieval where required (see section 6.2.3.6 
above), sections were loaded onto the autostainer. The autostainer was programmed to 
dispense, incubate, rinse and remove excess buffer as follows.  
 
Initially, sections were treated with 200µL of 0.3% hydrogen peroxide enzyme block 
(DakoCytomation Inc., CA, USA) to quench the endogenous peroxidase activity in 
each section, incubated for 5 minutes, rinsed with Automation Buffer 
(DakoCytomation Inc., CA, USA) and the excess buffer blown off with forced air. 
(This enzyme block was replaced by 3% hydrogen peroxide (Sigma Aldrich, St. 
Louis, MO, USA) in water for RALDH2 staining.) Next, 200µL of a manually 
prepared dilution of primary antibody was added to all sections for staining and 
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200µL of the isotype matched, appropriately diluted negative control serum (detailed 
in Table 6.5) to the negative control section. Sections were incubated for 30 minutes. 
The sections were again rinsed with buffer, the excess buffer removed, and 200µL of 
Peroxidase Labelled Polymer (DakoCytomation Inc., CA, USA) added to each 
section. The sections were incubated for 30 minutes, then rinsed twice with buffer and 
the excess buffer was removed. Waste collection was switched to hazardous waste, 
and 200µL of prepared DAB+substrate added to the sections. Sections were incubated 
for 5 minutes, rinsed with buffer, and then rinsed with tap water. The water remained 
on the slides to keep them moist until able to be removed from the autostainer for 
couterstaining. 
 
Counterstaining involved immersing the sections in Harris’s Haematoxylin for 30 
seconds followed by tap water for 30 seconds or until the excess stain was washed 
away, differentiated by 1 dip in acid alcohol followed immediately by tap water, then 
blued by immersion in Scott’s Blueing solution for 30 seconds. Sections were then 
washed well in tap water and the counterstaining assessed microscopically. Following 
counterstaining, the sections were dehydrated by successive 30 second immersions in 
70%, 95%, 95%, 100% and 100% ethanol, a minimum of 5 minutes in 2 changes of 
Histo-clear and mounted in DPX and cover-slipped. The final conditions were 
determined from optimal positive staining in the control sections with no staining 
observed in the corresponding negative control sections. These conditions, including 
antibody dilutions, are detailed in Table 6.5 and optimal staining of positive control 
sections shown in Figure 6.3. In a number of cases, duplicate sections were stained in 
different staining runs.  
 
A                         B                       C
1
2
3
4
5
6
Figure 6.2 Multiple sections of 3 punches on the tissue array showing the optimisation of IHC and 
examples of intensity grading of IHC. Punch A is a secondary hyperplasia (not included in the study), 
B is carcinoma 78G, and C is HPT-JT 1765G. Stains are listed 1-6, where 1 is H&E, 2 is 
RALDH2@1/6000 diln, 3 is RALDH2@1/8000 diln, 4 is PGP9.5 @1/350 diln, 5 is PGP9.5@1/600 
diln, and 6 is VCAM1 @ 1/100 diln. Positive staining is indicated by a brown marking. Examples of
the intensity grading used in Table 6.6 are shown in red (0 – 3+). All images were taken at original 
magnification x200 by the candidate.
3+
3+
2+
1+
2+
0
1+
0
1+
0
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3+
2+
2+
Figure 6.3 Control differential immunohistochemical staining of tissues or tissue elements 
known to stain positively for each antibody. PGP9.5, RALDH2 and VCAM1 staining was 
performed on formalin-fixed paraffin embedded tissue, and CD200 staining performed on 
acetone fixed cryosections. Positive staining is indicated by a brown marking and negative
staining by blue counterstain. CD200 and PGP9.5 both show differential staining of nerve 
bundles and negative staining of surrounding cells in parathyroid tissue; RALDH2 shows 
positive cytoplasmic staining of parathyroid epithelial cells in parathyroid hyperplasia, but 
negative staining of endothelial cells; VCAM1 shows positive membranous staining of 
tonsil follicles and negative staining of surrounding cells. CD200, PGP9.5 and RALDH2 
images were taken at original magnification, x400; VCAM1 at original magnification, x100. 
All images were taken by the candidate.
CD200
PGP9.5
VCAM1
RALDH2
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6.2.3.8 Optimisation of staining for CD200 
Positive staining for CD200 has been demonstrated in thymus, spleen, tonsil, lymph 
nodes, nerve bundles, and several other tissues (Wright et al. 2001). A number of 
conditions varying the tissue fixative, antibody concentration and antigen retrieval 
(enzyme as well as heat) were trialled for CD200.  
 
 The CD200 antibody gave negative results when stained as described in sections 
6.2.3.7 above, using antibody dilutions of 1:50, 1:100 and 1:200 with formalin fixed 
paraffin embedded thymus control tissue (with and without heat retrieval as described 
in 6.2.3.6), Histochoice®-fixed (described in section 6.2.3.1) paraffin embedded 
lymph node and parathyroid hyperplastic tissue, and acetone fixed frozen sections of 
lymph node. The above conditions, with the addition of enzymatic antigen retrieval 
using Proteinase K (15 minutes at room temperature) as an alternative to heat retrieval 
for formalin fixed paraffin embedded sections were repeated with manual staining.  
 
Prior to manual staining, the sections were immersed in 3% hydrogen peroxide for 5 
minutes. Following pre-treatment (as detailed above), 100µL aliquots of antibody 
were added to the section and the sections incubated overnight at 4oC in a Shandon 
Sequenza staining rack (Thermo Electron, Thermo Trace Ltd., Noble Park, Vic, 
Australia). Following antibody incubation the sections were allowed to come to room 
temperature and the steps detailed in 6.2.3.7 were followed manually with the 
exception that 100µL Peroxidase labelled Polymer was applied to each section. 
Counterstaining was a progressive Haematoxylin protocol (Bancroft 1996) and 
stained sections were mounted in Eukitt (O. Kindler GmbH & Co., Freiburg, 
Germany). Positive staining was seen only in all the acetone fixed frozen sections. 
 
Using the above conditions for the acetone fixed frozen sections, further serial 
dilutions of the antibody were trialled. Counterstaining was extended to 5 minute in 
Mayer’s Haematoxylin (Bancroft 1996), followed by brief washing in tap water and 5 
minutes staining in Scott’s Blueing solution. These extended counterstaining times 
were required for effective nuclear staining of the acetone fixed sections. The final 
conditions, resulting in positive staining of nerve bundles and no staining in the 
matched negative control are listed in Table 6.5 and optimal staining of a positive 
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control section shown in Figure 6.3. All manual staining was performed in the 
Institute of Bone and Joint Research, with the guidance of Ms Sue Smith.  
 
Table 6.5 Final assay conditions and antibody details for immunohistochemical 
staining 
Antibody Details Staining conditions Controls & reported  
cellular localisation 
(CL) 
VCAM1  
 
Monoclonal Mouse 
Anti-Human 
Clone 1.4C3 
(M7106) * 
 
Formalin fixed paraffin embedded 
sections 
Antigen retrieval with Tris EDTA pH9   
1:100 antibody dilution (autostainer) 
 Final IgG conc: 3.0mg/mL 
30 minute incubation at RT 
 
Positive: Tonsil   
Negative: Mouse 
IgG1 (X0931) * 
CL: Membranous1 
 
PGP9.5  Purified Rabbit 
polyclonal 
(Z5116) * 
 
Formalin fixed paraffin embedded 
sections 
Antigen retrieval with Tris EDTA pH9   
1:600 antibody dilution (autostainer) 
 Final protein conc: 0.002mg/mL 
30 minute incubation at RT 
Positive: Small 
intestine and 
parathyroid nerve 
bundles 
Negative: Rabbit 
Immunoglobulin 
Fraction (X0936)* 
CL: cytoplasmic &  
0 -5% nuclear2 
 
RALDH2 Unpurified rabbit 
polyclonal † 
Formalin fixed paraffin embedded 
sections 
1:8000 antibody dilution (autostainer) 
Final protein conc ~ 2.5mg/mL 
30 minute incubation at RT 
Positive: parathyroid 
hyperplastic tissue 
Negative: Rabbit 
serum (normal) 
(X0902)* 
CL: cytoplasmic3 
 
CD200  Monoclonal Mouse 
Anti-Human 
clone MRC OX104 
(MCA1960) § 
 
Acetone fixed frozen sections 
1:600 antibody dilution (manual) 
 Final IgG conc: 0.002mg/mL 
Overnight incubation in Sequenza at 
4oC 
Positive: Nerve 
bundles in lymph and 
parathyroid tissue 
Negative: Mouse 
IgG1 (X0931)* 
CL: membranous / 
cytoplasmic4 
 
Legend: 
 “conc” refers to the final working concentration for both the antibody and corresponding negative 
control; “RT” is room temperature 
 *DakoCytomation Inc; † gift from Peter McCaffrey, Department of Cell Biology, University of 
Massachusetts Medical School, Waltham, MA, USA; § Serotec, Australian Laboratory Services Pty 
Ltd, Sydney Markets, NSW, Australia. 
 1Maeda et al. 2002; 2Wilson et al. 1988; 3Peter McCaffrey (personal communication); 4Wright et al. 
2001. 
 
6.2.3.9 Assessment of immunohistochemical staining 
All staining was assessed by 1 and in some cases, 2 histopathologists (A/Prof Jeanette 
Philips and Dr Anthony Gill) to confirm positive and negative staining, verify cellular 
localisation, identify cell types and possible artefacts.  
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6.2.3.10 Grading of immunohistochemical staining  
Numerical grading was devised following advice and examples from Dr Anthony 
Gill. Sections were scored according to the percentage of section (0 – 100%) that was 
stained positive (brown with DAB), and the intensity of staining (0 – 3+). No 
apparent  brown  colouration or positivity was graded as “0”, pale brown as “1+”, 
medium brown as “2+” and dark brown as “3+”. Where different intensities were 
observed in the same section, an average of the intensities observed was recorded. 
Examples of the intensity gradings are shown in the tissue array sections in Figure 
6.2. The final result was a combination of these 2 scores (Percentage x Intensity). The 
scattergraphs and histograms were produced from this numerical grading. 
Scattergraphs were created in SPSS, and histograms in Deltagraph. 
 
6.2.3.11 Statistical Analysis of immunohistochemical staining 
Conservative statistical analysis using Fisher’s Exact Test was performed for the IHC 
data. Sections were scored as either positive or negative, rather than using the 
numerical grading described in 6.2.3.10 above, to reduce subjectivity and errors 
introduced due to the possible non-linearity of the staining intensities. Sections 
displaying greater than 10% staining were regarded as positive (Torhorst et al. 2001).  
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6 .3  RESULTS  
6.3.1 Quantitative PCR 
6.3.1.1 Overview 
The qPCR results for the individual samples normalised to two different genes (18s 
and Signal Sequence Receptor, gamma (translocon-associated protein gamma 
(SSR3)) are graphed as box plots in Figures 6.4 and 6.5. The mean individual results 
for each sample (mean ratio to either 18s or SSR3, generated by SPSS as described in 
section 6.2.2.6) are listed in Appendix 6.1.  
 
Adenoma sample q3 (82A) was noted to be an extreme outlier for both MOX2 and 
RALDH2 and adenoma q5 (89A) an extreme outlier for MOX2 and CaSR. These 
outlier results are circled in yellow in Figure 6.4 – 6.5. No association between loss of 
heterozygosity (LOH), or retention of heterozygosity (R) at either 1q or 11q for the 
adenoma class samples was observed (Table 6.1 and Figures 6.4 – 6.5). Re-evaluation 
of the 2 patients from which these tumours were resected, revealed no unifying or 
unusual clinical or histopathological presentation. 
 
The class results for qPCR results normalised to 18s, are graphed as box plots in 
Figures 6.6 – 6.8 and show the Adenoma class results, both, including the above 2 
outlier adenomas (“Adenoma (all)”), as well as excluding these 2 outliers (“Adenoma 
(8)”). The group summary reports, found in Appendix 6.2 for 18s normalised results, 
and Appendix 6.3 for SSR3 normalised results, include results of each group (mean, 
standard error, standard deviation, 95% confidence intervals, generated by SPSS) as 
well as the adenoma group excluding the 2 outliers (q3(82A) and q5(89A)) noted 
above.  
 
Comparisons of class median values for qPCR (relative to 18s) with microarray data 
as tumour/UHR ratios (obtained as described in section 5.2.8.2) are shown in Figures 
6.6 - 6.8. HRPT2 was not represented on the arrays, and microarray results were not 
available for the normal parathyroid tissue pool. These figures may be used to 
compare expression trends for the tumour classes across the 2 different methods 
(qPCR versus microarray), but not actual values. qPCR produced ratios are expressed 
relative to a reference or normaliser gene, whereas microarray produced ratios were 
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relative to a reference sample. Further manipulation of either data set would simply 
increase the variance of the data. Comparison of the corresponding graphs 
demonstrate that the trends originally observed in the microarray data, for genes 
assayed by both methods, were also evident by qPCR.  
 
6.3.1.2 Normalising genes for quantitative PCR of parathyroid tumour subtypes 
SSR3 fulfilled the screening criteria for a putative normalising gene for parathyroid 
tissue described in section 6.2.2.5. This gene is located on chromosome 3q25.31, a 
region not identified as frequently aberrant in parathyroid tumours (Table 1.2). It 
appears to be ubiquitously expressed (UniGene Cluster Hs.28707), and while the 
function is largely unknown, the predicted function appears to be related to the 
essential, putative housekeeping process of intracellular protein trafficking (LocusID: 
6747; OMIM 606213). 
 
 The qPCR results normalised to SSR3 are displayed side-by-side with qPCR results 
normalised to 18s in Figures 6.4 – 6.5. The ratios show similar trends, although a 
broader range of ratios was noted for SSR3 normalised HRPT2 results, relative to 
those normalised to 18s (Figure 6.4). No significant class differences were found by 
REST-XL, when SSR3 was normalised to 18s.  
 
For reasons of space, clarity, and established protocols, all further analyses were 
performed with normalisation to 18s.  
 
Figure 6.4 Box plots showing the median and quartiles of the qPCR results for 
individual samples for genes CaSR, HRPT2 and MOX2 normalised to 18s (A) and 
SSR3 (B). The numbers on the x-axis are qPCR numbers 1-30 detailed in Table 6.1.  
The adenoma results are highlighted in pink, the hyperplasia results are highlighted 
in green and the HRPT2/carcinoma results are highlighted in blue. The normal tissue 
result is not highlighted, but circled in red, and UHR is q22. Obvious outliers in the 
adenoma group (q3:82A and q5:89A) are also circled in yellow.
A                                 B
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Figure 6.5 Box plots showing the median and quartiles of the qPCR results for 
individual samples for genes RALDH2, UCHL1 and VCAM1 normalised to 18s (A) 
and SSR3 (B). The numbers on the x-axis are qPCR numbers 1-30 detailed in Table 
6.1. The adenoma results are highlighted in pink, the hyperplasia results are 
highlighted in green and the HRPT2/carcinoma results are highlighted in blue. The 
normal tissue result is not highlighted, but circled in red, and UHR is q22. The 
obvious outlier in the adenoma group (q3:82A) is also circled in yellow.
A                                B
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Figures 6.6 - 6.8
Box plots showing the class median and quartiles of qPCR results for 
each gene normalised to 18s. 
The coloured boxes contain 50% of the data (data within 1 quartile 
length of the median (black line within the box)).; the whiskers
represent the data >1 and <1.5 quartiles from the median; outliers are 
shown as red circles (A) and extreme outliers as red asterisks (/)
(refer to SPSS).
“Adenoma (all)” included the results of all 10 adenomas, and 
“Adenoma (8)” excluded the results of the two outlier adenomas 
(q3(82A) and q5(89A)) noted in Figures 6.4-6.5. The “Hyperplasia” 
group consisted of 10 tumours, and “HRPT2_carcinoma” group 
consisted of 7 tumours. “Normal “consisted of 5 normal parathyroid 
gland fragments pooled into 1 sample and “UHR” was the Universal
Human Reference RNA.
The smaller box plots show the microarray class results for each  
corresponding gene (if assessed by microarray) using AMAD 
normalised (refer to section 5.2.8.1) Tumour/UHR microarray results, 
where for adenoma, n=13, for hyperplasia, n=12, and for HRPT2 / 
carcinoma, n=8 (2 outlier carcinoma tumours were excluded). No 
microarray results were available for the pooled normal. 
Class differences which achieved statistical significance by qPCR
using Pair-Wise Fixed Reallocation Randomisation Tests are defined 
by joined arrows and marked as 2 blue daggers (††) where p < 0.05 
and 1 blue dagger (†) where p < 0.001. 
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Figure 6.6 Box plots showing the median and quartiles of qPCR results (left) and microarray results 
(right) for each class for (A) CaSR and (B) HRPT2. HRPT2 was not represented on the microarrays and 
CaSR was not detectable in UHR by qPCR.
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Figure 6.7 Box plots showing the median and quartiles of qPCR (left) and microarray results (right) for 
each class for (A) MOX2 and (B) RALDH2. 
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Figure 6.8 Box plots showing the median and quartiles of qPCR (left) and microarray results (right) 
for each class for (A) UCHL1 and (B) VCAM1. 
0.0000 1.0000 2.0000 3.0000
VCAM1_18s
Adenoma (8)
Adenoma (all)
HRPT2_carcinoma
Hyperplasia
Normal
UHR
cl
as
s
A
S
S
0.0000 1.0000 2.0000 3.0000
UCHL1_18s
Adenoma (8)
Adenoma (all)
HRPT2_carcinoma
Hyperplasia
Normal
UHR
cl
as
s
000000 10.000000 20.000000 30.000000
UCHL1
A
S
S
0.000000 40.000000 80.000000 120.000000
VCAM1
S
†
†
†
††
†
†
†
A
B
Legend
p < 0.001
p < 0.05
†
††
Microarray
qPCR
- 219 -
   - 220 - 
6.3.1.3 Differential Expression determined by quantitative PCR 
The 3 pathological classes showed reduced expression of CaSR compared with the 
pooled normal parathyroid tissue (Figure 6.6A). Further, the level of expression of 
CaSR in the HRPT2-class was significantly less than the expression in the other 2 
pathological classes (with the 2 outlier adenomas, q3(82A) and q5(89A) described in 
6.3.1.1 above, removed from the Adenoma class) (p<0.001). The 2 outlier adenomas 
were found to have the highest CaSR expression of all the tumours assessed. One of 
these, q5(89A) is circled in yellow in Figure 6.4A. All 3 pathological classes also 
showed reduced expression of HRPT2 relative to the normal pool, although only the 
expression for the Hyperplasia class was significantly different (p<0.001) (Figure 
6.6B).  
 
The Gene-Rave analysis prediction of the combination of MOX2 and RALDH2 as 
discriminators between the Hyperplasia and Adenoma classes (section 5.3.3.2 and 
Figure 5.14) was confirmed by qPCR. The Hyperplasia class showed significantly 
increased expression (p<0.001) of MOX2 relative to the HRPT2 and Adenoma classes 
(with adenoma outliers removed) (Figure 6.7A). RALDH2 expression was also 
significantly higher in Hyperplasia than Adenoma (p<0.001) (Figure 6.7B). 
 
VCAM1 and UCHL1 were both highly expressed in the HRPT2 class by microarray, 
compared with other tumour classes, and as such, each were predicted by Gene-Rave 
as discriminators for this class (with VCAM1 paired with PVALB) (section 5.3.3.4). 
Similar results were obtained by qPCR, with highly significant differences (p<0.001) 
between HRPT2 and the other 2 pathological classes (Figure 6.8). 
 
Scattergraphs of pairwise discrimination of qPCR results showed a clear separation of 
the HRPT2 class, most noticeably with UCHL1 when paired with VCAM1 (Figure 
6.9). A three-dimensional scattergraph was able to separate all 3 classes to differing 
degrees, with the most effective separation of the HRPT2 class by the combination of 
UCHL1, VCAM1 and RALDH2 (Figure 6.10A-B).  
 
Unsupervised hierarchical clustering using the software programs CLUSTER and 
TREEVIEW (described in section 5.2.8 of this thesis) was utilised to assess the 
robustness of the expression levels of the 6 genes for classification of parathyroid 
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tumours (Figure 6.11). Twenty-four of the twenty-seven tumour samples were 
classified correctly. Three adenomas were misclassified as hyperplasia samples. The 
strength of a relationship is gauged by the length and number of branches separating 
the samples, with the shortest branches and fewest interconnecting branches 
indicating the highest degree of similarity. Adenoma 82A(q3) and to a lesser extent 
adenoma 89A(q5), bore strong similarity to the hyperplasia samples, but adenoma 
101A(q9), by virtue of the long branch separating it from its nearest neighbour, 
appeared to have little similarity to any of the classes. The RALDH2 transcript level 
for this tumour was within the range observed for the Hyperplasia class (Figure 6.5A) 
rather than the Adenoma class, and this likely contributed to the misclassification of 
this tumour. Clinical and histological re-evaluation of this tumour confirmed a case of 
primary hyperparathyroidism due to a single adenoma with no unusual features. The 
strongest clustering was within the HRPT2 class samples. Of interest, this class was 
separable, using the qPCR genes, into sporadic (q30(2119G), q29(2077G) and 
q26(78G)) and familial samples (q27(1765G), q24(4A), q28(1613G) and q23(54A)). 
However, testing of a larger sample set would be required to determine if these results 
were significant.  The Hyperplasia class showed the most heterogeneity and loosest 
clustering. The pooled normal parathyroid clustered with the Hyperplasia class. This 
positioning of the pooled normal parathyroid with the Hyperplasia class had also been 
observed in unsupervised clustering of the microarray results (Figure 5.3A) 
 
 
Figure 6.9 Pairwise scattergraphs of the means of the individual qPCR results 
normalised to 18s. Adenoma outlier samples 82A(q3) and 89A(q5) are shown 
separately. The combination of UCHL1 and VCAM1 was predicted to separate the 
HRPT2 class from the rest and clear separation is observed. The combination of 
UCHL1 with any other gene also shows separation of the HRPT2 class. Clear 
separation of the hyperplasia and adenoma classes is not observed.
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Figure 6.10 Three-dimensional scattergraphs of the means of the individual qPCR results 
normalised to 18s. Outlier adenoma samples q3(82A) and 89A(q5) are shown separately. 
Two gene combination sets are shown (A: CASR vs RALDH2 vs MOX2; and B: VCAM1 vs
RALDH2 vs UCHL1)  with each set able to discriminate between the classes to differing 
degrees. The samples of each class are joined to show the centroid position for each class. 
The pooled normal is obscured in Figure B. 
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Colour legend:
Figure 6.11 TREEVIEW generated dendrogram and heatmap of unsupervised 
hierarchical clustering of mean qPCR (normalised to 18s) results. Results were log2
transformed and median centered across the genes. The median-centered values are 
represented by colours as shown in the legend.  The relationships between the genes 
are represented by the nodes at the left of the diagram. For both the tumours and 
genes, the strength of a relationship is gauged by the length and number of branches 
separating the samples, with the shortest branches and fewest interconnecting 
branches indicating the highest degree of similarity. The strongest clustering is 
demonstrated by the HRPT2 class. Within this class, separation of the sporadic and 
familial samples was also evident. The Hyperplasia class demonstrated the greatest 
intraclass heterogeneity with multiple branches of  varying lengths. Three adenomas 
and the Normal clustered with the Hyperplasia  class. 
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6.3.2 Immunohistochemical Staining 
6.3.2.1 Staining patterns 
Representative staining of each class for each of the 4 antibodies is shown in Figures 
6.12 – 6.15. The graded results are listed in Table 6.6 and box plots showing the 
median and quartile ranges for these results are shown in Figure 6.16. Examples of the 
numerical scale for the intensity grading are shown in red in Figure 6.2.  
 
Cytoplasmic staining of parathyroid cells was observed in sections stained with 
RALDH2, CD200 (MOX2) and PGP9.5 (UCHL1) and membranous staining of 
parathyroid cells observed in VCAM1 sections. Apparent nuclear staining was 
observed in 1 - 5% of stained parathyroid cells in 2 sections for PGP9.5 and 1 section 
for RALDH2 (Table 6.6). This pattern of nuclear and cytoplasmic localisation of 
PGP9.5 has been previously reported (Wilson et al. 1988; Caballero et al. 2002). Both 
PGP9.5 (UCHL1) and CD200 (MOX2) are known neuronal markers, and staining of  
nerve bundles in the parathyroid tumour sections was observed for both antibodies 
(Figure 6.3) (Wilson et al. 1988; Wright et al. 2001). Some interstitial staining was 
also observed for RALDH2 (Figure 6.13A-Normal). 
 
For the majority of tumours and antibodies, the staining patterns were focal, with 
often intense staining in discrete regions of the tumour. This was observed most 
dramatically in the RALDH2 stained sections. Intense positive staining was in some 
cases directly adjacent to areas of negative staining, as shown in Figures 6.13B1, 
6.13B3 and 6.2A3 for 3 different hyperplasia specimens. These staining patterns were 
found to reproducible in these tumours. VCAM1 positive staining tended to be 
observed in regions surrounding vascular endothelium.  
 
Both RALDH2 and CD200 (MOX2) showed positive staining in the normal 
parathyroid tissue sections. RALDH2 staining of normal parathyroid cells was patchy, 
weak in intensity (1+) and generally both cytoplasmic and interstitial (Figure 6.13-
Normal). This staining pattern was also observed in the normal rims of several of the 
adenomas, with otherwise negative staining. CD200 (MOX2) staining in normal 
parathyroid tissue was observed most consistently in the mesenchymal rather than 
parenchymal cells, with intense positive cytoplasmic staining of sub-endothelial 
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fibroblasts (Figure 6.12-Normal). This staining was reduced relative to cellularity in 
many of the adenomas (Figure 6.12-Adenoma). In contrast, the strongly positive 
diffuse staining observed in the majority of hyperplasia sections, and some adenoma 
sections, was localised to parathyroid cells (Figure 6.12-Hyperplasia).   
 
6.3.2.2 Class separation 
Pair-wise and 3-dimensional scattergraphs of IHC results for VCAM1, PGP9.5 and 
RALDH2 showed clear separation of the HRPT2 class (Figure 6.17). Separation of 
the Adenoma and Hyperplasia class is also apparent, but there is an area of overlap 
due to two of the three Adenoma outliers identified by qPCR and misclassified as 
Hyperplasia by unsupervised clustering (82A(q3) and 101A(q9)) (Figure 6.11). Both 
are shown separately in Figure 6.17. The IHC results for 82A(q3) reflected those 
noted by qPCR, specifically very high expression of both RALDH2 and CD200 
(MOX2) (Figures 6.4-6.5 and Table 6.6). This expression pattern was again more 
closely aligned to that found in the hyperplasia class rather than the adenoma class 
(Figures 6.9 and 6.17). Adenoma 101A(9q) was misclassified as Hyperplasia by 
unsupervised clustering of the qPCR results likely due to the elevated transcript level 
for RALDH2 (Figures 6.11 and 6.5). The IHC results similarly showed this tumour to 
have elevated RALDH2, and thus more closely resembled Hyperplasia than Adenoma 
in the scattergraphs (Table 6.6 and Figure 6.17). The IHC results for the third 
adenoma outlier identified by qPCR, 89A(q5), also reflected the qPCR results, with 
very high expression for CD200 (MOX2) (Figure 6.4 and Table 6.6). It did not appear 
as an outlier in Figure 6.17 as CD200 was not included in the scattergraphs 
(corresponding results were not available for all of the paraffin embedded samples 
used for VCAM1, RALDH2 and UCHL1). 
 
The differential expression observed by IHC attained significance using Fisher’s 
Exact Test for the HRPT2 class when compared with the other classes for VCAM1 
(p<0.05) and PGP9.5 (p<0.001) (Figure 6.18). In addition, significant differences in 
RALDH2 expression were found between the Hyperplasia class and both Adenoma 
and Normal (p<0.001). The class differences for CD200 did not reach significance.  
 
Normal
Adenoma
Hyperplasia
Figure 6.12 Representative CD200 staining of normal parathyroid tissue, 
adenoma and hyperplasia. Intense positive cytoplasmic staining of sub-
endothelial fibroblast mesenchymal cells was observed in both normal tissue 
and the majority of adenoma sections. Intense positive cytoplasmic staining of 
parathyroid cells was observed in hyperplasia sections and some normal 
sections. All images were taken at original magnification x400 by the 
candidate.
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Figure 6.13 Representative RALDH2 staining. Panel A shows representative staining of the different 
classes. Low level staining with some interstitial staining was evident in normal parathyroid sections. No 
RALDH2 staining was observed in the  majority of adenoma sections. Cytoplasmic and some interstitial 
staining of variable intensity was observed in the majority of hyperplasia and HRPT2 mutation positive 
tumour sections. The HRPT2 tumour shown also appeared to have some nuclear RALDH2 staining. All 
images at 400x original magnification. Panel B(1-3) show the different patterns of focal staining 
observed in hyperplasia sections. Panel B(4) shows the pattern of staining for Adenoma outlier 82A(q3). 
Panel B(3) was taken at original magnification x40 and the rest at original magnification x100. All 
images were taken by the candidate. 
A B
Normal
Adenoma
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HRPT2
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Figure 6.14 Representative VCAM1 staining. No staining was observed in the majority 
of normal parathyroid tissue, adenoma and hyperplasia sections. Intense membranous 
staining was observed in HRPT2 mutation positive tumour sections. All images were 
taken at original magnification x400 by the candidate.
Normal
Adenoma
Hyperplasia
HRPT2
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Figure 6.15 Representative PGP9.5 staining. No staining was observed in the
majority of normal parathyroid tissue, adenoma and hyperplasia sections. Intense 
cytoplasmic staining was observed in HRPT2 mutation positive tumour sections. 
All images were taken at original magnification x400 by the candidate.
Normal
Adenoma
Hyperplasia
HRPT2
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qID Sample ID Class
% I Result % I Result % I Result % I Result
1 9A Adenoma 0 0 0 0 0 0 0 0 0 10 3 30
2 14A Adenoma 0 0 0 0 0 0 0 0 0 10 2 20
3 82A Adenoma 0 0 0 1 3 3 90 3 270 100 3 300
4 100A Adenoma 0 0 0 0 0 0 0 0 0 10 2 20
5 89A Adenoma 0 0 0 1 1.5 1.5 0 0 0 100 3 300
6 99A Adenoma 0 0 0 1 1 1 0 0 0
7 88A Adenoma 0 0 0 0 0 0 0 0 0
8 93A Adenoma 0 0 0 5 1 5 0 0 0
9 101A Adenoma 0 0 0 1 3 3 40 1 40
10 78A Adenoma 60 2 120
T32B6 Adenoma 10 3 30
T31I4 Adenoma 60 3 180
11 95A 2_Hyperplasia 0 0 0 0 0 0 100 2 200 100 3 300
12 1293G 2_Hyperplasia 0 0 0 1 2 2 20 2 40
13 2082G 2_Hyperplasia 0 0 0 0 0 0 60 2 120
14 1749G 2_Hyperplasia 0 0 0 0 0 0 60 1 60
15 866G 2_Hyperplasia 0 0 0 0 0 0 80 3 240
16 2358G 2_Hyperplasia 0 0 0 20 1 20 60 1 60
17 1363G 2_Hyperplasia 0 0 0 5 2 10 40 3 120
18 2636G 2_Hyperplasia 0 0 0 20 1.5 30 30 2 60
19 1417G 2_Hyperplasia 0 0 0 1 2 2 60 2 120
20 2356G 2_Hyperplasia 30 3 90 0 0 0 80 3 240
17A 2_Hyperplasia 100 3 300
34A 2_Hyperplasia 100 3 300
20A 3_Hyperplasia 10 2 20
87A 1_Hyperplasia 60 2 120
86A 3_Hyperplasia 60 3 180
P915 2_Hyperplasia 100 3 300
21 NORMAL 5 3 15 0 0 0 1 1 1 60 2 120
NORMAL 0 0 0 0 0 0 5 1 5 20 2 40
NORMAL 0 0 0 0 0 0 10 1 10 20 2 40
NORMAL 5 1 4 0 0 0 5 1 5 20 1 20
NORMAL 5 2 10 0 0 0 1 1 1
NORMAL 1 1 1 0 0 0 1 1 1
NORMAL 0 0 0 0 0 0 10 1 10
NORMAL 0 0 0 0 0 0 0 0 0
23 54A HRPT2 (FIHP) 40 2 80 80 1 80 60 2 120
24 4A HRPT2 (FIHP) 60 3 180 80 1.5 120 90 2 180 60 2 120
26 78G HRPT2 (Carc) 0 0 0 90 2 180 0 0 0
27 1765G HRPT2 (HPTJT) 20 2 40 80 1 80 80 3 240
28 1613G HRPT2 (HPTJT) 0 0 0 80 2 160 60 2 120
30 2119G HRPT2 (Carc) 40 3 120 60 1 60 0 0 0
VCAM1 PGP9.5 RALDH2 CD200
Table 6.6 Graded results for immunohistochemical staining, listing the percentage of positive staining (“%”) and the
intensity of staining (“I”) for each section and each antibody. The final result (“Result”) is the Percentage positive x
Intensity. Sections where nuclear staining was observed in some cells is denoted with an asterisk. The listed numerical results
were used for the graphs in Figures 6.16 - 6.18. Tests for statistical significance using Fisher’s Exact Test were based on a
positive or negative score only. Percentage positive staining greater than 10% was scored as positive, and less than 10% was
scored as negative. Positive scores are highlighted in yellow.
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Figure 6.16 Boxplots showing the median and quartiles for IHC results graded as % positive x intensity. The 
coloured boxes contain 50% of the data (data within 1 quartile length of the median (black line within the 
box)).; the whiskers represent the data >1 and <1.5 quartiles from the median; outliers defined by SPSS are 
shown as red circles (A) and extreme outliers as red asterisks (/).
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Figure 6.17 Scattergraphs of the individual IHC results for the paraffin-embedded sections. Adenoma 
82A(q3), the extreme adenoma outlier for RALDH2 and MOX2(CD200) identified by qPCR and 
misclassified as hyerplasia by unsupervised clustering, is shown separately. Adenoma 101A(q9) 
which was also misclassified as hyperplasia, likely due to high transcript level of RALDH2, is also 
shown separately. 89A(q5), an adenoma outlier for CD200 identified by qPCR and also misclassified 
as hyerplasia, clustered with the adenoma group for the above IHC results, and thus was not shown 
separately. CD200 was not included in the scattergraphs because corresponding results were not 
available for all of the paraffin-embedded samples. 
Figure A shows the pairwise scattergraphs of the individual IHC results. 
Figure B shows the 3-dimensional scattergraph for the combination of all 3 antibodies. The samples 
of each class are joined to show the centroid position for each class.  In all graphs, the Adenoma class 
is obscured by the overlaid Normal class, and thus not separable from the Normal class. Clear 
separation of the HRPT2 class is evident. Both outlier adenomas shown separately, appear to cluster 
with the Hyperplasia class rather than the Adenoma class.
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6.3.3 Comparison of quantitative PCR and 
immunohistochemical results 
The class results for transcript and protein are presented together in Figure 6.18 and 
summarised in Table 6.7. The differences in protein expression observed from the 
IHC staining were consistent with differences in transcript expression found by qPCR.  
 
Both the transcript and protein expression of UCHL1 (PGP9.5) in the HRPT2 class 
were significantly higher than in the Adenoma, Hyperplasia and Normal classes 
(p<0.001 except for qPCR HRPT2 versus Normal: p<0.05). Similarly, transcript and 
protein expression for VCAM1 in the HRPT2 class were significantly higher than in 
the Adenoma and Hyperplasia classes (qPCR: p<0.001, IHC: p<0.05).  VCAM1 
protein expression was also significantly higher in the HRPT2 class than in the 
normal parathyroid class (p<0.05), but did not reach significance by qPCR. This was 
likely due to the qPCR testing of normal parathyroid in a single pool, rather than as 
multiple specimens as was possible by IHC.  
 
Both the transcript and protein expression of RALDH2 in the Hyperplasia class were 
found to be significantly higher than in the Adenoma class (qPCR: p<0.05, IHC: 
p<0.001). Low RALDH2 transcript expression was observed in the sporadic 
carcinoma samples within the HRPT2 class (Figure 6.5) and these (q26(78G) and 
q30(2119G)) similarly showed negative immunostaining for RALDH2. Different 
relative expression levels of transcript and protein were found in the normal 
parathyroid tissue class for RALDH2. The reason for this is uncertain, but may reflect 
the reduced sensitivity of IHC at low levels. RALDH2 protein expression was evident 
in the majority of normal sections as sparse focal RALDH2 staining of low intensity. 
This staining pattern was also noted in the normal rim remnants of the adenoma 
sections (where present). However, no staining was observed in 7 of 9 adenomas.  
MOX2 (CD200) transcript levels for the Hyperplasia class were significantly higher 
than those of the HRPT2 class (p<0.001) and the Adenoma class when the two 
outliers with extremely high expression (q3(82A) and q5(89A)) were removed 
(p<0.001). IHC testing for CD200 (MOX2) required tumours for which frozen tissue 
was available and thus a partially different set of tumours was tested. While the IHC 
results for tumours with qPCR results showed similar expression patterns, no 
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significant differences in CD200 (MOX2) protein expression between the classes 
were found. The protein expression in the Adenoma class was mixed, with equal 
numbers of tumours showing positive (>10% staining) and negative expression (< 
10% staining). Only 1 HRPT2 class tumour was able to be assessed. 
 
Table 6.7 Summary of significant results for quantitative real-time PCR and 
immunohistochemical staining. The class listed in the “High Expression” column had 
significantly higher expression than the class or classes listed in the “Low Expression” column. The 
number of tumours assessed in each group is listed in brackets. “Adenoma (8)” refers to the adenoma 
group with the 2 outlier adenomas identified by qPCR (q3(82A) and q5(89A)) excluded. The level of 
significance for each comparison is shown.  
Molecule Method High expression   low expression         Significance 
level 
CaSR qPCR 
qPCR 
qPCR 
Normal (1*)          
Hyperplasia (10)  
Adenoma (8)           
Hyperplasia (10)   
HRPT2 (7) 
Hyperplasia (10)  
 
p<0.05 
p<0.001 
p<0.001 
HRPT2 qPCR Normal (1*)         Hyperplasia (10) 
 
p<0.05 
MOX2 qPCR Hyperplasia (10)   HRPT2 (7), Adenoma (8)  p<0.001 
CD200 IHC  No significant differences 
 
 
RALDH2 qPCR 
qPCR 
Hyperplasia (10)     
Hyperplasia (10)   
Adenoma (8)  
Adenoma (10) 
p<0.001 
p<0.05 
RALDH2 IHC Hyperplasia (10)  Adenoma (9), Normal (8)  p<0.001 
     
UCHL1 qPCR 
qPCR 
HRPT2 (7)          
HRPT2 (7)                
Adenoma (10), Hyperplasia (10) 
Normal (1*) 
p<0.001 
p<0.05 
PGP9.5 IHC HRPT2 (6)  
HRPT2 (6)               
Adenoma (9), Hyperplasia (10), 
Normal (8) 
p<0.001 
p<0.001 
     
VCAM1 qPCR HRPT2 (7)          Adenoma (10), Hyperplasia (10) p<0.001 
 IHC HRPT2 (6)      
HRPT2 (6)      
Adenoma (9) , Hyperplasia (10), 
Normal (8) 
p<0.05 
p<0.05 
     
Legend: *While the qPCR Normal consisted of 5 parathyroid fragments, these were combined into 1 
pooled sample. 
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Figure 6.18 Histograms of the median class results for both IHC and qPCR for each molecule. For each graph 
the left hand side y-axis of each graph represents the qPCR results as transcript of interest relative to 18S. The 
right hand side y-axis represents the IHC results as % positive x intensity. Class differences for IHC which 
attained significance by Fisher’s Exact Test are indicated by joined arrows and 2 blue daggers where p < 0.05 
and joined arrows and a single blue dagger where p < 0.001. 
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6 .4  D ISCUSS ION 
6.4.1 Overview 
The quantitative assessment of transcript levels of the 5 genes (CaSR, MOX2, 
RALDH2, VCAM1 and UCHL1; HRPT2 was not represented on the arrays) described 
in this chapter validate the differential expression trends revealed by microarray 
analysis of parathyroid tumours described in chapter 5 of this thesis (Figures 6.6 – 
6.8). The 4 genes for which both transcript and protein expression were assessed, 
displayed similar patterns of differential expression at both levels (Figure 6.18). The 
protein results provide additional validation of the trends identified by microarray, 
although protein expression may not necessarily correlate with transcript expression 
in all cases. Post-translational modifications such as phosphorylation, glycosylation 
and ubiquitination may modulate molecular interactions, localisation and stability of 
the protein. 
 
6.4.2 Genes for normalisation in parathyroid tissue 
Endogenous ribosomal RNA was first suggested for normalisation of RNA quantity in 
1994 (Bhatia et al. 1994) and has since been shown to be preferable to other widely 
used housekeeping genes such as Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and beta-actin in some cell types (Goidin et al. 2001). GAPDH is known to 
contribute to cellular functions including nuclear RNA transport, DNA replication and 
repair (Sirover 1999). GAPDH has also been implicated in a p53 apoptotic pathway 
leading to neuronal loss in Parkinson’s disease (Tatton et al. 2003) and has been 
reported to be regulated by calcitriol in human breast carcinoma cell lines (Desprez et 
al. 1992). Published qPCR results for parathyroid samples have been normalised 
using GAPDH (Correa et al. 2002b; Correa et al. 2002a; Segersten et al. 2002).   
 
The qPCR results in this study were normalised to 2 different active reference or 
“housekeeping” genes, 18s and SSR3, a putative housekeeping gene identified from 
the microarray work presented in chapter 5 of this thesis. Similar patterns of 
expression were evident regardless of the gene used for normalisation (Figures 6.4 – 
6.5). Each gene has advantages and disadvantages regarding its use. 18s is established 
as a gene suitable for normalisation of tumour RNA but has extremely high 
expression that is often, as found for the genes in this study, well above the range of 
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expression levels of the genes to be assessed (Bustin 2002). SSR3 is a novel putative 
housekeeping gene for parathyroid tissue with expression levels in the same range as 
the genes of interest in this study. The work described in this chapter is the first report 
of the use of 18s and SSR3 for normalisation of transcript levels in parathyroid tissue. 
The close correlation of differential expression trends by microarray, qPCR and IHC 
suggest that 18s and SSR3 are both suitable active reference genes for parathyroid 
tissue.  
 
6.4.3 Comparison of Normal tissue and Universal Human 
Reference expression 
An interesting observation was the comparison of normal parathyroid tissue and UHR 
expression (Figures 6.6 - 6.8). UHR is a mix of 10 cell lines derived from different 
tissues. RALDH2, UCHL1 and VCAM1 showed equivalent mRNA expression for both 
normal and UHR. CaSR, which is not widely expressed outside of parathyroid tissue, 
was undetectable in UHR, and HRPT2 and MOX2 showed higher expression in 
normal parathyroid, suggesting higher basal expression levels of these genes in 
parathyroid tissue than in other tissues, and, like CaSR, important roles in parathyroid 
function. 
 
6.4.4 HRPT2 transcript expression 
The results described in chapter 3 of this thesis provide evidence for a tumour 
suppressor role for HRPT2 in sporadic parathyroid carcinomas and HPT-JT-
associated tumours. Little is known though, of the function of HRPT2 and its 
relevance to parathyroid tumours which do not harbour inactivating HRPT2 mutations 
or loss of the wild type allele. The qPCR results in this chapter, showed that all 
tumour classes – those that harbour mutations in addition to those where mutations 
have not been found (Table 6.1) have reduced HRPT2 expression relative to the 
normal pool of parathyroid tissue (Figure 6.6B). There was no significant correlation 
of transcript expression with the presence of a HRPT2 mutation or loss of the wild 
type allele, and only the Hyperplasia class showed significantly reduced expression 
relative to the normal parathyroid tissue (p<0.001). These results suggest that HRPT2 
expression is integral to normal parathyroid function and mechanisms in addition to 
the presence of a mutation may be involved in the down-regulation of HRPT2 
   - 239 - 
transcript. This work is the first investigation reported of HRPT2 transcript 
expression, and should be considered with caution until substantiated in a larger 
cohort of both tumour and normal parathyroid tissue. This further work is beyond the 
scope of this thesis. 
 
6.4.5 CaSR transcript expression 
Unlike the HRPT2 expression patterns, significantly reduced CaSR expression was 
found in the HRPT2 class relative to both Normal and the Hyperplasia class (p<0.001) 
(Figure 6.6A). These results provide real-time PCR assessment of CaSR transcript for 
three different classes of parathyroid tumours. The results are in agreement with the 
reduced transcript levels previously reported in parathyroid adenomas and 
hyperplastic glands (Gogusev et al. 1997; Farnebo et al. 1998; Corbetta et al. 2000).  
 
Two adenomas (q3(82A) and q5(89A)) were noted to be extreme outliers for several 
of the molecules studied. These 2 samples were noted to have the highest CaSR 
expression of all the tumours studied (Figure 6.4: q5(89A) is circled in yellow and 
q3(82A) has the next highest level in the tumours) which may provide a clue to their 
atypical behaviour relative to the majority of tumours studied.  
 
6.4.6 Novel biomarkers of parathyroid disease 
The validation of different expression patterns also confirmed the genes predicted by 
Gene-Rave analysis (chapter 5) to be useful biomarkers for the different classes of 
parathyroid disease. Both PGP9.5 and VCAM1 were found to be statistically 
significant biomarkers for discrimination between the HRPT2 class and the other 
pathological classes at both the transcript and protein level (p<0.001 and p<0.05 
respectively) (Table 6.7). The Hyperplasia class could be discriminated from the 
Adenoma class (with outliers removed) by both MOX2 and RALDH2 (p<0.001) 
(Table 6.7). At the protein level, differences in RALDH2, but not CD200 (MOX2) 
expression reached significance (p<0.001). In combination, PGP9.5, VCAM1 and 
RALDH2 were able to effectively discriminate between the 3 classes of parathyroid 
disease, with a small area of overlap between Adenoma and Hyperplasia. 
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6.4.7 Adenoma and Hyperplasia 
Histopathological discrimination of adenoma and hyperplasia is inherently difficult. 
This difficulty may reflect the heterogeneous nature of the 2 histological classes. The 
majority of hyperplasia samples studied in the work described in this chapter arose 
through a physiological response to the biochemical imbalances of chronic renal 
failure (Table 6.1 and section 6.1.2). The hyperplastic glands have a high rate of 
proliferation (Erickson et al. 1999), and thus an increased chance of accumulation of 
mutations. If mutations confer a further growth advantage, monoclonal populations of 
neoplastic cells may arise within these hyperplastic glands. The majority of secondary 
hyperplastic glands return to normal following correction of the biochemical 
imbalance, however approximately 5% become refractory to these corrections 
(Mizumoto et al. 1994). Those that become refractory may have become monoclonal 
due to the accumulation of advantageous mutations. Clonality studies of parathyroid 
tumours (described in section 1.4.5) have not found clear distinctions between 
hyperplastic and neoplastic glands. The majority of adenomas and a lesser proportion 
of hyperplastic glands studied have been reported to be monoclonal. It is possible the 
different pattern of gene expression observed between the Adenoma and Hyperplasia 
classes may be associated with differences in clonality. 
 
 Unsupervised cluster analysis of the transcript expression revealed a somewhat loose 
and variable pattern within the Hyperplasia class (Figure 6.11). This pattern may 
reflect early and variable neoplastic transformation of polyclonal hyperplasia by the 
accumulation of monoclonal populations (nodules) of neoplastic tumour. The normal 
tissue and 3 adenomas also clustered with the Hyperplasia class. Adenoma 101A(q9) 
appears to be unrelated to all classes, however Adenomas 82A(q3) and 89A(q5) 
appear to be non-typical adenomas with greater similarity to Hyperplasia than 
Adenoma. These adenomas may belong to the minority of tumours which are 
predominantly polyclonal in nature. Grouping of sporadic parathyroid adenomas into 
two different clusters has also been observed by microarray analysis of these tumours 
(Figure 5.3A, Morrison et al. 2004). No Hyperplasia class samples were misclassified 
by clustering thereby suggesting that these samples were predominantly polyclonal.  
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6.4.8 Putative biomarker CD200 
In line with the hypothesis that the Hyperplasia class is primarily polyclonal and 
hyperplastic, expression changes observed between this class and normal tissue have 
likely developed from normal physiological responses. Increased expression in the 
Hyperplasia class relative to Normal was apparent for CD200 (MOX2). CD200 is a 
member of the immunoglobulin superfamily and is a widely expressed cell membrane 
protein involved in cell-cell interactions possibly via its receptor CD200R (Wright et 
al. 2001). It is involved in controlling immunological responses to prevent damage to 
self, with increased expression proposed to arrest the inflammatory cascade and 
promote the release of growth factors and tissue repair, and decreased levels 
providing a signal for clearance of apoptotic cells (Elward and Gasque 2003). A 
recent study of CD200-null mouse dendritic cells however, found a direct association 
between increased CD200 expression and apoptosis and suggested that CD200 is a 
p53-target gene (Rosenblum et al. 2004). IHC staining of parathyroid sections 
revealed that the basal level of parathyroid CD200 expression was due primarily to 
mesenchymal and dendritic cells (Figure 6.12) with variable expression by the 
parenchymal parathyroid cells within the glands. Hyperplasia sections displayed 
intense staining of the majority of the parenchymal cells (Figure 6.12 and Table 6.6). 
This increased expression may be a physiological response to the inflammatory 
processes of chronic renal failure as increased levels were restricted primarily to the 
secondary hyperplasia samples.  
 
6.4.9 Putative biomarker RALDH2 
RALDH2 was also highly expressed in the Hyperplasia and HRPT2 classes relative to 
Adenoma. Reduced expression was observed in the majority of the Adenoma class 
samples compared with normal parathyroid tissue. RALDH2 is involved in the 
synthesis of all-trans retinoic acid (ATRA) and as such, is an important, rate-limiting 
component of the retinoid signalling pathway (reviewed by Napoli 1999) (Figure 
6.19). This pathway, via its activation of the transcription of a number of genes, has 
important roles in embryonic development, immune response, cell proliferation and 
modulation of inflammation. ATRA is now an established and widely used anti-
cancer therapeutic (reviewed by Okuno et al. 2004). The chemo-preventative effects 
of ATRA include the delay or arrest of G1-S transition by post-translational 
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repression of cyclin D1 and cyclin E proteins (Langenfeld et al. 1997; Boyle et al. 
1999; Spinella et al. 1999).  
 
 
 
 
The importance of RALDH2 in embryonic development both, in general, and 
specifically to the parathyroid glands, has been demonstrated by targeted inactivation 
of raldh2 in mice. Raldh2-null mice are embryonic lethal with agenesis of the enteric 
ganglia reminiscent of human Hirschsprung’s disease, and raldh2-heterozygous mice 
demonstrate abnormal development which includes lack of development of the 
parathyroid gland (Niederreither et al. 2003).  
 
Previous studies have established parathyroid cells as both sites of synthesis of ATRA 
and targets for the effects of ATRA (Liu et al. 1996; Melhus et al. 2001). These 
studies showed that ATRA inhibited the secretion of PTH and cell proliferation 
independently of 1,25-(OH)2D and inhibition of PTH was enhanced in the presence of 
both ATRA and 1,25-(OH)2D.  
Figure 6.19 RALDH2 is involved 
in the synthesis of all-trans
retinoic acid (at-retinoic 
acid:ATRA) from all-trans 
retinaldehyde which is transported 
bound to Cellular Retinol Binding 
Protein (CRBP). Following the 
cytoplasmic synthesis of at-
Retinoic acid it is bound to 
Cellular Retinoic Acid Binding 
Protein (CRABP) and transported 
to the nucleus where it binds to its 
receptors (Retinoic Acid 
Receptors (RARs) alpha, beta, 
gamma). RARs form 
heterodimers with Retinoic X 
Receptors (RXRs) with a possible 
48 combinations.  These bind 
RAR and RXR response elements 
(RARE and RXRE) and initiate 
transcription of genes containing 
these response elements such as 
TGF-β. Initiation of transcription 
cannot occur unless at-Retinoic 
Acid (ATRA) is bound to RAR. 
RXRs bind to 9-cis-Retinoic Acid 
and also serve as partners for 
several important receptors 
including VDR, peroxisome 
proliferator activated receptor
(PPAR) and thyroid hormone 
(THR). 
Transcription of genes 
involved in regulation of 
proliferation, inflammation….
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The high levels of RALDH2 observed in hyperplasia secondary to chronic renal 
failure may be a consequence of the elevated Vitamin A levels reported in patients 
with chronic renal failure (Ha et al. 1996). High levels of RALDH2 were also found 
in some of the HRPT2 class tumours, however the Vitamin A status of HPT-JT 
affected individuals is unknown. These levels would be of interest to measure, but are 
beyond the scope of this thesis. Alternately, elevated RALDH2 may be a 
physiological response to elevated PTH levels in hyperparathyroidism, however this 
was not observed in the Adenoma class. 
 
 Reduced levels of RALDH2 relative to Normal as well as to other tissue types 
indicated by UHR expression, were observed in the Adenoma class and the sporadic 
carcinomas in the HRPT2 class (Figure 6.7 and Table 6.6). The results described in 
this chapter in addition to previously reported findings regarding ATRA (Liu et al. 
1996) and the loss of expression of some retinoic acid signalling components in 
parathyroid adenomas (Melhus et al. 2001) (reviewed in section 1.5.12) suggest that 
RALDH2 is down-regulated in adenomas. This may be a secondary effect. 
Alternately, these results may provide support for a hypothesis that RALDH2 is lost 
in sporadic adenoma, and that this gives rise to monoclonal populations that may be 
distinguished by their lack of RALDH2 staining. This loss or down-regulation was 
not apparent in the outlier adenomas 82A (Figure 6.13B4) and 101A suggesting that 
they may be polyclonal in nature. Several hyperplastic glands with nodular elements 
showed strikingly contrasting staining between the nodules (postulated here as 
monoclonal) which stained negative, and the surrounding (likely polyclonal) 
positively stained tissue (Figure 6.13B1&3). Further circumstantial support for this 
hypothesis comes from metaphase CGH data. RALDH2 is located on chromosome 
15q21.2 and loss at 15q is a common finding in sporadic adenomas (Tables 1.2 and 
5.6B). The presence of inactivating RALDH2 mutations and LOH in parathyroid 
adenomas would confirm a major role for RALDH2 in the development of these 
tumours. This work however, is beyond the scope of the work in this thesis.  
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6.4.10 Putative biomarker VCAM1 
The 2 further molecules studied, PGP9.5 (UCHL1) and VCAM1, were both highly 
expressed only in the HRPT2 class (Figure 6.18). VCAM1 is a member of the 
immunoglobulin gene superfamily. It is involved in pro-inflammatory response to 
injury and binds circulating monocytes and lymphocytes expressing specific integrins, 
following their recruitment from the bloodstream to sites of tissue injury (Bochner et 
al. 1991). VCAM1 expression is induced by TNFα under the mediation of p38MAP 
kinase (Ju et al. 2002). TNFα activates VCAM1 via two NFκβ binding sites in the 
VCAM1 promoter region. Cell-type specificity may be modulated by additional 
octomer elements in the promoter (Iademarco et al. 1993). Increased expression of 
VCAM1 leads to increased signalling between cells and induction of pro-
inflammatory chemokines including CXCL13. VCAM1 has also been shown to bind 
tumour cells suggesting a role in metastasis (Rice and Bevilacqua 1989). The IHC 
results showed the expression of VCAM1 primarily in the regions surrounding 
vascular endothelium. Increased levels of VCAM1 have also been reported in 
astrocytomas (Boon et al. 2004) and conjunctival melanomas (Anastassiou et al. 
2004).  
 
The increased expression of VCAM1 in the HRPT2 class suggests an association 
between inflammation and parathyroid malignancy or malignant potential. Parallels 
between inflammation and malignancy are evident in many cancers with complex 
chemokine networks that influence the immune-cell infiltration of a tumour, as well 
as tumour cell growth, survival and migration, and angiogenesis (reviewed in 
Balkwill 2004). 
 
6.4.11 Putative biomarker UCHL1 
PGP9.5 (UCHL1) is a component of the ubiquitin-proteasome pathway of 
intracellular protein degradation. It is a de-ubiquitinating enzyme involved in both the 
processing of pro-ubiquitinated gene products, and in the release of ubiquitin from 
tagged proteins. This enzyme can either accelerate proteolysis through the release of 
free ubiquitin or inhibit it by removing the ubiquitin moieties from mistakenly tagged 
proteins (reviewed by Ciechanover 1998). Ubiquitin-mediated proteolysis is the major 
mechanism of degradation of cell cycle regulator proteins (Ciechanover 1998).  
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The transcription factor b-Myb is a known substrate of the ubiquitin-proteasome 
pathway (Charrasse et al. 2000) and has recently been shown as a likely stimulator of 
UCHL1 (Long et al. 2003). This stimulation may in turn liberate b-Myb from 
proteolytic regulation with the resulting overexpression contributing to tumorigenesis 
by acceleration of the cell cycle.  
 
PGP9.5 (the protein product of UCHL1) is expressed in neuronal and neuroendocrine 
tissues (Wilson et al. 1988) and has been shown to be expressed during the embryonic 
development of the parathyroid glands in the rat (Luts and Sundler 1997). Highly 
increased expression has been reported in lung cancer and the frequency of this 
expression associated with advanced staging of the cancer (Hibi et al. 1999; Chen et 
al. 2002; Kakinuma et al. 2003). High expression has also been reported in colorectal 
cancer (Yamazaki et al. 2002), oesophageal squamous cell carcinoma (Takase et al. 
2003), medullary thyroid carcinoma (Takano et al. 2004) and pancreatic cancer (Tezel 
et al. 2000). Co-localisation and interaction of PGP9.5 and p27 has been reported in 
lung cancers, suggesting PGP9.5 degradation of p27 (Caballero et al. 2002). Low 
levels of p27 in colorectal cancer have been correlated with aggressiveness (Loda et 
al. 1997) in these tumours and also attributed to activation of the ubiquitin system. 
Reduced p27 expression has also been reported parathyroid carcinomas (Erickson et 
al. 1999; Stojadinovic et al. 2003).  
 
The overexpression of PGP9.5 observed in the HRPT2 class is in agreement with the 
findings in other neuroendocrine carcinomas. This overexpression may be involved in 
the dysregulation of expression of cell cycle proteins (Figure 1.3) such as the reduced 
expression of p27. In addition, it may also have a role in the overexpression of cyclin 
D1, which is found in many parathyroid tumours, and for which an oncogenic role in 
parathyroid tumorigenesis has been demonstrated (reviewed in 1.5.5). 
 
6.4.12 Conclusions 
In conclusion, the genes and corresponding proteins investigated in this chapter have 
been shown to be significant and putative biomarkers for different pathological 
classes of parathyroid tumours. Classification of parathyroid lesions is of importance 
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to clinical management of HPT-affected patients. This classification is dependent on 
the histopathological diagnosis which, however, is inherently difficult because of 
overlaps in the histopathological criteria (reviewed in section 1.4). The discriminatory 
positive immunostaining of the proteins in this study (in particular PGP9.5, VCAM1 
and RALDH2) for different parathyroid lesions is amenable to inclusion in routine 
histopathological assessment of parathyroid lesions. These proteins may provide 
valuable additional diagnostic information for the management of HPT-affected 
individuals. Assessment of these biomarkers in a larger cohort is warranted but 
beyond the scope of this thesis. 
 
The expression pattern for VCAM1 and PGP9.5 suggest that these two molecules are 
strongly influenced by the presence of a HRPT2 mutation. It would be of interest to 
assess these molecules, their functions and their interactions in hrpt2-null mice or in-
vitro knock-out models once these are developed.  
 
RALDH2 has been shown to be able to discriminate between adenoma and 
hyperplasia. The expression levels of both RALDH2 and CD200 appear to be 
independent of the presence of a HRPT2 mutation. The over-expression of these 2 
molecules may be a physiological response to the metabolic imbalance leading to 
secondary hyperplasia. Low expression of RALDH2 was observed in adenomas 
suggesting loss of RALDH2 may have a role in the development on these tumours. 
Mutational investigation of RALDH2 in sporadic tumours may substantiate or refute 
this hypothesis. The differential expression of these molecules in parathyroid tumours, 
and the postulated mechanisms of action described, suggest that inflammation, the 
retinoic acid signalling and the ubiquitin-proteasome degradation pathways may be 
important contributors to parathyroid tumorigenesis that warrant further investigation. 
 
   - 247 - 
 
 
 
 
SEVEN 
 
 
Summary and future directions 
 
 
7 .1  OVERVIEW 
HPT, a disease of the parathyroid glands, is a common endocrinopathy characterised 
by calcium insensitive hypersecretion of parathyroid hormone, and increased cell 
proliferation. While approximately 95% of tumours associated with primary HPT are 
sporadic, insights into the genetic events associated with these tumours have been 
gleaned from the study of both idiopathic and the familial syndromes in which HPT 
occurs (Marx et al. 2002).  
 
Prior to the commencement of the work for this thesis, the genes associated with the 
familial syndromes MEN 1 and 2 had been identified. Affected individuals in MEN 1 
or 2 families harbour germline mutations in MEN1 or RET respectively (Donis-Keller 
et al. 1993; Chandrasekharappa et al. 1997; Lemmens et al. 1997). Somatic mutations 
in MEN1, but not in RET have also been found in some tumours from patients with 
sporadic adenomas. Further, loss of the wild type allele at the MEN1 locus 11q13 is 
common in MEN 1-associated parathyroid tumours and sporadic parathyroid 
   - 248 - 
adenomas (reviewed in section 1.5.4). These findings indicate a role for MEN1 and 
the protein it encodes, menin, as a tumour suppressor in the formation of both MEN 1 
and sporadic benign parathyroid tumours. Overexpression of cyclin D1 protein in both 
benign and malignant tumours, not necessarily in association with PTH-cyclin D1 
rearrangement, has also indicated a role for cyclin D1 in parathyroid tumorigenesis 
(reviewed in section 1.5.5).  
 
At the time of commencement of this candidature, the genes for the familial 
syndromes, HPT-JT and FIHP, designated HRPT2 and HRPT1 respectively, had not 
been identified. HRPT2 had been localised to 1q24-32, and the finding of allelic loss 
at this locus in a small number of HPT-JT associated tumours and sporadic adenomas, 
hinted at a tumour suppressor role for this gene, similar to that for MEN1 (reviewed in 
section 1.5.10). However, whether in fact FIHP was a separate entity was uncertain 
following reports of germline MEN1 mutations in some apparent FIHP kindreds 
(reviewed in section 1.3.2.2.4). 
 
While inactivation of MEN1, activation of RET, and translocation and overexpression 
of cyclin D1 have been shown to provide the initiating triggers, or act as gatekeepers 
for the development of familial MEN-associated tumours and some sporadic 
adenomas, the underlying events leading either directly, or indirectly to the 
development of a large proportion of parathyroid lesions are still largely unknown. 
Subsequent genetic events which drive or enhance neoplastic transformation by the 
generation of an abnormal stromal environment such as the promotion of cellular 
immunity and angiogenesis, are also largely unknown.  
 
From a clinical perspective, while the treatment for familial as well as sporadic 
tumours, tertiary and some cases of unresolved secondary HPT includes 
parathyroidectomy, the extent of surgery and the follow-up monitoring regime, are 
dependent on accurate clinical and histopathological classification of the tumour. 
However, overlaps in histopathological and morphological features confound 
distinctions between the three main classifications of adenoma, hyperplasia and 
carcinoma. As a result, the histopathological diagnosis of tumours of the parathyroid 
glands remains challenging, and in a minority of cases, may be retrospective based on 
recurrence and development of distant metastasis.  
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7.2 HRPT2 MUTATION: A MARKER OF MALIGNANCY  
In December 2002 (during this candidature) HRPT2, the gene associated with HPT-JT 
was identified (Carpten et al. 2002). Germline mutations were reported in 
approximately 60% of HPT-JT kindreds analysed and also in one of two FIHP 
kindreds. In addition, somatic mutations were reported in two of forty-seven cystic 
parathyroid adenomas studied. In chapter 3 of this thesis, HRPT2 mutation analysis of 
sixty parathyroid tumours, and LOH analysis at the HRPT2 locus at 1q24-32, in 
thirty-nine of these tumours are described. The tumours consisted of familial HPT-JT, 
FIHP, MEN 1, MEN 2A, sporadic adenoma and carcinoma, as well as tumours 
associated with lithium therapy, secondary and tertiary HPT. HRPT2 mutations were 
identified in 100% (4/4) of sporadic carcinomas, but not in any of the other forty-four 
non-familial non-carcinoma tumours. The mutations identified in these tumours are 
all predicted to truncate parafibromin, the protein encoded by HRPT2. In addition, 
one of these carcinomas harboured two truncating mutations, and one carcinoma 
harboured one mutation as well as loss of the wild type allele. These findings are 
consistent with Knudson’s “2-hit” hypothesis (Knudson 1971) and are highly 
suggestive of a role for HRPT2 as a tumour suppressor gene in sporadic parathyroid 
tumorigenesis. 
 
Chapter 3 also describes the finding of germline HRPT2 mutations in all five tumours 
studied from two HPT-JT families and confirmation of a previously identified 
germline mutation in two tumours from one of the two FIHP families studied. These 
results support the findings of Carpten and co-workers (Carpten et al. 2002) that 
mutation of HRPT2 is the primary event in HPT-JT and a subset of FIHP. Of 
additional significance was the finding of a “2nd-hit” in four of these seven tumours 
harbouring germline HRPT2 mutations. Loss of the wild type allele at the HRPT2 
locus was demonstrated in three of these tumours, and one tumour harboured a 
somatic frameshift mutation in addition to the germline mutation.  
 
The findings from this study, which were published in 2003, also hypothesised that 
HRPT2 mutation may lead to parathyroid malignancy, and intragenic mutation of 
HRPT2 was suggested as a marker of parathyroid malignant potential (Howell et al. 
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2003). Since the publication of this study, evidence in support of this hypothesis has 
included the finding of HRPT2 mutations in parathyroid carcinomas from an 
additional fourteen of twenty-two patients (Shattuck et al. 2003; Cetani et al. 2004). 
To date, HRPT2 mutations have been detected in 70% (18/26) of patients with 
parathyroid carcinomas, some of which were determined to be present in the 
germline. In comparison, testing of an additional thirty-five sporadic adenomas has 
identified only one further HRPT2 somatic mutation, suggesting a mutation frequency 
of approximately 2% (3/126, 2 of which had cystic changes) in non-familial, non-
carcinoma lesions, of the parathyroid glands (Carpten et al. 2002; Howell et al. 2003; 
Shattuck et al. 2003; Cetani et al. 2004).  
 
7.3 DHPLC MUTATION SCANNING FOR MEN1 & HRPT2 
The work described in chapter 3 of this thesis, as well as additional reports, have 
established HRPT2 as an important gene for investigation in suspected HPT-JT 
families and patients with apparent sporadic parathyroid carcinomas, but less so in 
FIHP families (Shattuck et al. 2003; Cavaco et al. 2004; Cetani et al. 2004; Simonds 
et al. 2004; Warner et al. 2004).  
 
Chapter 4 describes the development of rapid scanning for mutations in two genes 
implicated in familial HPT, HRPT2 and MEN1. Mutation scanning by DHPLC detects 
heteroduplex species (in addition to homoduplex species) formed due to the presence 
of heterozygous variants with an estimated sensitivity of approximately 95%. It is in 
use for the detection of mutations in a number of tumour suppressor genes, including 
BRCA1, BRCA2 and p53 (Wagner et al. 1999; Gross et al. 2001). DHPLC mutation 
scanning was developed for MEN1 using a set of ten amplicons which covered the 
nine coding exons and flanking intronic regions. These amplicons were assessed using 
DNA samples from forty-six different individuals known to harbour different MEN1 
mutations or variants. All mutations were successfully detected. Unknown mutations 
in a small set of three further individuals scanned using this protocol developed by the 
candidate were successfully identified.  
 
HRPT2 is composed of seventeen exons. Of the forty-one mutations identified to date, 
approximately 80% are located in exons 1, 2 and 7 (Table 4.2). DHPLC mutation 
   - 251 - 
scanning of these three exons, in addition to exon 13 in which several polymorphisms 
have been detected, was developed. DHPLC was shown to not only detect all nine 
mutations assessed, but also delineate these from the polymorphisms identified in 
chapter 3 of this thesis. Following establishment of DHPLC scanning for HRPT2, an 
adolescent with a parathyroid adenoma and a history of recurrent kidney stones was 
diagnosed with HPT-JT by the finding of a germline truncating HRPT2 mutation in 
exon 7 using this technique followed by confirmation with sequencing. This case is 
the first published report of a molecular diagnosis of HPT-JT, and highlights the 
importance of consideration of HTP-JT in adolescents with recurrent kidney stones 
(Howell et al. 2004).  
 
The development of rapid mutation scanning of these two genes implicated in familial 
HPT provides a rapid, sensitive and cost-effective method of assessing prospective 
families, as well as individuals within families with previously identified germline 
mutations.  
 
7.4 GENE EXPRESSION PROFILING  
In chapter 5 of this thesis, microarray analysis complementary to the mutation studies 
is presented. cDNA microarrays were utilised to generate gene expression profiles for 
fifty-three parathyroid specimens from eleven different entities of parathyroid lesions 
as well as for normal parathyroid tissue. Cluster analysis of these profiles identified 
three broad groupings of tumours (Figure 5.3A). Cluster 1 comprised predominantly 
hyperplastic specimens (primary, secondary and tertiary) and also included the normal 
tissue. Cluster 2, which was found to be the most robust of the clusters, consisted of 
tumours which had been identified in chapter 3 of this thesis, as harbouring HRPT2 
mutations. The HPT-JT-associated tumours, both benign and malignant, 2 FIHP-
associated tumours, and sporadic carcinomas, comprised this cluster. Cluster 3 
contained the majority of the sporadic adenoma specimens, three of the five tumours 
clinically classified as tertiary hyperplasia as well as one secondary hyperplasia 
specimen. All of the MEN 1-associated tumours and two FIHP tumours for which 
linkage to the MEN1 locus could not be excluded, also clustered with the sporadic 
adenomas. The distinctive and separate clustering observed, is strongly suggestive 
that parathyroid tumours with somatic HRPT2 mutation, or tumours developing on a 
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background of germline HRPT2 mutation, follow pathways distinct from those 
involved in mutant MEN 1-related parathyroid tumours. The results of this work 
provide strong evidence for an adenoma to carcinoma progression model for 
parathyroid tumorigeneis in the presence of a germline HRPT2 mutation.  
 
Analysis of the microarray data using patented Gene-Rave algorithms identified small 
sets of novel genes able to distinguish between the various tumour sub-types. 
Expression levels of UCHL1 and CD24 individually, and the pairing of VCAM1 and 
PVALB, were each predicted to accurately discriminate HRPT2-associated tumours 
from other tumours. The combination of the expression levels of MOX2 and RALDH2 
was predicted to discriminate adenoma from hyperplasia.  
 
7.5 PUTATIVE BIOMARKERS OF PARATHYROID 
TUMOURS 
Chapter 6 describes the further investigation of four of the Gene-Rave identified 
genes from chapter 5, predicted to have high accuracy of discrimination between 
various parathyroid tumour subtypes. Transcript levels were accurately assessed by 
quantitative real-time PCR, and protein expression assessed by immunohistochemical 
staining for VCAM1, UCHL1 (PGP9.5), RALDH2 and MOX2 (CD200). Transcript 
levels of two additional genes were also assessed: CaSR, important in parathyroid 
function, and HRPT2. A set of twenty-eight specimens from three tumour classes, 
sporadic adenoma, hyperplasia (predominantly secondary) and HRPT2 mutation 
positive (which consisted of HPT-JT-associated tumours and sporadic parathyroid 
carcinomas), as well as a pool of normal tissue were assessed by quantitative PCR. 
The majority of these specimens were also assessed by immunohistochemistry.  
 
Prior to the work in this study, transcript levels in parathyroid tissue had been 
normalised to GAPDH, a gene implicated in a p53 apoptotic pathway (Tatton et al. 
2003) and reported to be regulated by 1,25-(OH)2D (Desprez et al. 1992). For these 
reasons alternative genes for normalisation were sought. Ribosomal 18s was chosen as 
the active reference for normalisation. In addition a novel putative active reference, 
SSR3, identified from the microarray data as it showed uniform expression across the 
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microarrays in all parathyroid tumour subtypes, was found to be a suitable alternative 
active reference for normalisation of transcript levels in parathyroid tissue 
 
The quantitation of HRPT2 transcript expression in parathyroid tumours described in 
this study is the first such report (Figure 6.6B). The results were surprising in that a 
trend of reduced HRPT2 transcript expression in all tumour classes relative to the 
pooled normal was observed, with significantly reduced levels found only in the 
hyperplasia class. These results suggest that HRPT2 expression is integral to normal 
parathyroid function. Recently, immunohistochemical studies of parafibromin, the 
protein encoded by HRPT2, have been published (Tan et al. 2004; Woodard et al. 
2004). Loss of parafibromin immunoreactivity was shown in parathyroid carcinomas 
and HPT-JT-associated tumours relative to other parathyroid tumour types, and 
variability in the intensity of staining was noted for sporadic adenomas and 
hyperplastic tissue. Further studies will be required to clarify the level of expression, 
and ultimately the level of function of this molecule in parathyroid tumours relative to 
normal parathyroid tissue. 
 
Reduced CaSR transcript expression in all tumours relative to the pooled normal 
tissue was also observed (Figure 6.6A), in agreement with previous reports of reduced 
transcript by semi-quantitative methods and reduced protein expression in parathyroid 
tumours (reviewed in section 1.5.7). The results in this study highlight the highly 
significant differences between HRPT2-mutated tumours and other tumours, as well 
as between normal parathyroid tissue and secondary hyperplasia. 
 
VCAM1 and UCHL1 (PGP9.5) were found to be significantly overexpressed in 
tumours harbouring an HRPT2 mutation at both the transcript and protein level. These 
two molecules are suggested as putative biomarkers for the discrimination of sporadic 
carcinoma or HPT-JT-associated tumours worthy of further investigation. RALDH2 
transcript and protein were highly significantly overexpressed in the hyperplasia class 
relative to the adenoma class, and this molecule is suggested as a putative biomarker 
for discrimination of these classes of parathyroid tumours. The differential expression 
patterns observed for all of these molecules suggest that inflammation, retinoic acid 
signalling and the ubiquitin-proteasome degradation pathways may be contributors to 
parathyroid tumorigenesis.  
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7.6 CONCLUSIONS 
The work described in this thesis has contributed to the understanding of parathyroid 
lesions of HPT and the diagnosis and prognosis of affected individuals. During this 
candidature, constitutive mutation of HRPT2 was associated with HPT-JT (Carpten et 
al. 2002). The work presented in this thesis identified the strong association of HRPT2 
mutation with sporadic parathyroid malignancy (Howell et al. 2003). Microarray 
analysis of parathyroid tumours demonstrated the close relationship between sporadic 
parathyroid carcinomas and HPT-JT associated tumours, both benign and malignant 
(Haven, Howell et al. 2004a). These results are highly suggestive of a malignant 
potential for apparent benign HPT-JT-associated lesions, highlighting the need for 
vigilant monitoring of all HPT-JT affected individuals. Novel putative biomarkers for 
different parathyroid tumour subtypes have also been identified. These biomarkers 
may assist in the accurate diagnosis and prognosis of parathyroid disease. Further 
studies of these putative markers may provide additional clues as to the processes 
involved in the development of these tumours, and may identify some of these genes 
as novel molecular targets for future therapeutics to treat this disease. In addition, 
assays for rapid mutation screening of two genes, MEN1 and HRPT2, now known to 
have significant roles in the development of both and sporadic parathyroid 
tumorigenesis, have been developed as part of this thesis.  
 
7.7 FUTURE DIRECTIONS 
Despite the progress in the understanding of the molecular genetics of HPT, many 
questions remain unanswered. Mutation of HRPT2 has been shown to be associated 
with the formation of sporadic parathyroid carcinomas as well as HPT-JT syndrome, 
and evidence is accumulating to pointing to a role for this gene as a tumour 
suppressor (chapter 3 of this thesis, Carpten et al. 2002; Shattuck et al. 2003; Cetani et 
al. 2004). However, the functions of parafibromin, the protein encoded by HRPT2 
remain to be elucidated.  
 
Recently, HRPT2 has been localised to both the cell nucleus and cytoplasm (Tan et al. 
2004; Villablanca et al 2004a; Woodard et al. 2004). Nuclear localisation was 
predicted from examination of its sequence (Figure 3.1). Similarity to yeast protein 
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Cdc73 and a putative binding site for the serine-threonine kinase PDK1 have likewise 
been noted from sequence analysis (Figure 3.1). The microarray analysis of 
parathyroid lesions described in chapter 6 of this thesis has revealed over 300 genes 
significantly over- or under-expressed in HRPT2 mutated lesions relative to non-
HRPT2 mutated parathyroid lesions (Appendix 5.2). The study of these genes, whose 
expression appear to be influenced by HRPT2, as well as PDK1-related pathways and 
Cdc73 in yeast may provide useful starting points for the functional interrogation of 
parafibromin. Further studies clarifying parafibromin’s localisation to different 
subcellular compartments and the identification of its interacting partners will 
highlight additional avenues of investigation into the pathways through which this 
gene / protein functions and likely influences parathyroid cell growth and death.  
 
The recent generation of antibodies to parafibromin (Tan et al. 2004; Villablanca et al 
2004a; Woodard et al. 2004) will enable further investigation of the consequences of 
the identified mutations, as well as its expression in a variety of normal tissues. The 
generation of additional tools, such as in vitro and in vivo models able to selectively 
abrogate HRPT2 expression by siRNA and transgenic animal technologies, will 
rapidly advance the study and understanding of HRPT2 / parafibromin function and 
its role in parathyroid tumorigenesis.  
 
The measurement of transcript levels in parathyroid tumour sub-types by real-time 
quantitative PCR in chapter 6 of this thesis, uncovered a trend towards reduced 
HRPT2 expression in all sub-types investigated (Figure 6.6B: adenoma, hyperplasia 
and HRPT2-mutated) relative to normal parathyroid tissue. This trend is not entirely 
apparent in the recent immunohistochemical studies of parafibromin expression in 
parathyroid tumours (Tan et al. 2004; Villablanca et al 2004a; Woodard et al. 2004). 
Additional studies of transcript levels in parathyroid tumours as well as in larger pools 
of normal tissue are warranted. Further work may also include investigation of the 
influence of epigenetic events on the expression of HRPT2 in parathyroid tumours 
and normal tissue. Examination of the CpG island in the HRPT2 promoter region, 
(noted in Figure 3.1), for evidence of hypermethylation has not been reported, but is 
important to either exclude or identify, as this may change current perspectives of the 
consequences of loss of function of HRPT2. 
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While the functions of parafibromin are yet to be elucidated, it is clear that 
identification of HRPT2 mutations is of critical clinical importance and will influence 
patient management and monitoring, as noted in section 4.4.3.1 (Howell et al. 2004). 
In chapter 4, assays for the rapid detection of mutations (and polymorphisms) in 
HRPT2 as well as MEN1 were established and validated. These will allow efficient, 
automated screening of these genes. Currently, mutations are identified in only 60% 
of HPT-JT and 70% of MEN 1 kindreds (section 4.1.1). More efficient DHPLC 
screening will allow resources to be directed to other strategies such as screening for 
large exon-spanning deletions and rearrangements using multiplex ligation-dependent 
probe amplification (MLPA), which has been reported for a number of genes 
(Hogervorst et al. 2003; Hartmann et al. 2004). To date, these large scale germline 
deletions are rare in MEN1, and have not been reported for HRPT2.  
 
With the identification of HRPT2, intensive sequence interrogation of this gene (in 
addition to MEN1 and CaSR) has been undertaken in FIHP kindreds. However, to 
date, HRPT2 mutations have only been found in 7% (4/57) of FIHP kindreds studied 
(chapter 3 of this study, Carpten et al. 2002; Cetani et al. 2004; Simonds et al. 2004; 
Villablanca et al. 2004; Warner et al. 2004). While improvements in mutation 
detection, such as those described above, may clarify some current diagnoses of FIHP 
as variants of HPT-JT (or MEN 1), it is unlikely to account for all of these cases. 
Whether FIHP is a distinct entity caused by the elusive HRPT1 gene remains 
unresolved. Genetic and epigenetic investigation of further genes at 1q25, 11q13 or at 
other loci identified by CGH (Table 1.4) may assist in the identification of further 
genes involved in both familial and sporadic parathyroid tumorigenesis. 
 
Studies in families presenting with familial hypercalcaemia but with no mutations 
detected in CaSR at 3q, have identified strong linkage to the chromosomal intervals 
19q13 and 19p13 (Heath et al. 1993; Lloyd et al. 1999). Novel CGMA analysis of the 
microarray data from fifty-three parathyroid lesions described in chapter 5 of this 
thesis (Figure 5.10), has predicted both 19q and 19p as regions of gains and 
overexpression in all parathyroid tumour sub-types. In addition, a number of genes in 
these regions were found to be significantly differentially expressed in the HRPT2-
mutated tumours (Appendix 5.2). These genetic data suggest that investigation of 
genes in these regions may identify genes in addition to CaSR that are important in 
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parathyroid gland function by their involvement in the mediation of calcium 
homeostasis. 
 
Of the many significantly differentially expressed genes identified in chapter 5 of this 
thesis, nine were identified by Gene-Rave algorithms as discriminators with high 
predictive accuracy of parathyroid tumour sub-type classification (section 5.3.3). 
Validation of four of these nine genes was performed in chapter 6 of this thesis. The 
demonstrated ability of these genes to classify tumour sub-types in this study warrants 
larger studies for both these genes, as well as the additional five genes not 
investigated in this study. Further studies are also warranted to determine whether 
these putative biomarkers identified in tumour tissue, if secreted, are also 
differentially expressed in the serum of HPT-affected individuals. This would enable 
pre-surgical diagnosis and the instigation of appropriate surgical and non-surgical 
strategies. The report of increased levels of Vitamin A in patients with chronic renal 
failure, who may develop secondary HPT, hints that this may be the case for at least 
one of the putative biomarkers (RALDH2) (Ha et al. 1996).  
 
Assessment of these genes using genomic tools such as in vitro and in vivo models of 
selective abrogation of HRPT2, will assist in determining whether these putative 
biomarkers of parathyroid lesions have primary or secondary roles in the formation of 
these lesions. Understanding the roles of these putative biomarkers in parathyroid 
tumorigenesis will ultimately determine whether these novel genes may be useful 
molecular targets for future therapeutics to treat the different clinical presentations of 
hyperparathyroidism.  
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The aim of this research project is to isolate and characterise new genes associated
with the formation of parathyroid tumours leading to hyperparathyroidism. Isolation
of a gene or genes will provide a better understanding of the reasons for the formation
of these tumours and will assist in developing new treatments. 
In order to detect the presence of any gene abnormalities, the genetic material (DNA)
from the parathyroid tumour will be compared with the DNA from the blood.
Differences between the blood DNA and the tumour DNA will show which genes
may be involved in tumour development.  Therefore, we need both tumour and blood
samples from people who have had parathyroid surgery. (If fresh frozen tissue is not
available, paraffin-embedded tissue routinely stored independently of this project, will
be requested from the pathology department.)
If one or more blood relatives (parents, siblings, cousins, aunts, uncles, children) also
have a history of parathyroid tumours, comparison of DNA from affected and
unaffected family members will greatly assist in determining the significance of any
gene abnormalities detected.  If there is a positive family history for parathyroid
tumours, permission to approach family members will be requested from the
individual undergoing parathyroid surgery.  If, and only if permission is granted,
family members will be asked to donate 20mL of blood for DNA analysis. Family
members under the age of 18 years (children) will not be approached, unless and until
the parents or guardians of that child have been offered counselling and have given
informed consent. Wherever possible, consent from the child will also be sought, with
inclusion in the project occurring only following such informed consent from the
child.
It is possible that this research may identify information which may be of clinical
relevance to the participant.  Participants will be asked whether or not they would like
to be contacted if such information is found. However, before any results of clinical
relevance can be issued, informed consent for diagnostic testing must be obtained
from the participant, and further blood samples collected and tested.
The procedure will involve:
For the individual undergoing parathyroid surgery:
1. After routine removal of the tumour, a small piece of the tumour will be stored in
liquid nitrogen for the research project.
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2. Either before, during or after surgery, 20mL of blood (approximately 4 teaspoons)
will be collected into EDTA tubes.
3. There is a possibility of being contacted by phone or by letter in the near future by
one of the researchers to arrange for an additional blood sample to be collected.
For family members of the individual undergoing parathyroid surgery:
4. 20mL of blood (approximately 4 teaspoons) will be collected into EDTA tubes.
5. There is a possibility of being contacted by phone or by letter in the near future by
one of the researchers to arrange for an additional blood sample to be collected.
There are some possible adverse effects:
Blood collection:
1. Some people may feel faint when blood is taken.
2. Slight bruising at the site of the blood test may occur.
Recruitment of other family members:
1. With your permission, your condition will become known to other family
members. (Relevant to patient undergoing parathyroid surgery only.)
2. Non-paternity or non-maternity of a presumed natural parent may be revealed.
3. If a genetic abnormality common to all affected family members is found, the
relative risk of a non-affected family member developing a similar condition may
be able to be predicted.
You may change your wishes, regarding obtaining information of personal clinical
relevance (should this eventuate), at any time by contacting the researchers. 
Any findings generated by this research project will not be released to a third party
without your permission.
Your involvement in this research project may be terminated at any time upon your
request and your fresh frozen tumour sample and blood samples destroyed.
If you require any further information, please do not hesitate to contact:
Dr Deborah Marsh, Dr Anne Nelson, Ms Viive Howell or Professor Bruce Robinson
on  9926 7176, or Professor Leigh Delbridge on 9926 7014.
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                    Cancer Genetics Department
Telephone:(61 2) 9926 7176
Fax: (61 2) 9926 8484
Consent Form to Participate in a Research Project 
for patients undergoing parathyroid surgery
I, _____________________________________________with date of birth _____________________
(name of participant)
of ______________________________________________     ________________________________
(street)                                    (suburb/town)  
   
  _______________________________________ and telephone number _________________________ 
       (state & postcode)
have been invited to participate in a research project entitled:
MOLECULAR GENETICS OF HYPERPARATHYROIDISM
In relation to this project I have read the Patient Information Sheet and have been informed of the following points:
1. Approval has been given by the Human Research Ethics Committee (HREC) of Northern Sydney Health.
2. The aim of the project is to identify and characterise gene abnormalities that result in parathyroid tumour
formation leading to hyperparathyroidism.  Isolation of such genes will provide a better understanding of the
reasons for parathyroid tumour formation and potentially new treatment strategies may be developed.
3. The results obtained from the study may or may not be of direct benefit to my medical management.
4. The procedure will involve collection of 20mL of blood (about 4 teaspoons) into EDTA tubes.  This blood will
be analysed, along with fresh frozen tissue, or if this is not available, paraffin-embedded tissue, for the presence
of any genetic abnormalities associated with parathyroid tumours.  I accept that I may be approached in the
future if additional blood is necessary. 
5. (Delete and initial if not relevant or if permission is denied) I give permission to approach my relatives with
and without a history of parathyroid tumours, to participate in this project. I understand that in doing so, my
condition will become known to other family members.  I also understand that participation of other family
members may reveal non-paternity or non-maternity of a presumed parent.  If I choose not to give such
permission, it will not affect my medical care.
6. There are some possible adverse effects or risks related to this project which include:
• some patients may feel faint when blood is taken;
• slight bruising may occur at the site of the blood test.
Date: _______________________________ Witness: __________________________________
(Please print name)
Signature: ___________________________ Signature: __________________________________
(of participant) (of witness)
Investigator’s Signature: _______________________________________________________________
Kolling Institute of Medical Research
Royal North Shore Hospital, St Leonards, NSW 2065, Australia
Phone: (61 2) 9926-8486  Fax: (61 2) 9926-8484
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Kolling Institute of Medical Research, 
Royal North Shore Hospital
Consent Form to Participate in a Research Project
for patients undergoing parathyroid surgery
MOLECULAR GENETICS OF HYPERPARATHYROIDISM
7. My involvement in this project may be terminated at any time I desire. 
8. Should I develop a problem which I suspect may have resulted from my involvement in this project, I am
aware that I may contact – 
• Dr Deborah Marsh (Researcher)
• Dr Anne Nelson (Researcher)  9926 7176
• Ms Viive Howell (Researcher)
• Professor Bruce Robinson (Endocrinologist)
• Professor Leigh Delbridge (Surgeon)  9926 7014
9. Should I have any problems or queries about the way in which the study was conducted, and I do not feel
comfortable contacting the research staff, I am aware that I may contact the Patient Representative who is an
independent person within the Hospital on 9926 7612.
10. I can refuse to take part in this project or withdraw from it at any time without affecting my medical care.
11. Participation in this project will not result in any extra medical and hospital costs to me.
12. (Delete and initial if you choose not to be informed) I would like to be contacted in the event that this research
identifies information which may be of clinical relevance to myself or my family. I understand that I may
change my choice at any time by notifying the researchers. I accept that in order to be contacted, I will notify
the researchers of any change in my address.
13. If the research findings using my samples or information regarding my medical history are published in a
scientific journal, my identity will not be revealed.
After considering all these points, I accept the invitation to participate in this project.
I also state that I have/have not participated in any other research project in the past 3 months.
If  I have, the details are as follows:
_______________________________________________________________________________________
Dr _____________________________________________  on  ____________________________________
(phone and page numbers)
Date: _______________________________ Witness: ______________________________________
(Please print name)
Signature: ___________________________ Signature: ______________________________________
(of participant) (of witness)
Investigator’s Signature: _____________________________________________________________
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Cancer Genetics Department
Telephone:(61 2) 9926 7176
Fax: (61 2) 9926 8484
Consent Form to Participate in a Research Project 
for relatives of patients undergoing parathyroid surgery
I, __________________________________________________with date of birth_________________
(name of participant)
of _______________________________________     _______________________________________
(street) (suburb/town)
     __________________________________ and telephone number  ____________________________
       (state & postcode)
being the ____________________________________________________________________________
                (relationship to patient undergoing parathyroid surgery, eg, brother, cousin, son)
of__________________________________________________________________________________
      (name of patient undergoing parathyroid surgery)
 have been invited to participate in a research project entitled:
MOLECULAR GENETICS OF HYPERPARATHYROIDISM
In relation to this project I have read the Patient Information Sheet and have been informed of the following points:
1. Approval has been given by the Human Research Ethics Committee (HREC) of Northern Sydney Health.
2. The aim of the project is to identify and characterise gene abnormalities which result in parathyroid tumour
formation leading to hyperparathyroidism.  Isolation of such genes will provide a better understanding of the
reasons for parathyroid tumour formation and potentially new treatment strategies may be developed.
3. The procedure will involve collection of 20mL of blood (about 4 teaspoons) into EDTA tubes.  This blood will be
analysed (along with fresh frozen tissue) for the presence of any genetic abnormalities associated with parathyroid
tumours.  I accept that I may be approached in the future if additional blood is necessary. 
4. I understand that participation may reveal non-paternity or non-maternity of a presumed parent. 
Date: _______________________________ Witness: ___________________________________
(Please print name)
Signature: ___________________________ Signature: ___________________________________
(of participant) (of witness)
Signature: ___________________________ Guardian: ___________________________________
(of guardian if participant is under 18 years of age) (Please print name)
Investigator’s Signature: ________________________________________________________________
Kolling Institute of Medical Research
Royal North Shore Hospital, St Leonards, NSW 2065, Australia
Phone: (61 2) 9926-8486  Fax: (61 2) 9926-8484
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Kolling Institute of Medical Research,
Royal North Shore Hospital
Consent Form to Participate in a Research Project
for relatives of patients undergoing parathyroid surgery
MOLECULAR GENETICS OF HYPERPARATHYROIDISM
5. There are some possible adverse effects or risks related to this project which include:
• some patients may feel faint when blood is taken;
• slight bruising may occur at the site of the blood test.
6. My involvement in this project may be terminated at any time I desire. 
7. Should I develop a problem which I suspect may have resulted from my involvement in this project, I am aware
that I may contact – 
• Dr Deborah Marsh (Researcher)
• Dr Anne Nelson (Researcher)  9926 7176
• Ms Viive Howell (Researcher)
• Professor Bruce Robinson (Endocrinologist)
• Professor Leigh Delbridge (Surgeon)  9926 7014
8. Should I have any problems or queries about the way in which the study was conducted, and I do not feel
comfortable contacting the research staff, I am aware that I may contact the Patient Representative who is an
independent person within the Hospital on 9926 7612.
9. Participation in this project will not result in any extra medical and hospital costs to me.
10. (Delete and initial if you choose not to be informed) I would like to be contacted in the event that this research
identifies information which may be of clinical relevance to myself or my family. I understand that I may change
my choice at any time by notifying the researchers. I accept that in order to be contacted, I will notify the
researchers of any change in my address.
11. If the research findings using my samples or information regarding my medical history are published in a scientific
journal, my identity will not be revealed.
After considering all these points, I accept the invitation to participate in this project.
I also state that I have/have not participated in any other research project in the past 3 months.
If  I have, the details are as follows: ________________________________________________________
Dr _____________________________________________  on  _________________________________
(phone and page numbers)
Date: _______________________________ Witness: ____________________________________
(Please print name)
Signature: ___________________________ Signature: ____________________________________
(of participant) (of witness)
Signature: ___________________________ Guardian: ____________________________________
(of guardian if participant is under 18 years of age) (Please print name)
Investigator’s Signature: ___________________________________________________________
Appendix 3.1 Primer sequences for microsatellites at 1q24-32 used in the work
described in section 3.2.4. Information derived from UniSTS at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unists and Kong et al 2002; "bp" is the predicted
minimum size of the amplicon in base pairs.
Microsatellite ID Forward primer (5'-3') Reverse primer (5'-3') bp
D1S238* ctaccatctcactttctccttcc taagcaaatgacagagagtcatcc 170
D1S422 ctatcatccatggggtatagc gctttatcactaatgtttccca 241
D1S2625** gctctaatcatcccaccgc tcctctgaactctcacagtgacttg 185
D1S533† catcccccccaaaaaatata ttgctaatcaaataacaatggg 193
D1S2757‡ ttttttaatgactgaccagtg tgccttctgctatgttg 223
D1S2794§ caggtggtgctgtgaatag caaatgttgtgaagcagatg 187
Legend: The microsatellites are also known as:
* AFM205xg1, SHGC-37, stSG704;
** A124ZD9, AFMa124zd9, HSA124ZD9, SHGC-21379, W2947, stSG14329;
† CHLC.809, CHLC.GATA10C02, CHLC.GATA10C02.809, CHLC.GATA10C02.P6886, GATA-D1S533,
GATA-P6886, SHGC-4044;(locus association with aggressive localised periodontitis);
‡ AFMb309xe1, B309XE1, HSB309XE1, SHGC-19945, W3244, stSG14440;(locus association with
branchiootic syndrome 2);
§ AFMb354ze1, B354ZE1, HSB354ZE1, SHGC-21380, W3288, stSG14470.
A4
Appendix 3.2 HRPT2 transcript AF312865 from 5’UTR to 3’UTR. With the exception of 
the predicted start and stop codons, which are in upper case black text, the exons alternate 
between upper case red text and lower case blue text to facilitate orientation. Primers, also listed 
in Table 3.1, are underlined, and primer pairs are highlighted in the same colour. The first 
amplicon, highlighted in yellow has 2 alternate forward primers.  
 
tgctgttggttcgtcgcggcggcgaaggaggaggaggaagagggcgaggcgacaagagaagaag
gaggcaggcgcggcggcagcggcggcgccccgagccggcggaggcgaggggggggaagATGGCG
GACGTGCTTAGCGTCCTGCGACAGTACAACATCCAGAAGAAGGAGATTGTGGTGAAGGGAGACG
AAGTGATCTTCGGGGAGTTCTCCTGGCCCAAGAATGTGAAGACCAACTATGTTGTTTGGGGgac
tggaaaggaaggccaacccagagagtactacacattggattccattttatttctacttaataac
gtgcacctttctcatcctgtttatgtccgacgtgcagctACTGAAAATATTCCTGTGGTTAGAA
GACCTGATCGAAAAGATCTACTTGGATATCTCAATGGTGAAGCGTcaacatcggcaagtataga
cagaagcgctcccttagaaataggtcttcagcgatctactcaagTCAAACGAGCTGCAGATGAA
GTTTTAGCAGAAGCAAAGAAACCACGAATTGAGgatgaagagtgtgtgcgccttgataaagaga
gattggctgcccgtttggagggtcacaaagaagggattgtacagactgaacagattagGTCTTT
GTCTGAAGCTATGTCAGTGGAAAAAATTGCTGCAATCAAAGCCAAAATTATGGCTAAGAAAAGA
TCTACTATCAAGACTGATCTAGATGATGACATAACTGCCCTTAAACAGAGGAGTTTTGTGGATG
CTGAGGTAGATGTGACCCGAGATATTGTCAGCAGAGAGAGAGTATGGAGGACACGAACAACTAT
CTTACAAAGCACAGGAAAGaatttttccaagaacatttttgcaattcttcaatctgtaaaagcc
agagaagaagggcgtgcacctgaacagcgacctgccccaaatgcagcacctgtgGATCCCACTT
TGCGCACCAAACAGCCTATCCCAGCTGCCTATAACAGATACGATCAGGAAAGATTCAAAGGAAA
AGAAGaaacggaaggcttcaaaattgacactatgggaacctaccatggtatgacactgaaatct
gtaacgGAGGGTGCATCTGCCCGGAAGACTCAGACTCCTGCAGCCCAGCCAGTACCAAGACCAG
tttctcaagcaagacctcccccaaatcagaagaaagGATCTCGAACACCCATTATCATAATTCC
TGCAGCTACCACCTCTTTAATAACCATGCTTAATGCAAAAGACCTTCTACAGGACCTGAAattt
gtcccatcagatgaaaagaagaaacaaggttgtcaacgagaaaatgaaactctaatacaaagaa
gaaaagaccagatgcaaccagggggcactgcaattagtgttacagtaccttatagagtagtaga
ccagccccttaaacttatgcctcaagactgGGACCGCGTTGTAGCCGTTTTTGTGCAGGGTCCT
GCATGGCAGTTCAAAGGTTGGCCATGGCTTTTGCCTGATGGATCACCAGTTGATATATTTGCTA
AAAttaaagccttccatctgaagtatgatgaagttcgtctggatccaaatgttcagaaatggga
tgtaacagtattagaactcagctatcacaaacgtcatttggatagaccagtgttcttacggttt
tgggaaacattggacagGTACATGGTAAAGCATAAATCGCACTTGAGATTCTGAattatttggc
tcctccatttctggaaattgagactcaagctttatgaatttatcaagaacttaaaaatgaagaa
ggtcacagattgatcttttataagaccttatttgatgctttgtgcttcaaggagtgatacctgt
catccatataagcaaactttttggcttacaactatttttttaatattagccttctagtctgtaa
tggaaattgtatattttgatagaagttttttctccattggttaaattagcattacttaaaattt
gtttctttagaaaataaatgcaggttataaatgtgtgtatatttagagattataaggctctctg
agccatcttctgatttttcattgctctataattctttttactgaaaatactatgttatgaatgg
tattaaattttagtctctggaacatccaaaaccaagcaaagggatgtgactattttgaatgaat
cagaatgtcaacttgtatgtacactatatctacacttactcattatttaaaaagaataatgaaa
aatctagatcaattcttcaatttgattgaactgttcagccttttcaagatttctttatttacaa
atgattacatttaaatgaatgtacattcttctcactgactttggtgattttgaacctagaatga
tgtgtttctatctgtaatatctttccatttgaaaaaaatctcaaaacacagattaaaaccac 
  A5 
Appendix 3.3 HRPT2 coding and genomic sequence, constructed using information  
from reference sequences NP_078805, AL390863 and AF312865, and sequencing of 
both transcript and genomic sequences performed in this study. The primer pairs for 
each amplicon, also listed in Table 3.2, are underlined and highlighted in yellow. 
 
Exon 1 amplicon 228bp 
gcggcctgggtggctactgcccctgctgctgtcgtaggcgaggacggctgttagtgctgctgctgttgg
ttcgtcgcggcggcgaaggaggaggaggaagagggCGAGGCGACAAGAGAAGAAGgaggcaggcgcggc
ggcagcggcggcgccccgagccggcggaggcgaggggggggaag 
Exon 1 (c1 – 131) 
1                                       31 
1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17 
Met Ala Asp Val Leu Ser Val Leu Arg Gln Tyr Asn Ile Gln Lys Lys Glu 
ATG GCG GAC GTG CTT AGC GTC CTG CGA CAG TAC AAC ATC CAG AAG AAG GAG 
52                                      82 
18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34 
Ile Val Val Lys Gly Asp Glu Val Ile Phe Gly Glu Phe Ser Trp Pro Lys  
ATT GTG GTG AAG GGA GAC GAA GTG ATC TTC GGG GAG TTC TCC TGG CCC AAG  
103                                  131 
35  36  37  38  39  40  41  42  43 
Asn Val Lys Thr Asn Tyr Val Val Trp 
AAT GTG AAG ACC AAC TAT GTT GTT TGG GG 
gTAAGTCCGGCATGGCT  
gtggcccagg ggtggcaggg cagagttggg cgcccccagg cgacctcttt cttaacccct 
ccccccgttt cccctgggga tgggataaaa cgggtgttcg gggaaaagaa agtttctctc 
tagagcagaa gttgcacttt tagggtaagg 
 
 
Exon 2 amplicon 247bp 
5341  
catgacagtc tattcattat tagattttat actttttttt tgttagctat gttaaactca 
ttgttgttag caaagttgtt tatataaa TG AATCCAGCCT GAAGAGTTG a attagaattg 
tcagtaaaaa aaatcttgcc ttaattattt Cag  
Exon 2 (c132 - 237) 
132                                      161 
44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Gly Thr Gly Lys Glu Gly Gln Pro Arg Glu Tyr Tyr Thr Leu Asp Ser Ile   
  G ACT GGA AAG GAA GGC CAA CCC AGA GAG TAC TAC ACA TTG GAT TCC ATT  
181                                       212 
61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77 
Leu Phe Leu Leu Asn Asn Val His Leu Ser His Pro Val Tyr Val Arg Arg  
TTA TTT CTA CTT AAT AAC GTG CAC CTT TCT CAT CCT GTT TAT GTC CGA CGT  
232    237 
78  79 
Ala Ala  
GCA GCT 
g taagtagaat tcattttact tatctaccta tttatcagtt ttatttttat ttatt TAAGA 
GACAGGGTCT GGCCT tgttg cccgggctag ggtgcagtgg 
 
 
Exon 3 amplicon 161bp 
10441  
aaaatacgtt ttttcaagat atgttggaat aaaattcaga cattacatgt taatatttat taa 
GTTGTGT ATCATTGTTA TTCATTTCAt atctcattta aaattttggt tttag 
Exon 3 (c238 - 307) 
238                                     268 
80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96 
Thr Glu Asn Ile Pro Val Val Arg Arg Pro Asp Arg Lys Asp Leu Leu Gly  
ACT GAA AAT ATT CCT GTG GTT AGA AGA CCT GAT CGA AAA GAT CTA CTT GGA  
289                     307 
  A6 
97  98  99  100 101 102 
Tyr Leu Asn Gly Glu Ala  
TAT CTC AAT GGT GAA GCG T 
gtgag tactttttaa a ttgttccca gtcttaaaca gacattgttt cttttttccc 
ctatgaaata atgattagag ggaagagaat ttgtatttcc accaaaaaat taacctacct 
TCATTTTTGT CCATGTGCTC Acctttttct tatacagtgg atgcactgtc tttgccctta 
tggccagtca ccccttcctt gtgtgtggat tccatctcct ttcacagtct caaagacttt 
gtcttcgtaa attgttgttt ctctgacatc atcagttttc tactttcttc tggatcattc 
ccttttagaa tacctacagt aagatttcat gtttaaaaaa tgtttttgat 
 
Exon 4 5 amplicon 326bp 
15661  
gagaaaatca ccatatagaa gtatataaaa aacctaaagc atttcacttg taataatatc 
caatatatat gttgaaatag taat CCTTAC GTGAATCTTT TTATGTCTTC ag 
Exon 4 (c308 - 370) 
 308                                     338 
103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 
Ser Thr Ser Ala Ser Ile Asp Arg Ser Ala Pro Leu Glu Ile Gly Leu Gln  
 CA ACA TCG GCA AGT ATA GAC AGA AGC GCT CCC TTA GAA ATA GGT CTT CAG  
358             370 
120 121 122 123 
Arg Ser Thr Gln 
CGA TCT ACT CAA G 
gtatg tcttgttgca tatttatatt gaactttcag aagcccattc caaaactaca 
catttattta cttctctttc ttttat ag 
Exon 5 (c371 - 423) 
 371                                      402 
124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 
Val Lys Arg Ala Ala Asp Glu Val Leu Ala Glu Ala Lys Lys Pro Arg Ile  
 TC AAA CGA GCT GCA GAT GAA GTT TTA GCA GAA GCA AAG AAA CCA CGA ATT  
421  
141 
Glu  
GAG 
g taaagaaa ctgtatttta aacaatttta tttatattgt tattgaaatt gggattcttt 
agtaac aagg attctttga TTGCAGTAACC TGA GGAGCTT tttttctgga 
 
Exon 6 amplicon 320bp 
18301  
gttattatct ttacgtagcc aaaagtagtc t TGAAGTTGG CCTAAAGACA CTG ataccta 
gaattgtaga ggtaggaaat ttggtaagga aaagttacat gtagcgtttt ttcttcctaa 
 aagttcaata aaaattttaa atgcattaac cagtggttat ttccag 
Exon 6 (c424 - 512) 
424                                     454 
142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 
Asp Glu Glu Cys Val Arg Leu Asp Lys Glu Arg Leu Ala Ala Arg Leu Glu  
GAT GAA GAG TGT GTG CGC CTT GAT AAA GAG AGA TTG GCT GCC CGT TTG GAG  
475                                               512 
159 160 161 162 163 164 165 166 167 168 169 170  
Gly His Lys Glu Gly Ile Val Gln Thr Glu Gln Ile  
GGT CAC AAA GAA GGG ATT GTA CAG ACT GAA CAG ATT AG 
gtaag aattcttttt aagtagaaag taggtagttt agatatatgt aaaagtataa 
ggaaaaggaa tattaaaa TG CTCTCCACAT TTACATTTAC C tcttggatt 
 
 
Exon 7 amplicon 367bp 
22081  
tgcagaatag caagtcagtc ttacagataa gaaaacctta attattgcca tgtaagtgtt 
tttaccagaa atttataaat gtaacaaaat atatttatga tacactcca G GAATGCCTGC 
TGTGAAAAT t taaaaaagaa attgctt tta g 
Exon 7 (c513 - 729) 
  A7 
  513                                   541 
171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 
Arg Ser Leu Ser Glu Ala Met Ser Val Glu Lys Ile Ala Ala Ile Lys Ala  
  G TCT TTG TCT GAA GCT ATG TCA GTG GAA AAA ATT GCT GCA ATC AAA GCC  
562                                     592 
188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 
Lys Ile Met Ala Lys Lys Arg Ser Thr Ile Lys Thr Asp Leu Asp Asp Asp  
AAA ATT ATG GCT AAG AAA AGA TCT ACT ATC AAG ACT GAT CTA GAT GAT GAC  
613                                     643 
205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 
Ile Thr Ala Leu Lys Gln Arg Ser Phe Val Asp Ala Glu Val Asp Val Thr  
ATA ACT GCC CTT AAA CAG AGG AGT TTT GTG GAT GCT GAG GTA GAT GTG ACC  
664                                     694 
222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 
Arg Asp Ile Val Ser Arg Glu Arg Val Trp Arg Thr Arg Thr Thr Ile Leu  
CGA GAT ATT GTC AGC AGA GAG AGA GTA TGG AGG ACA CGA ACA ACT ATC TTA  
715               729 
239 240 241 242 243 
Gln Ser Thr Gly Lys  
CAA AGC ACA GGA AAG 
gt aattaaaata ttttactcat tcattggagt gagagagaga gagagagagt gcgtttaatc 
tgtggttata gaattggtta aact TTGCTT TTAGGTGGAA GTTTCA agtt ttatctcttt 
gaaagctcag taataatgta gatttccaga tggccatttt taccattcca 
 
Exon 8 amplicon 260bp 
28141  
TaTGTAGTAG GGAAGAATCG ATAGTAAGA  taacttagtct taaattatca actaaattta 
 ctattgtata tttaaagtgg gcttaattaa aatccattta tattttag 
Exon 8 (c730 - 828) 
730                                     760 
244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 
Asn Phe Ser Lys Asn Ile Phe Ala Ile Leu Gln Ser Val Lys Ala Arg Glu  
AAT TTT TCC AAG AAC ATT TTT GCA ATT CTT CAA TCT GTA AAA GCC AGA GAA  
781                                     811                   828 
261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 
Glu Gly Arg Ala Pro Glu Gln Arg Pro Ala Pro Asn Ala Ala Pro Val  
GAA GGG CGT GCA CCT GAA CAG CGA CCT GCC CCA AAT GCA GCA CCT GTG 
g ta agaatgcttt actgctttac agtaga TTTAATGAAGTTGC CACTTATATT GC 
agtgtagt aacgttgaag acatcttcac attttaaaat 
 
Exon 9 amplicon 215bp 
30601 
Cta CTGCACT CCAGCACATT AAA  taagtga catttaaaaa tattaacaag  
30661 taactcataa ttaatttttt tacag 
Exon 9 (c829 - 907) 
829                                     859 
277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 
Asp Pro Thr Leu Arg Thr Lys Gln Pro Ile Pro Ala Ala Tyr Asn Arg Tyr  
GAT CCC ACT TTG CGC ACC AAA CAG CCT ATC CCA GCT GCC TAT AAC AGA TAC  
880                                 907 
294 295 296 297 298 299 300 301 302 
Asp Gln Glu Arg Phe Lys Gly Lys Glu 
GAT CAG GAA AGA TTC AAA GGA AAA GAA G 
gcaagt tgcttaattc ttatcttccc cttagtgtgg ttgtgttg AA CTTGAGAGGC 
AGTGTGGC ct gatgtttaag ggtaagggtt ggcaaagtaa tgtctacaga ccagatctta 
cccactgcaa tttttcttaa 
 
Exon 10 amplicon 225bp 
32641  
T TCAAGGCTT TGTATATTAT TGAACCA  tca cattcaatgt agattattac tttagatttg 
 ttataggtca taagatacat gatctataaa atcttaacaa taagcctctt ttttttcgt ag  
  A8 
Exon 10 (c908 - 972) 
 908                                    937 
303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 
Glu Thr Glu Gly Phe Lys Ile Asp Thr Met Gly Thr Tyr His Gly Met Thr  
 AA ACG GAA GGC TTC AAA ATT GAC ACT ATG GGA ACC TAC CAT GGT ATG ACA  
 
958               972 
320 321 322 323 324 
Leu Lys Ser Val Thr  
CTG AAA TCT GTA ACG 
g taa gttaatttgg ctgta GATGT TCTTTTGTTC CAGGGA tttt atgtgagtag 
ca catgttga agtaaatctt tagtctctca tattttttat ttcaaacatt tttctttatt 
 
 
Exon 11 amplicon 244bp 
84001  
gttttcattt ttattttttt cttaaactgt aggtcataac atgtt 
CAGTGGAGTAACCAACTGAGTGA  ga aaaacagaac aagagacaga gagatatgag 
atttctttgg aataattaaa gtgtttatta tgtaaagaaa ctttgatctt atatatcaat 
tcttattctt ttaaag  
Exon 11 (c973 - 1030) 
973                                     1003 
325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 
Glu Gly Ala Ser Ala Arg Lys Thr Gln Thr Pro Ala Ala Gln Pro Val Pro  
GAG GGT GCA TCT GCC CGG AAG ACT CAG ACT CCT GCA GCC CAG CCA GTA CCA  
1024    1030 
342 343 
Arg Pro  
AGA CCA G 
Gtagaa atatagaact ttgctttttg ttttct TTCA AAAGATCGTA ACAGTGCAA g 
tttttagtat gcgtataatg ctttgaacaa acttaaattt tacttaaaat acattgcaaa 
gtcatgtttc 
 
 
Exon 12 amplicon 141bp (+ 5bp gc clamp) 
92221  
tatggatgtt gtatattcac tttccttttg actacagatt gttgaataat gcattttaat 
atttttgtca aacagtgttg agaagatagt tgtaaaaaaa gtcttctgat ttacagttag 
tcatatggga atacacataa tttaaaaaat atcccttatt tgtaagtttg aaaataagaa ta 
TGGTTTTT ATGACACAGA GTTGTGA  ttt tttttctttt tcac ag  
Exon 12 (c1031 - 1066) 
 1031                                   1060    1066 
344 345 346 347 348 349 350 351 352 353 354 355 
Val Ser Gln Ala Arg Pro Pro Pro Asn Gln Lys Lys  
 TT TCT CAA GCA AGA CCT CCC CCA AAT CAG AAG AAA G 
g tgaggtt gtgcatatga ttttaaactt aactttaaaa agt AAATGAT TGCAAAACCA GGC  
ctgataa ttttcttgtg cagctgtatc acatgtttgt gcttggtatc cattctgatt 
tattagtgcc caagccacac tgattattaa atatttttta 
 
 
Exon 13 amplicon 298bp  
92581  
gcttggtatc cattctgatt tattagt GCC CAAGCCACAC TGATTAT taa atatttttta 
atatccactg gcttaaaata ttttttagat caaaagttaa agttacaatt tataatcttt 
taacttttag tagagaaagt aagtataatt tctaataata tattttctac ctgtaaattt 
tgtctttat ag  
Exon 13 (c1067 - 1154) 
 1067                                   1096 
356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372  
Gly Ser Arg Thr Pro Ile Ile Ile Ile Pro Ala Ala Thr Thr Ser Leu Ile  
 GA TCT CGA ACA CCC ATT ATC ATA ATT CCT GCA GCT ACC ACC TCT TTA ATA  
  A9 
1117                                    1147     1154 
373 374 375 376 377 378 379 380 381 382 383 384 
Thr Met Leu Asn Ala Lys Asp Leu Leu Gln Asp Leu  
ACC ATG CTT AAT GCA AAA GAC CTT CTA CAG GAC CTG AA 
g taagtaattt attaaactat CCTGTACGTA GGATATTGAG ATACCAttgg  
aaaatagtag ttactgaatc agtattactt atttggaaaa aacaaaattt cggtttctgt 
gctataggcc ttacacatag tatgaagcat 
 
Exon 14 amplicon 269bp 
113221  
gttgcagtga gccaagattg caccactgca ctctagcctg ggcaataaga aaaaactctg 
   113281 tctcaaaaaa aaaaaatatt tcaaattata gtttatctt  
CCCATTTTCATCACGTGGAA t acattgactt tttctcatct ctgttttttc aaag  
Exon 14 (c1155 - 1316) 
  1155                                  1183 
385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 
Lys Phe Val Pro Ser Asp Glu Lys Lys Lys Gln Gly Cys Gln Arg Glu Asn  
  A TTT GTC CCA TCA GAT GAA AAG AAG AAA CAA GGT TGT CAA CGA GAA AAT  
1204                                    1234 
402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 
Glu Thr Leu Ile Gln Arg Arg Lys Asp Gln Met Gln Pro Gly Gly Thr Ala  
GAA ACT CTA ATA CAA AGA AGA AAA GAC CAG ATG CAA CCA GGG GGC ACT GCA  
1255                                    1285 
419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 
Ile Ser Val Thr Val Pro Tyr Arg Val Val Asp Gln Pro Leu Lys Leu Met  
ATT AGT GTT ACA GTA CCT TAT AGA GTA GTA GAC CAG CCC CTT AAA CTT ATG  
1306         1316 
436 437 438 
Pro Gln Asp  
CCT CAA GAC TG 
gtaa gatagtctct atatatatat cttttcaCAG GTGTTGAACCCAAGAGAA tg 
aatgttgtta ttgccgttga tgacgttgct ttttaagaga tggggtctca ctatgttgcc 
taggcagaac ttgaactcct gggctctgtc agtcctcctg cctcaggctc 
 
Exon 15 amplicon 218bp 
116401  
gacttaggtg taaaaaccag atacatgaga agtatagcaa tcattaatac attctaatgg 
caatatcata ttgaaaaggt ggtaagtact gtatttgctt catggaagga ttgataagac 
tctttcacat gaatgtttat gggactgttg cctaagggat ttatagtagc taaagctcaa 
gtttgaaat a atctccgtct gtcccctac c t CCCCCCACC CACTTTTCTA CT tgtag  
Exon 15 (c1317 - 1417) 
  1317                                  1345 
439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 
Trp Asp Arg Val Val Ala Val Phe Val Gln Gly Pro Ala Trp Gln Phe Lys  
  G GAC CGC GTT GTA GCC GTT TTT GTG CAG GGT CCT GCA TGG CAG TTC AAA  
1366                                    1396                        
456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 
Gly Trp Pro Trp Leu Leu Pro Asp Gly Ser Pro Val Asp Ile Phe Ala Lys  
GGT TGG CCA TGG CTT TTG CCT GAT GGA TCA CCA GTT GAT ATA TTT GCT AAA A 
gt aagattctct ttgtatttac tgtatccagt atagaaatgt tctcacttta tttaagagaa 
acagtcatat AGTTCTGCGCATATGATGTG tatgtcaaaa gattgctgtt aagtaacata 
tgttaatgtt taagcatctg 
 
 
Exon 16 amplicon 346bp  
   9061  
tttatcttac cttattcctc attttagtgt ccagtggctg gcgtgtataa accctgaatg 
tttttaaaga   taatatttta aaagatcact ttagttata A TACGGCTTCA GTTGGTGGAa 
taaagaaatt tttttctttt tttttatttt gagtaaaaat gataacttct ctccaccctc 
tctatag 
Exon 16 (c1418 - 1559) 
  A10 
1418                                    1447 
473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 
Ile Lys Ala Phe His Leu Lys Tyr Asp Glu Val Arg Leu Asp Pro Asn Val  
 TT AAA GCC TTC CAT CTG AAG TAT GAT GAA GTT CGT CTG GAT CCA AAT GTT  
1468                                    1498 
490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 
Gln Lys Trp Asp Val Thr Val Leu Glu Leu Ser Tyr His Lys Arg His Leu  
CAG AAA TGG GAT GTA ACA GTA TTA GAA CTC AGC TAT CAC AAA CGT CAT TTG  
1519                                    1549         1559 
507 508 509 510 511 512 513 514 515 516 517 518 519 
Asp Arg Pro Val Phe Leu Arg Phe Trp Glu Thr Leu Asp  
GAT AGA CCA GTG TTC TTA CGG TTT TGG GAA ACA TTG GAC AG 
g ta attccgat tctaaaatat gcttgtg tgt gttttattgt aatttttctg tctcagttaa 
attttaagtt ccatagagtt gtcagtctta ttc CCTAATT CCCTTCTTTC AACAT taact 
tgatgcttat cttcagtaca taattaacaa 
 
 
Exon 17 amplicon 249bp 
10021  
ggagtgttat ttctagctta ttccagagtc tttatatttc cagttttcta gaaaacagca 
ttttattctg ttgattttaa gttttaa GAA ATGTCAACTT GTTTTTACAT GC Attattct 
aaaaattcta aaattcctat agtcattata acctaccata atattttttt cag   
Exon 17 (c1560 - 1596) 
  1560                                            1596 
520 521 522 523 524 525 526 527 528 529 530 531 end 
Arg Tyr Met Val Lys His Lys Ser His Leu Arg Phe   
  G TAC ATG GTA AAG CAT AAA TCG CAC TTG AGA TTC TGA 
attatttggctcctcc 
atttctggaaattgagactcaagctttatgaatttatcaagaacttaaaaatgaagaagg 
tcacagattgatcttttataagaccttattTGATGCTTTGTGCTTCAAGGagatgatacc 
tgtcatccatataagcaaactttttggcttacaactatttttttaatattagccttctag 
tctgtaatggaaattgtatattttgatagaagttttttctccattggttaaattagcatt 
acttaaaatttgtttctttagaaaataaatgcaggttataaatgtgtgtatatttagaga 
ttataaggctctctgagccatcttctgatttttcattgctctataattctttttactgaa 
aatactatgttatgaatggtattaaattttagtctctggaacatccaaaaccaagcaaag 
ggatgtgactattttgaatgaatcagaatgtcaacttgtatgtacactatatctacactt 
actcattatttaaaaagaataatgaaaaatctagatcaattcttcaatttgattgaactg 
ttcagccttttcaagatttctttatttacaaatgattacatttaaatgaatgtacattct 
tctcactgactttggtgattttgaaacctagaatgatgtgtttctatctgtaatatcttt 
ccatttgaaaaaaatctcaaaacacagattaaaaccac 
 
  A11 
Appendix 3.4 HRPT2  mutation and loss of heterozygosity at 1q24-32 results
Chromosomal region microsatellite markers / HRPT2  polymorphism or mutation
1q24-32
HRPT2
Tumour type  
Specimen ID Age Sex D1
S
21
8
D
1S
23
8
D
1S
42
2
D
1S
26
25
D
1S
08
1
c3
3C
→T
 (Y
11
Y
)
IV
S
2+
28
C
→T
 
IV
S
7+
33
(G
A
)8
IV
S
12
 p
ol
ys
H
R
P
T2
 m
ut
at
io
n 
1
D
1S
53
3
D
1S
27
57
D
1S
27
94
D
1S
47
7
FIHP
60A 52 F nmd
54A 19 F 8 c191T→C (L64P) [G]
4A 22 M 8 c191T→C (L64P) [G]
HPT-JT
1613G 20 M T/T c76delA [G], 686del4 [S]
1765G 51 M c76delA [G]
IV-3 27 F c679delAG [G]
IV-4 38 F c679delAG [G]
5771 36 F c679delAG [G]
MEN 1
1996G 42 M T/T nmd
1540G 37 F nmd
18964 42 F nmd
MEN 2A
6887 46 F nmd
Carcinoma
2119G 42 M c165C→G (Y54X)
1798G 34 F c76delA
2077G 56 M IVS6-1delG [S], c165C→A (Y55X) [S]
10977 32 M c165delC
Hyperplasia - secondary
784G 26 M nmd
2158G 51 F TG nmd
2190G 56 F nmd
2085G 33 M nmd
1749G 47 M nmd
1293G 59 F nmd
381G 40 F CT nmd
95A 62 F CT nmd
17A 66 F nmd
86A 70 M U4 nmd
7102 23 M nmd
Hyperplasia - tertiary
34A 56 F nmd
407G 27 M U4 nmd
770G 58 M T/T TG nmd
866G 29 F nmd
8263 42 F nmd
2950 29 F nmd
Lithium
76A 78 F nmd
80A 50 F nmd
Adenoma
79A 60 F nmd
57A 62 F TG nmd
9A 55 F nmd
14A 66 M nmd
101A 68 M nmd
85A 73 F nmd
99A 69 M nmd
91A 50 M nmd
88A 60 M nmd
93A 69 M nmd
77A 55 M nmd
103A 75 F nmd
75A 55 F nmd
78A 74 M nmd
84A 55 M nmd
89A 56 F nmd
96A 42 M nmd
82A 67 M nmd
10163 42 M CT nmd
10643 56 F TG nmd
4131 76 M T/T nmd
6937 24 M nmd
3064 44 F nmd
9885 71 F TG nmd
90A 78 M nmd
Legend
R i f h i / h setent on o eterozygos ty eterozygou 8 IVS7+33(GA)8
Homozygous / uninformative marker TG Heterozygous for IVS12-109T→G
Loss of heterozygosity CT Heterozygous for IVS12-86C→Τ
T/T Homozygous for IVS+28T nmd No HRPT2 mutation detected
U4 Heterzygous for IVS2+28del4 [G] germline mutation
Blank spaces indicate LOH not performed [S] somatic mutation
A12
ResGenAccNr ClusterID Symbol Name Cyto Fold change
AA778392 Hs.185055 BENE   BENE protein  2q13 4.8
H23979 Hs.79015 MOX2   mrc ox-2 antigen; mox2  3q13.2 4.7
AA630374 Hs.180383 DUSP6   MAP kinase phosphatase 3  12q21.33 3.9
AA732931 Hs.83734 STX4A   syntaxin 4A (placental)  16p11.2 3.8
AA463257 Hs.271986 ITGA2   integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)  5q11.2 3.6
AA447978 Hs.95197 ALDH1A2  retinaldehyde dehydrogenase 2  15q21.3 3.3
AA708201 Hs.70337 IGSF4   immunoglubulin superfamily, member 4; igsf4  11q23.3 3.3
AA190401 Hs.172894 BID   bh3-interacting domain death agonist; bid  22q11.21 2.9
AA487486 Hs.82932 CCND1   cyclin D1 (PRAD1: parathyroid adenomatosis 1)  11q13.3 2.4
AA279429 Hs.287115 ECE1   endothelin converting enzyme 1  1p36.12 2.3
AA448660 Hs.49349  BACE1   beta-site APP-cleaving enzyme 1  11q23.3 2.3
R76394 Hs.25338 SPUVE   protease, serine, 23  11q14.2 2.3
H51318 Hs.11759  C2orf18   chromosome 2 open reading frame 18  2p23.3 -2.4
AA432152 Hs.103378  C10orf45   chromosome 10 open reading frame 45  10p13 -2.6
AA670438 Hs.433347  UCHL1   ubiquitin c-terminal esterase l1; uchl1, park5  4p14 -2.9
AA446361 Hs.6872   Clone IMAGE:3632546, mRNA -3.3
AA447480 Hs.401954 LOC338769   CDNA FLJ12927 fis, clone NT2RP2004743 -3.4
AA419229 Hs.372651 MGC29643   G protein-coupled receptor 39  2q21.2 -3.7
H59916 Hs.375108 CD24 CD24 antigen 6q21 -5.8
H72122 Hs.453054  -  - -6.2
R85090 Hs.104925 ENC1   ectodermal-neural cortex (withBTB-like domain)  5q13.3 -7
Appendix 5.1 Differentially expressed genes in cluster 1 identified by CIT (p<0.05). "ResGenAccNr" is the Genbank
Accession number; "cyto" is the chromosomal location of the gene; and "fold change" is the difference in mean expression
values for each cluster versus the remaining arrays. 
A13
ResGenAccNr ClusterID Symbol Name Cyto Fold change
AA670438 Hs.433347  UCHL1  ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)  4p14 36.8
H59915 Hs.375108 CD24  -  - 26.8
W30988 Hs.9613 ANGPTL4  angiopoietin-like 4  19p13.2 8.4
AA626797 Hs.372651 MGC29643  hypothetical protein MGC29643  2q21.2 7.6
AA496283 Hs.125359 THY1  Thy-1 cell surface antigen  11q23.3 5.8
AA916325 Hs.78183 AKR1C3
aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase)  10p15.1 5.4
R98344 Hs.8037 TM4SF9  transmembrane 4 superfamily member 9  4q23 5.2
R54846 Hs.748 FGFR1  -  - 5
R93124 Hs.78183 AKR1C3
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II)  10p15.1 4.9
AA634103 Hs.426138 TMSB4X  thymosin, beta 4, X-linked  Xp22.22 4.8
AA451911 Hs.44197 GPR126  G protein-coupled receptor 126  6q24.2 4.7
AA634267 Hs.76918 NPC1  Niemann-Pick disease,type C1  18q11.2 4.7
T98394 Hs.194693 SLC7A7
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 7  14q11.2 4.7
N50556 Hs.159201 TMSB4Y  thymosin, beta 4, Y-linked  Yq11.221 4.4
N73101 Hs.29981 SLC26A2  solute carrier family 26 (sulfate transporter), member 2  5q33.1 4.4
AA489648 Hs.15053 HCMOGT-1  sperm antigen HCMOGT-1  17p11.2 4.4
AA630328 Hs.411701 GALIG  lectin, galactoside-binding, soluble, 3 (galectin 3)  14q22.3 4.4
T66816 Hs.7644 HIST1H1C  histone 1, H1c  6p22.2 4.3
AA453105 Hs.28777 HIST1H2AC  histone 1, H2ac  6p22.2 4.2
R93543 Hs.14838 ENAH  -  - 4.2
N21019 Hs.154654 CYP1B1  cytochrome P450, family 1, subfamily B, polypeptide 1  2p22.2 4.1
AA128553 Hs.177486 APP
amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer 
disease)  21q21.3 4.1
AA663710 Hs.14838 ENAH  enabled homolog (Drosophila)  1q42.12 4.1
H70775 Hs.356901 HIST1H2BC  histone 1, H2bc  6p22.2 3.9
R85090 Hs.104925 ENC1  ectodermal-neural cortex (with BTB-like domain)  5q13.3 3.9
AA598507 Hs.1640 COL7A1
collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, 
dominant and recessive)  3p21.31 3.9
AA704222 Hs.302738  SLC26A2  solute carrier family 26 (sulfate transporter), member 2  5q33.1 3.8
AA004862 Hs.10669 DDEF1  development and differentiation enhancing factor 1 3.8
AA034268 Hs.28988 GLRX  glutaredoxin (thioltransferase)  5q15 3.7
AA419251 Hs.458286 IFITM1  interferon induced transmembrane protein 1 (9-27)  11p15.5 3.7
N32904 Hs.44197 GPR126  solute carrier family 30 (zinc transporter),  member 9  6q24.2 3.6
R85090 Hs.104925 ENC1  ectodermal-neural cortex (with BTB-like domain)  5q13.3 3.6
AA704230 Hs.105633 WINS1  WINS1 protein with Drosophila Lines (Lin) homologous domain  15q26.3 3.6
N67039 Hs.180059  CDK6  cyclin-dependent kinase 6; cdk6, plstire  7q21.2 3.5
T83646 Hs.3343 PHGDH  -  - 3.5
AA432152 Hs.103378  C10orf45  chromosome 10 open reading frame 45  10p13 3.4
R60170 Hs.239147 GDA  -  - 3.4
T59948 Hs.10669 DDEF1  development and differentiation enhancing factor 1 3.3
AA437212 Hs.40368 AP1S2  adaptor-related protein complex 1, sigma 2 subunit  Xp22.22 3.2
AA019209 Hs.82124 LAMB1  laminin, beta 1  7q31.1 3.2
AI207202 Hs.38481 CDK6  cyclin-dependent kinase 6  7q21.2 3.2
AA453105 Hs.28777 HIST1H2AC  histone 1, H2ac  6p22.2 3.2
AI671174 Hs.194657 CDH1  cadherin 1, type 1, E-cadherin (epithelial)  16q22.1 3.2
AA126947 Hs.17377 CORO1C  coronin, actin binding protein, 1C  12q24.11 3.2
T61913 Hs.179902 CDW92  CDW92 antigen  9q31.1 3.1
AA165678 Hs.139336 ABCC4  ATP-binding cassette, sub-family C (CFTR/MRP), member 4  13q32.1 3.1
H92347 Hs.121817 NAP1L4  nucleosome assembly protein 1-like 4  11p15.4 3.1
AA101348 Hs.406648 GA17  dendritic cell protein  11p13 3.1
AA905702 Hs.6349 BC008967  -  - 3.1
R91904 Hs.234642 AQP3  aquaporin 3  9p13.3 3
H23187 Hs.155097 CA2  carbonic anhydrase II  8q21.2 3
AA489582 Hs.377973 LMNA  lamin A/C  1q22 3
AA873060 Hs.406269 STMN1  stathmin 1/oncoprotein 18  1p36.11 3
AA464250 Hs.182265 KRT19  keratin 19  17q21.2 3
AA425938 Hs.18069 LGMN  legumain  14q32.12 3
AA456063 Hs.17377 CORO1C  coronin, actin binding protein, 1C  12q24.11 3
N71982 Hs.247817 HIST1H2BK  -  - 3
AA136921 Hs.445687  PARD6B  partitioning defective-6 homolog beta (par-6 beta) (par-6b). 3
N68399 Hs.454216 HIST1H2BO  histone 1,  H2bn 3
R25156 Hs.271568  Transcribed sequences 3
AA401441 Hs.69771 BF  B-factor, properdin  6p21.32 2.9
Appendix 5.2 Differentially expressed genes in cluster 2 identified by CIT (p<0.05). "ResGenAccNr" is the Genbank Accession
number; "cyto" is the chromosomal location of the gene; and "fold change" is the difference in mean expression values for each
cluster versus the remaining arrays. 
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ResGenAccNr ClusterID Symbol Name Cyto Fold change
R62612 Hs.287820 FN1  fibronectin 1  2q35 2.9
AA010223 Hs.451883  HIST2H2BE  histone 2, H2be  1q21.2 2.9
AA143773 Hs.301350 FXYD3  FXYD domain containing ion transport regulator 3  19q13.12 2.9
AA479093 Hs.430136  ITPR2  inositol 1,4,5-triphosphate receptor, type 2  12p12.1-11.23 2.9
AA456394 Hs.239069 FHL1  four and a half LIM domains 1  Xq26.3 2.8
AA446994 Hs.165950 FGFR4  fibroblast growth factor receptor 4  5q35.2 2.8
AA293182 Hs.85100 WDR1  WD repeat domain 1  4p16.1 2.8
AA001432 Hs.83450 LAMA3  laminin, alpha 3  18q11.2 2.8
AA704777 Hs.283716 MSCP  -  - 2.8
H70631 Hs.283716 MSCP  mitochondrial solute carrier protein  8p21.2 2.7
AA046639 Hs.283716 MSCP  mitochondrial solute carrier protein  8p21.2 2.7
AA463830 Hs.43697 ETV5  ets variant gene 5 (ets-related molecule)  3q27.2 2.7
R97340 Hs.4082 LGALS8  lectin, galactoside-binding, soluble, 8 (galectin 8)  1q43 2.7
AA430382 Hs.75514 NP  nucleoside phosphorylase  14q11.2 2.7
AA419251 Hs.458286 IFITM1  interferon induced transmembrane protein 1 (9-27)  11p15.5 2.7
AA149637 Hs.76536 TBL1X  transducin (beta)-like 1X-linked  Xp22.31-.22 2.6
AA496334 Hs.166161 DNM1  dynamin 1  9q34.11 2.6
H44051 Hs.355214 KRT14  keratin-14; krt14  17q21.2 2.6
AA432023 Hs.6349 BC008967  hypothetical gene BC008967  16p13.11 2.6
AA282445 Hs.82548 MADD  MAP-kinase activating death domain  11p11.2 2.6
H09113 Hs.6685  JMJD1C  PROTEIN : thyroid hormone receptor interactor 8  10q21.3 2.6
AA700604 Hs.387822  -  - 2.6
AA454591 Hs.374181  loc388134  LOC388134 2.6
AA677085 Hs.117030
Transcribed sequence with moderate similarity to protein 
pir:T46448 (H.sapiens) T46448 hypothetical protein 
DKFZp434N1429.1 - human 2.6
R68021 Hs.149383  Transcribed sequences 2.6
R39111 Hs.74088 EGR3  bridging integrator 3  8p21.3 2.5
AA446251 Hs.82124 LAMB1  laminin, beta 1  7q31.1 2.5
AA190871 Hs.37009 ALPI  alkaline phosphatase, intestinal  2q37.1 2.5
AA453175 Hs.193163 BIN1  bridging integrator 1  2q14.3 2.5
AA454654 Hs.24956 FLJ22056  hypothetical protein FLJ22056  14q32.33 2.5
Hs.301417  AHNAK  AHNAK nucleoprotein (desmoyokin)  11q12.3 2.5
AA495786 Hs.433685  SHB  SHB (Src homology 2 domain containing) adaptor protein B  9p13.1 2.4
N51612 Hs.27267 MGC50844  hypothetical protein MGC50844  7q32.1 2.4
AA504534 Hs.154045 KIAA0082  KIAA0082  6p21.2 2.4
AA187977 Hs.61638 MYO10  myosin X  5p15.1 2.4
AA452981 Hs.198862 FBLN2  fibulin 2  3p25.1 2.4
AA486238 Hs.81008 FLNB  filamin B, beta (actin binding protein 278)  3p14.3 2.4
N47468 Hs.59757 ZNF281  zinc finger protein 281  1q32.1 2.4
AA029956 Hs.82251 MYO1E  myosin IE  15q22.2 2.4
AA971742 Hs.1619 ASCL1  achaete-scute complex-like 1 (Drosophila)  12q23.2 2.4
AA446120 Hs.394 ADM  adrenomedullin  11p15.4 2.4
R20650 Hs.21379 GL012  -  - 2.4
AA487146 Hs.34549  hypothetical gene supported by BC062364; BX647289 2.4
AA490477 Hs.296842 MYH10  myosin, heavy polypeptide 10, non-muscle 2.4
AA633872 Hs.432934 KIAA0256  KIAA0256 gene product 2.4
Hs.456730
Transcribed sequence with weak  similarity to protein sp:P39188 
(H.sapiens) ALU1_HUMAN Alu subfamily J sequence 
contamination warning entry 2.4
N33927 Hs.180779 HIST1H2BD  histone 1, H2bd  6p22.2 2.3
AA285018 Hs.362996 KIAA0779  KIAA0779 protein  3q22.1 2.3
AA598508 Hs.183650 CRABP2  cellular retinoic acid binding protein 2  1q23.1 2.3
AA488073 Hs.89603 MUC1  mucin 1, transmembrane  1q22 2.3
H73239 Hs.433642  FRS2  fibroblast growth factor receptor substrate 2  12q15 2.3
AA598517 Hs.242463 KRT8  keratin 8  12q13.13 2.3
AA487812 Hs.297753 VIM  vimentin  10p13 2.3
R93069 Hs.2575 CAPN1  -  - 2.3
H24311 Hs.7076 DDHD1  -  - 2.3
AA487846 Hs.47026
Transcribed sequence with weak  similarity to protein pir:S57447 
(H.sapiens) S57447 HPBRII-7 protein - human 2.3
H24311 Hs.7076 DDHD1  DDHD domain containing 1 2.3
AA026641 Hs.251754 SLPI  secretory leukocyte protease inhibitor (antileukoproteinase)  20q13.12 2.2
AA455094 Hs.183037 PRKAR1A
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue 
specific extinguisher 1)  17q24.2 2.2
AA775616 Hs.313 SPP1  -  - 2.2
AA131576 Hs.445426  LOC152078  hypothetical protein BC010062 2.2
AA456078 Hs.59982  hypothetical gene supported by AK096951 2.2
T55407 Hs.444847  CDNA clone IMAGE:4140029, partial cds 2.2
AA701929 Hs.106880 BYSL  bystin-like  6p21.1 2.1
AA279990  - 2.1
AA865464 Hs.77667 LY6E  RETINOIC ACID-INDUCED GENE E  8q24.3 2
AA458878 Hs.273330 AGRN  agrin 2
AA447507 Hs.397210  RPS6KA2  ribosomal protein S6 kinase, 90kDa, polypeptide 2  6q27 -2
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AA644448 Hs.19718 PTPRU  protein tyrosine phosphatase, receptor type, U  1p35.3 -2
AA953254 Hs.169825 COL4A5  -  - -2
T74714 Hs.301664 RPS6KA2  -  - -2
AA136612 Hs.18136 NNT  nicotinamide nucleotide transhydrogenase  5p12 -2.1
N67822 Hs.5884  MITF  microphthalmia-associated transcription factor  3p13 -2.1
AA451904 Hs.2719 WFDC2  WAP four-disulfide core domain 2  20q13.12 -2.1
H98636 Hs.25648 TNFRSF5  tumor necrosis factor receptor superfamily, member 5  20q13.12 -2.1
AA417994 Hs.6853  CHST5  carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5  16q23.1 -2.1
AA478066 Hs.77783 PKMYT1
CDC2-INHIBITORY KINASE, MEMBRANE-ASSOCIATED AND 
TYROSINE/THREONINE-SPECIFIC,  16p13.3 -2.1
AA598872 Hs.8083 FLJ10769  hypothetical protein FLJ10769  13q34 -2.1
AA004832 Hs.426296 C10orf104  chromosome 10 open reading frame 104  10q22.1 -2.1
R32952 Hs.2962 S100P  -  - -2.1
R41798 Hs.186547 KIAA1374  KIAA1374 protein -2.1
AA486261 Hs.102135 SSR4
solute carrier family 6 (neurotransmitter transporter,  creatine),  
member 8  Xq28 -2.2
H81554 Hs.108502 BSPRY  B-box and SPRY domain containing  9q32 -2.2
AA486753 Hs.150011  ETV1  mucin 7,  salivary  7p21.2 -2.2
AA425001 Hs.279696  PHKG1  phosphorylase kinase, gamma 1 (muscle)  7p11.2 -2.2
W68281 Hs.227789 MAPKAPK3  mitogen-activated protein kinase-activated protein kinase 3  3p21.31 -2.2
AA147641 Hs.79741 FLJ10116  hypothetical protein FLJ10116  2q35 -2.2
AA428182 Hs.355874 RABL2B  RAB, member of RAS oncogene family-like 2B  22q13.33 -2.2
AA029283 Hs.25220 LARGE  acetylglucosaminyltransferase-like protein; large  22q12.3 -2.2
AA429034 Hs.26670 MGC17330  HGFL gene  22q12.2 -2.2
AA455146 Hs.14779 ACAS2  acetyl-Coenzyme A synthetase 2 (ADP forming)  20q11.22 -2.2
H18064 Hs.241205 PXMP4  peroxisomal membrane protein 4, 24kDa  20q11.22 -2.2
AA430552 Hs.35101 PRRG2
transmembrane gamma-carboxyglutamic acid protein 2 precursor 
(proline- rich gla protein 2) (proline-rich gamma-carboxyglutamic 
acid protein 2).  19q13.33 -2.2
H15718 Hs.83341 AXL  AXL receptor tyrosine kinase  19q13.2 -2.2
H22481 Hs.84154 NPTX1  neuronal pentraxin I  17q25.3 -2.2
T63046 Hs.239625 ITM2B  integral membrane protein 2B  13q14.2 -2.2
AA134749 Hs.170133 FOXO1A  forkhead box O1A (rhabdomyosarcoma)  13q14.11 -2.2
AA432271 Hs.6061 PRKAB1  protein kinase, AMP-activated, beta 1 non-catalytic subunit  12q24.23 -2.2
AA157499 Hs.178695 MAPK13  -  - -2.2
AA402915 Hs.334707 ACY1  -  - -2.2
H87106 Hs.121068 TM4SF6  -  - -2.2
R41329 Hs.74655 LOC124512  -  - -2.2
AA485453 Hs.30089  CDNA clone IMAGE:4099512, partial cds -2.2
AA418888 Hs.62515 KIAA0494  KIAA0494 gene product -2.2
AA449738 Hs.7857 EPB41L2  erythrocyte membrane protein band 4.1-like 2  6q23.1 -2.3
AA126862 Hs.352406 LOC92689  hypothetical protein BC001096  4p14 -2.3
AA862999 Hs.272429 CASR
calcium-sensing receptor (hypocalciuric hypercalcemia 1, severe 
neonatal hyperparathyroidism)  3q21.1 -2.3
H15910 Hs.148101 CDC42EP1  CDC42 effector protein (Rho GTPase binding) 1  22q13.1 -2.3
AA461071 Hs.82042 SLC23A2  solute carrier family 23 (nucleobase transporters), member 2  20p13 -2.3
N78582 Hs.50732 PRKAB2  protein kinase, AMP-activated, beta 2 non-catalytic subunit  1q21.1 -2.3
AA443119 Hs.29759 PTRF  polymerase I and transcript release factor  17q21.2 -2.3
T69563 Hs.424099 EPPB9  B9 protein  17p11.2 -2.3
AA129933 Hs.17409 SLC38A6  solute carrier family 38, member 6  14q23.1 -2.3
N73307 Hs.30213 CLN5  ceroid-lipofuscinosis, neuronal 5  13q22.3 -2.3
H22826 Hs.5978 LMO7  LIM domain only 7  13q22.2 -2.3
AA486514 Hs.80423 PBP  phosphatidylethanolamine-binding protein; pbp  12q24.23 -2.3
H84153 Hs.75586 CCND2  cyclin D2  12p13.32 -2.3
AA129135  - -2.3
AA489813 Hs.105298  -  - -2.3
H15910 Hs.148101 CDC42EP1  -  - -2.3
AA927187 Hs.50477 RAB27A  -  - -2.3
R93591 Hs.35156  -  - -2.3
AA669183 Hs.349326  arylsulfatase D -2.3
AA702949 Hs.113082 GASP  G protein-coupled receptor-associated sorting protein  Xq22.1 -2.4
R83837 Hs.80887 LYN  ONCOGENE LYN  8q12.1 -2.4
AA425001 Hs.279696  PHKG1  phosphorylase kinase, gamma 1 (muscle)  7p11.2 -2.4
H10192 Hs.356487  leukemia inhibitory factor receptor  5p13.1 -2.4
N66061 Hs.132355  RABL3  RAB, member of RAS oncogene family-like 3  3q13.33 -2.4
AI302412 Hs.173374  DCBLD2  discoidin, CUB and LCCL domain containing 2  3q12.1 -2.4
N59532 Hs.102 AMT  aminomethyltransferase (glycine cleavage system protein T)  3p21.31 -2.4
AA152101 Hs.12854 AGTRAP  angiotensin II receptor-associated protein  1p36.22 -2.4
AA457707 Hs.32343 ZD52F10  hypothetical gene ZD52F10  19q13.12 -2.4
AA827287 Hs.50842 IFI35  interferon-induced protein 35  17q21.31 -2.4
AA424509 Hs.227835 KIAA1049  KIAA1049 protein  16q24.3 -2.4
AA481507 Hs.159492 SACS  spastic ataxia of Charlevoix-Saguenay (sacsin)  13q12.12 -2.4
AA857851 Hs.397489  cullin 5  11q22.3 -2.4
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N40945 Hs.93837 PITPNM1  phosphatidylinositol transfer protein, membrane-associated 1  11q13.2 -2.4
AA456318 Hs.10824 LRP16  LRP16 protein  11q13.1 -2.4
AA292074 Hs.425777 UBE2L6  ubiquitin-conjugating enzyme E2L 6  11q12.1 -2.4
AA136707 Hs.41270 PLOD2  -  - -2.4
AA931161 Hs.83951 HPS1  -  - -2.4
W86653 Hs.7557 FKBP5  -  - -2.4
W68542 Hs.62515 KIAA0494  KIAA0494 gene product -2.4
N34466 Hs.109857  C9orf88  chromosome 9 open reading frame 88 -2.4
AA598631 Hs.28491 SAT  spermidine/spermine N1-acetyltransferase  Xp22.11 -2.5
AA862465 Hs.71 AZGP1  alpha-2-glycoprotein 1, zinc  7q22.1 -2.5
W84486 Hs.286161 UTRN  utrophin (homologous to dystrophin)  6q24.2 -2.5
AA046321 Hs.286161 UTRN  utrophin (homologous to dystrophin)  6q24.2 -2.5
R63647 Hs.1906 PRLR  prolactin receptor  5p13.2 -2.5
AA485401 Hs.82432 KIAA0089  KIAA0089 protein  3p24.1 -2.5
N66957 Hs.82568 CYP27A1  cytochrome P450, family 27, subfamily A, polypeptide 1  2q35 -2.5
H99813 Hs.77490 GSTT1  glutathione S-transferase theta 1  22q11.23 -2.5
AA857015 Hs.399713 EFNA1  ephrin-A1  1q22 -2.5
AA455222 Hs.179657 PLAUR  plasminogen activator, urokinase receptor  19q13.31 -2.5
H07926 Hs.356176 ACAA2
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-
Coenzyme A thiolase)  18q21.1 -2.5
R45970 Hs.412433  aryl hydrocarbon receptor interacting protein  11q13.2 -2.5
AA863086 Hs.258 ADORA3  -  - -2.5
W521821  - -2.5
AA873499  - -2.5
T51539 Hs.278657 MSTP9  macrophage stimulating, pseudogene 9 -2.5
AA775325 Hs.76240 AK1  adenylate kinase 1  9q34.11 -2.6
R59998 Hs.197873 PCDHA12  protocadherin alpha 8  5q31.3 -2.6
AA150183 Hs.154248 ALS2CR3
gamma-aminobutyric acid receptor-interacting factor 1; grif1, 
als2cr3, kiaa0549  2q33.1 -2.6
AA074535 Hs.8068 PBXIP1  pre-B-cell leukemia transcription factor interacting protein 1  1q22 -2.6
AA497001 Hs.288959 FLJ20920  hypothetical protein FLJ20920  17q21.33 -2.6
W80730 Hs.28355  MAN2C1  mannosidase, alpha, class 2C, member 1  15q24.2 -2.6
AI167261 Hs.173135 DYRK2  dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2  12q15 -2.6
N71061 Hs.334437  C10orf58  chromosome 10 open reading frame 58  10q22.3 -2.6
R53980 Hs.183171 FLJ22002  threonine synthase-like 1 (bacterial)  10p12.1 -2.6
AI091540 Hs.24684 KIAA1376  -  - -2.6
R67688 Hs.15098 THTPA  -  - -2.6
R70685 Hs.91143 JAG1  -  - -2.6
H94262 Hs.267997 EPB41L4B  erythrocyte membrane protein band 4.1 like 4B  9q31.3 -2.7
R72185 Hs.146662  SAMD6  sterile alpha motif domain containing 6  9q22.33 -2.7
AA625806 Hs.457710  NINJ1  ninjurin 1  9q22.31 -2.7
T61792 Hs.8364 PDK4  pyruvate dehydrogenase kinase, isoenzyme 4  7q21.3 -2.7
AA704713 Hs.288771 DKFZP586A0522  DKFZP586A0522 protein  12q13.12 -2.7
AA699931  - -2.7
Hs.395406  SGK  serum/glucocorticoid regulated kinase  6q23.2 -2.8
N35086 Hs.390567  FYN  FYN oncogene related to SRC, FGR, YES  6q21 -2.8
AA463206 Hs.310729  KREMEN1  kringle containing transmembrane protein 1  22q12.1 -2.8
AA167130 Hs.25132 KAB  KARP-1-binding protein  1q44 -2.8
T53404 Hs.206501 LOC57228  hypothetical protein from clone 643  12q13.13 -2.8
N51362 Hs.70337 IGSF4  immunoglobulin superfamily, member 4  11q23.3 -2.8
AA446290 Hs.79265 ST5  ribosomal protein L27a  11p15.4 -2.8
AA460833 Hs.197335 PGCP  -  - -2.8
AA469923 Hs.294133 HEBP1  -  - -2.8
AA699427 Hs.574 FBP1  fructose-1,6-bisphosphatase 1  9q22.32 -2.9
H16793 Hs.283683 C8orf4  chromosome 8 open reading frame 4  8p11.21 -2.9
AA810225 Hs.113207 GPR30  G protein-coupled receptor 30  7p22.3 -2.9
AA779888 Hs.203846 TEAD3
transcriptional enhancer factor tef-5 (tea domain family member 3) 
(tead-3) (dtef-1).  6p21.31 -2.9
R93162 Hs.107944 ALS2CR12
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 12  2q33.1 -2.9
AA457119 Hs.271411 BACE2  beta-site APP-cleaving enzyme 2  21q22.3 -2.9
N67766 Hs.7218 ACAS2L  acetyl-Coenzyme A synthetase 2 (AMP forming)-like  20p11.21 -2.9
AA857035 Hs.76289 BLVRB  biliverdin reductase B (flavin reductase (NADPH))  19q13.2 -2.9
W15319 Hs.8185 SQRDL  sulfide quinone reductase-like (yeast)  15q21.1 -2.9
N70948 Hs.288771 DKFZP586A0522  DKFZP586A0522 protein  12q13.12 -2.9
AA404286 Hs.173125 PPIF  peptidylprolyl isomerase F (cyclophilin F)  10q22.3 -2.9
AA485271 Hs.118625 HK1  hexokinase 1  10q22.1 -2.9
AA460149 Hs.35225 MBNL3  muscleblind-like 3 (Drosophila)  Xq26.2 -3
R88992 Hs.180612 PXMP3  peroxisomal membrane protein 3, 35kDa (Zellweger syndrome)  8q21.13 -3
H75599 Hs.296323 SGK  serum/glucocorticoid regulated kinase  6q23.2 -3
AA043412 Hs.110364 PPIC  peptidylprolyl isomerase C (cyclophilin C)  5q23.2 -3
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AA035450 Hs.198443 ITPR1  inositol 1,4,5-triphosphate receptor, type 1  3p26.1 -3
AA495818 Hs.57655 TSAP6  dudulin 2  2q14.2 -3
W74533 Hs.24212 LPHN2  latrophilin 2  1p31.1 -3
R36207 Hs.25092 MGC10744  hypothetical protein MGC10744  17p13.1 -3
AA679907 Hs.5337 IDH2  isocitrate dehydrogenase 2 (NADP+), mitochondrial  15q26.1 -3
AI025982 Hs.7797 TINF2  TERF1 (TRF1)-interacting nuclear factor 2  14q11.2 -3
AA953973 Hs.118087 SPG20  spastic paraplegia 20, spartin (Troyer syndrome)  13q13.3 -3
AA668726 Hs.132834 HEM1  hematopoietic protein 1  12q13.2 -3
T50041 Hs.288771 DKFZP586A0522  hypothetical protein (fragment).  12q13.12 -3
AA621202 Hs.7946 MTSG1  mitochondrial tumor suppressor 1 -3
AI091540 Hs.24684 ARRDC3  arrestin domain containing 3  5q14.3 -3.1
AI262981 Hs.173374 ESDN  discoidin, CUB and LCCL domain containing 2  3q12.1 -3.1
AA599177 Hs.304682 CST3  cystatin C (amyloid angiopathy and cerebral hemorrhage)  20p11.21 -3.1
R43271 Hs.274319  POLR3E  polymerase (RNA) III (DNA directed) polypeptide E (80kD)  16p12.2 -3.1
R26785 Hs.75799 PRSS8  protease, serine, 8 (prostasin)  16p11.2 -3.1
AA446819 Hs.75485 OAT  ornithine aminotransferase (gyrate atrophy)  10q26.13 -3.1
R32437  - -3.1
R60927 Hs.449575  CDNA FLJ46484 fis, clone THYMU3026350 -3.1
H72937 Hs.81548 DECR1  2,4-dienoyl CoA reductase 1, mitochondrial  8q21.3 -3.2
AA487346 Hs.288181 CTSH  cathepsin H  15q25.1 -3.2
H05580 Hs.173125 PPIF  peptidylprolyl isomerase F (cyclophilin F)  10q22.3 -3.2
H26426 Hs.154151 PTPRM  -  - -3.2
AA497042 Hs.265848 PDE4DIP  phosphodiesterase 4D interacting protein (myomegalin) -3.2
N80593 Hs.456985  GABBR1  gamma-aminobutyric acid (GABA) B receptor, 1  6p22.1 -3.3
R89615 Hs.284180 PCDHGC3  protocadherin gamma subfamily C, 3  5q31.3 -3.3
N40917 Hs.93836  DFNB31  deafness, autosomal recessive 31 -3.3
W60701 Hs.181244 HLA-A  major histocompatibility complex, class I, A  6p22.1 -3.4
AA171606 Hs.17144 SDR1  dehydrogenase/reductase (SDR family) member 3  1p36.21 -3.4
R44048 Hs.171889 CHPT1  choline phosphotransferase 1  12q23.2 -3.4
H02294 Hs.171889  SYCP3  synaptonemal complex protein 3  12q23.2 -3.4
W02617 Hs.38516  MGC15887  hypothetical gene supported by BC009447  1q42.2 -3.5
AA009840 Hs.171889 CHPT1  choline phosphotransferase 1  12q23.2 -3.5
N70841 Hs.167017 GABBR1  gamma-aminobutyric acid (GABA) B receptor, 1  6p22.1 -3.6
AA460282 Hs.24587 EFS  embryonal Fyn-associated substrate  14q11.2 -3.6
 T50661  - -3.6
AA056693 Hs.434057 PPAP2B  -  - -3.6
H96654 Hs.15984  WBP5  WW domain binding protein 1  Xq22.1 -3.7
W67140 Hs.6272 LYNX1  Ly-6 neurotoxin-like protein 1  8q24.3 -3.7
AA043412 Hs.110364 PPIC  peptidylprolyl isomerase C (cyclophilin C)  5q23.2 -3.7
W37778  - -3.7
W60701 Hs.181244 HLA-A  CDNA FLJ32165 fis, clone PLACE6000424 -3.7
AA425612 Hs.75317 SLC16A2
solute carrier family 16 (monocarboxylic acid transporters), 
member 2 (putative transporter)  Xq13.2 -3.8
W30935 Hs.111460 CAMK2D  calcium/calmodulin-dependent protein kinase (CaM kinase) II delta  4q26 -3.8
T61792 Hs.8364 PDK4  pyruvate dehydrogenase kinase, isoenzyme 4  7q21.3 -3.9
W86202 Hs.284243  TM4SF13  transmembrane 4 superfamily member 13  7p21.1 -3.9
AA464525 Hs.82112 IL1R1  interleukin 1 receptor, type I  2q11.2 -3.9
AA872020 Hs.75799 PRSS8  -  - -3.9
AI277138 Hs.33010 COBL  cordon-bleu homolog (mouse)  7p12.1 -4
AA156802 Hs.90291 LAMB2  laminin, beta 2 (laminin S)  3p21.31 -4
N26008 Hs.12532 C1orf21  chromosome 1 open reading frame 21  1q25.3 -4.1
AA708201 Hs.70337 IGSF4  immunoglobulin superfamily, member 4  11q23.3 -4.1
R97516 Hs.124696 DHRS6  dehydrogenase/reductase (SDR family) member 6  4q24 -4.3
N92502  - -4.3
AA071473 Hs.19368 MATN2  matrilin 2  8q22.1 -4.4
N26008 Hs.12532 C1orf21  chromosome 1 open reading frame 21  1q25.3 -4.5
W48726 Hs.294101 PBX3  pre-B-cell leukemia transcription factor 3  9q33.3 -4.6
AA100957 Hs.209100 DKFZP434C171  DKFZP434C171 protein  5q33.1 -4.6
AA487505 Hs.70337 IGSF4  immunoglobulin superfamily, member 4  11q23.3 -4.6
W48726 Hs.294101 PBX3  pre-B-cell leukemia transcription factor 3  9q33.3 -4.7
AA600214 Hs.296398 LAPTM4B  lysosomal associated protein transmembrane 4 beta  8q22.1 -4.7
AA010609 Hs.295449 PVALB  parvalbumin  22q12.3 -4.8
R66310 Hs.83920 PAM  peptidylglycine alpha-amidating monooxygenase  5q21.1 -4.9
W25368 Hs.150826 RAB25  RAB25, member RAS oncogene family  1q22 -5.1
AA400457 Hs.173802 TBC1D4  TBC1 domain family, member 4 -5.4
N90246 Hs.89839 EPHA1 EphA1  7q34 -5.8
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AA490338 Hs.177926 LOC81691   exonuclease NEF-sp  16p12.3 5.3
AA424568 Hs.355689   Transcribed sequences 4.9
AA010609 Hs.295449 PVALB   parvalbumin  22q12.3 4.7
R85090 Hs.104925 ENC1   ectodermal-neural cortex (withBTB-like domain)  5q13.3 3.8
H72122 Hs.453054  -  - 3.6
AA102130 Hs.104925 ENC1   ectodermal-neural cortex (withBTB-like domain)  5q13.3 3.5
R63647 Hs.1906 PRLR   prolactin receptor  5p13.2 3.1
N90246 Hs.89839 EPHA1   EphA1  7q34 2.7
H63532 Hs.22785 GABRE   gamma-aminobutyric acid (GABA) A receptor, epsilon  Xq28 2.5
AA505117 Hs.31438 KIAA0435   hypothetical protein FLJ11383  1q42.2 2.4
AA199586 Hs.159425 SPOCK3   testican 3  4q32.3 -2.5
AA630374 Hs.180383 DUSP6   MAP kinase phosphatase 3  12q21.33 -2.5
H93086 Hs.30237
  Transcribed sequence with weak  similarity to protein sp:P39188 
(H.sapiens) ALU1_HUMAN Alu subfamily J -2.5
R62612 Hs.287820 FN1   fibronectin 1  2q35 -3
AA598945 Hs.177536 CPXM   carboxypeptidase X (M14 family)  20p13 -3.3
AA447978 Hs.95197 ALDH1A2   retinaldehyde dehydrogenase 2  15q21.3 -3.7
AA670438 Hs.433347  UCHL1   ubiquitin c-terminal esterase l1; uchl1, park5  4p14 -4.5
Appendix 5.3 Differentially expressed genes in cluster 3 identified by CIT (p<0.05). "ResGenAccNr" is the Genbank
Accession number; "cyto" is the chromosomal location of the gene; and "fold change" is the difference in mean expression
values for each cluster versus the remaining arrays. 
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Canonical variate 1 (119 genes)
AA453579
T55704
AA404286 Hs.381072 Peptidylprolyl isomerase F (cyclophilin F) 10q22-q23
W02227 Hs.516376 WD repeat domain 33 2q14.3
AA404239 Hs.497893 Enabled homolog (Drosophila) 1q42.12
AA488087 Hs.103934 FK506 binding protein 9, 63 kDa 7p11.1
T61913 Hs.536961 Transcribed locus
AA490059 Hs.497893 Enabled homolog (Drosophila) 1q42.12
N48970
AA916728 Hs.102336 Rho GTPase activating protein 8 22q13.31
W96149 Hs.28249 KIAA1166 Xq11.2
N94404 Hs.533050 NAD(P)H dehydrogenase, quinone 2 6pter-q12
T67028 Hs.74563 Ornithine decarboxylase antizyme 2 15q22.31
N93392 Hs.491308 RAB25, member RAS oncogene family 1q22
AA460149 Hs.105134 Muscleblind-like 3 (Drosophila) Xq26.2
N50797 Hs.484950 Histone 1, H2ac 6p21.3
H20547 Hs.301394 Hypothetical protein MGC3101 16q24.3
AA600214 Hs.492314 Lysosomal associated protein transmembrane 4 beta 8q22.1
AA417994 Hs.156784 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 16q22.3
AA872020 Hs.75799 Protease, serine, 8 (prostasin) 16p11.2
AA699931
R54850 Hs.10136 Biphenyl hydrolase-like (serine hydrolase; breast epithelial mucin-associated antigen) 6p25
H16591
H18472 Hs.533655 Trypsin domain containing 1 10q22.1
AA469923
H14604 Hs.135126 Pantothenate kinase 1 10q23.31
R26785 Hs.75799 Protease, serine, 8 (prostasin) 16p11.2
R36144 Hs.220864 Chromodomain helicase DNA binding protein 2 15q26
AA010360 Hs.90756 Klotho beta like 4p14
AA479093 Hs.512235 Inositol 1,4,5-triphosphate receptor, type 2 12p11
AA455146 Hs.517034 Acetyl-Coenzyme A synthetase 2 (ADP forming) 20q11.22
N24869
AA443119 Hs.437191 Polymerase I and transcript release factor 17q21.2
N63835 Hs.507087 Signal peptide peptidase 3 12q24.31
AA293182 Hs.128548 WD repeat domain 1 4p16.1
H07072
AA446820 Hs.523332 Ornithine aminotransferase (gyrate atrophy) 10q26
N69286 Hs.497159 Chromosome 1 open reading frame 21 1q25
W37778
AA443127 Hs.213061 Homo sapiens, clone IMAGE:4860149, mRNA
AA670438 Hs.518731 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 4p14
AA890136
T54298 Hs.9613 Angiopoietin-like 4 19p13.3
AA285018 Hs.535687 CDNA: FLJ22198 fis, clone HRC01218
AA455521 Hs.443072 Hypothetical gene supported by BC055092 8q21.2
AA101348 Hs.502244 Dendritic cell protein 11p13
T50661
AA487146 Hs.530157 FP15737
R49592 Hs.154601 Transcribed locus
AA455056 Hs.519276 Mitogen-activated protein kinase-activated protein kinase 2 1q32
AA634267 Hs.464779 Niemann-Pick disease, type C1 18q11-q12
AA102107 Hs.435765 Glutamyl aminopeptidase (aminopeptidase A) 4q25
H96654 Hs.533287 WW domain binding protein 5 Xq22.2
AA147056 Hs.462392 Hypothetical protein FLJ20308 17p11.2
W88571 Hs.302740 Transient receptor potential cation channel, subfamily V, member 6 7q33-q34
AA497001 Hs.288959 Hypothetical protein FLJ20920 17q21.33
AA402915 Hs.536341 Transcribed locus
H04771 Hs.132994 DKFZP434C171 protein 5q33.1
AA599177 Hs.304682 Cystatin C (amyloid angiopathy and cerebral hemorrhage) 20p11.21
AA007402 Hs.525549 BTB (POZ) domain containing 7 14q32.13
N34974 Hs.433512 ARP3 actin-related protein 3 homolog (yeast) 2q14.1
T59948 Hs.106015 Development and differentiation enhancing factor 1 8q24.1-q24.2
AA857015 Hs.516664 Ephrin-A1 1q21-q22
H05099 Hs.461647 KIAA0182 protein 16q24.1
N65985 Hs.124696 Dehydrogenase/reductase (SDR family) member 6 4q24
AA410708 Hs.431045 Sperm antigen HCMOGT-1 17p11.2
H48472 Hs.508829 Full length insert cDNA YU10E03
T52320 Hs.413416 Jumonji domain containing 1C 10q21.3
AA417912
AA398234 Hs.221497 PRO0149 protein 16p13.2
H59259 Hs.487540 Replication protein A3, 14kDa 7p22
Appendix 5.4 Gene list for the three canonical variates identified by Profile analysis of Gene-Rave normalised data
A20
GenBank ID Unigene-ID Gene Name Cytoband
AA281945 Hs.82548 MAP-kinase activating death domain 11p11.2
H29322 Hs.434875 Calcium/calmodulin-dependent protein kinase I 3p25.3
AA456636 Hs.10842 RAN, member RAS oncogene family 12q24.3
AA156802 Hs.439726 Laminin, beta 2 (laminin S) 3p21
AA704230 Hs.105633 WINS1 protein with Drosophila Lines (Lin) homologous domain 15q26.3
H05115 Hs.381072 Peptidylprolyl isomerase F (cyclophilin F) 10q22-q23
T51849 Hs.437008 EPH receptor B4 7q22
AA447551 Hs.535224 Transcribed locus
R63543 Hs.448588 Nerve growth factor receptor (TNFRSF16) associated protein 1 Xq22.2
R33103 Hs.440414 Spastic paraplegia 20, spartin (Troyer syndrome) 13q13.3
AA459935 Hs.501991 Male sterility domain containing 2 11p15.2
N50556 Hs.159201 Thymosin, beta 4, Y-linked Yq11.221
N73083
AA490938 Hs.533050 NAD(P)H dehydrogenase, quinone 2 6pter-q12
AA679907 Hs.513141 Isocitrate dehydrogenase 2 (NADP+), mitochondrial 15q26.1
R42685 Hs.367992 Inositol(myo)-1(or 4)-monophosphatase 2 18p11.2
W81524 Hs.468442 Calmodulin 2 (phosphorylase kinase, delta) 2p21
R95684 Hs.406461 Asparagine-linked glycosylation 1 homolog (yeast, beta-1,4-mannosyltransferase) 16p13.3
AA707889 Hs.502244 Dendritic cell protein 11p13
AA001444 Hs.526754 Meis1, myeloid ecotropic viral integration site 1 homolog (mouse) 2p14-p13
T62040 Hs.74047 Electron-transfer-flavoprotein, beta polypeptide 19q13.3
H17973
T57765
H96734 Hs.496191 TERF1 (TRF1)-interacting nuclear factor 2 14q11.2
AA485453 Hs.213061 Homo sapiens, clone IMAGE:4860149, mRNA
AA464526 Hs.516249 Interleukin 1 receptor, type I 2q12
N21309 Hs.203691 Discoidin, CUB and LCCL domain containing 2 3q12.1
AA146963 Hs.23585 KIAA1078 protein 1q32.1
AA634103 Hs.522584 Thymosin, beta 4, X-linked Xq21.3-q22
AA598507 Hs.476218 Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) 3p21.1
N26008 Hs.497159 Chromosome 1 open reading frame 21 1q25
R59165 Hs.497684 Protein phosphatase 2, regulatory subunit B (B56), alpha isoform 1q32.2-q32.3
R85257
R36109 Hs.513933 Hypothetical protein MGC10744 17p13.1
AA043412 Hs.110364 Peptidylprolyl isomerase C (cyclophilin C) 5q23.2
AA486417 Hs.477789 ATPase, Na+/K+ transporting, beta 3 polypeptide 3q23
AA701655
N40939 Hs.199579 Mitochondrial ribosomal protein L42 12q22
R93543
AA464707 Hs.334831 Fibroblast growth factor receptor substrate 2 12q15
H70775 Hs.458395 Histone 1, H2bc 6p21.3
H59916 Hs.375108 CD24 antigen (small cell lung carcinoma cluster 4 antigen) 6q21
R39221 Hs.25209 Mitogen-activated protein kinase 10 4q22.1-q23
AA132086 Hs.109752 Chromosome 6 open reading frame 108 6p21.1
AA676404 Hs.110364 Peptidylprolyl isomerase C (cyclophilin C) 5q23.2
AA291163 Hs.28988 Glutaredoxin (thioltransferase) 5q14
R49124 Hs.444612 Solute carrier family 2 (facilitated glucose transporter), member 9 4p16-p15.3
R72185 Hs.406890 Sterile alpha motif domain containing 6 9q22.33
Canonical variate 2 (49 genes)
AA598668 Hs.380138 Chimerin (chimaerin) 1 2q31-q32.1
AA424564 Hs.374509 Similar to ataxin-1 ubiquitin-like interacting protein 3q24
R70462
AA427401 Hs.17118 Hypothetical protein FLJ11730 1p35.3-p33
H23979 Hs.79015 CD200 antigen 3q12-q13
AA599178 Hs.523463 Hypothetical protein MGC10850 11p15
AA058323 Hs.458414 Interferon induced transmembrane protein 1 (9-27) 11p15.5
AA487505 Hs.370510 Immunoglobulin superfamily, member 4 11q23.2
T77729 Hs.536442 Transcribed locus
R97066 Hs.73828 T-cell acute lymphocytic leukemia 1 1p32
N24910 Hs.187667 Cystinosis, nephropathic 17p13
AA136133 Hs.408355 Low density lipoprotein receptor-related protein 11 6q25.1
H11063 Hs.529023 Zinc finger protein 532 18q21.32
N35067 Hs.233552 Cell division cycle 2-like 5 (cholinesterase-related cell division controller) 7p13
N29465 Hs.401954 ARG99 protein 12p11.22
AA043133 Hs.75231 Solute carrier family 16 (monocarboxylic acid transporters), member 1 1p12
H06284 Hs.13480 Clone 24875 mRNA sequence
AA430625 Hs.335034 Dihydropyrimidine dehydrogenase 1p22
W93891 Hs.25723 Mouse Mammary Turmor Virus Receptor homolog 1 11q23
AA411618 Hs.98077 Transcribed locus
H77595 Hs.445775 Protein tyrosine phosphatase, non-receptor type 9 15q23
AA680244 Hs.388664 Ribosomal protein L11 1p36.1-p35
N39240 Hs.200285 Transcription factor 4 18q21.1
H10713
W15241 Hs.443874 Solute carrier family 6 (neurotransmitter transporter, GABA), member 1 3p25-p24
A21
GenBank ID Unigene-ID Gene Name Cytoband
AA152178 Hs.502116 Neuron navigator 2 11p15.1
AA416785 Hs.461954 Serine racemase 17p13
AA443284 Hs.493585 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated9p22
H22136 Hs.24258 Guanylate cyclase 1, soluble, alpha 3 4q31.3-q33
AA147032 Hs.518618 Corin, serine protease 4p13-p12
AA022645 Hs.523173 Ectonucleoside triphosphate diphosphohydrolase 1 10q24
W72079 Hs.379253 Full length insert cDNA clone ZD69D05
N63505 Hs.443874 Solute carrier family 6 (neurotransmitter transporter, GABA), member 1 3p25-p24
R00047
AA464743 Hs.529580 Transcribed locus
H95792 Hs.81934 Acyl-Coenzyme A dehydrogenase, short/branched chain 10q25-q26
H58645 Hs.165859 Anthrax toxin receptor 1 2p13.1
AA026418 Hs.524438 Keratin 6B 12q12-q13
AA630374 Hs.298654 Dual specificity phosphatase 6 12q22-q23
AA279429 Hs.195080 Endothelin converting enzyme 1 1p36.1
N70015 Hs.283315 MRNA sequence.
T49657
H09086 Hs.288178 Sjogren syndrome antigen A2 (60kDa, ribonucleoprotein autoantigen SS-A/Ro) 1q31
R63515 Hs.502458 BRAF35/HDAC2 complex (80 kDa) 11p11.2
N51859 Hs.134830 Collagen, type VIII, alpha 1 3q12.3
H51318 Hs.516034 Chromosome 2 open reading frame 18 2p23.3
N79548 Hs.427236 I-mfa domain-containing protein 7q31.1-q31.2
H95065 Hs.288761 Hypothetical protein FLJ21749 11q13.2
AA708201 Hs.370510 Immunoglobulin superfamily, member 4 11q23.2
Canonical variate 3 (48 genes)
N35250
H69022 Hs.484363 Ring finger protein 130 5q35.3
AA706311
T98244 Hs.466729 Hypothetical protein LOC255104 1p36.13
AA035450 Hs.374613 Inositol 1,4,5-triphosphate receptor, type 1 3p26-p25
N48294 Hs.46850 MGC4170 protein 12q23.3
AA608556 Hs.443258 Sterol regulatory element binding transcription factor 2 22q13
N59148 Hs.516182 KIAA1387 protein 2p16.1
W52353
[AA487457
AA443099 Hs.183435 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 7kDa 14q32.12
AA458994 Hs.91728 Exosome component 9 4q27
R52679 Hs.106432 Hypothetical protein DKFZp761B107 4p15.2
T90375 Hs.369670 Kinesin family member 3B 20q11.21
R15832 Hs.435714 P21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 11q13-q14
AA402889 Hs.535555 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 19p13.3
N47003 Hs.195058 KIAA0828 protein 7q32.3
AA504455 Hs.211800 Component of oligomeric golgi complex 2 1q42.2
H56655 Hs.132629 KIAA1727 protein 4q31.3
AA431406
AA457544 Hs.203691 Discoidin, CUB and LCCL domain containing 2 3q12.1
N22978 Hs.4973 Chromosome 2 open reading frame 24 2q35
H41165 Hs.438429 Ribosomal protein S19 19q13.2
N35025 Hs.515696 Similar to Zinc finger protein 93 (Zinc finger protein HTF34) 19p12
W90128 Hs.437638 X-box binding protein 1 22q12.1
H10988 Hs.471381 Tensin 2q35-q36
R07268
AA725564 Hs.2420 Superoxide dismutase 3, extracellular 4p16.3-q21
AA620357 Hs.5009 Transcription termination factor-like protein 12q24.1
AA018457 Hs.420036 Glutamate decarboxylase 1 (brain, 67kDa) 2q31
N54296
R97798
R56793 Hs.106576 Alanine-glyoxylate aminotransferase 2-like 1 4q25
R69244
AA427715 Hs.487933 5'-nucleotidase, cytosolic III 7p14.3
AA682855 Hs.166204 PHD finger protein 1 6p21.3
AA486112 Hs.484188 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e 5q35.1
N29850 Hs.44098 Transcribed locus
AA505117 Hs.520606 Hypothetical protein FLJ11383 1q42.2
AA039595 Hs.153408 TEA domain family member 1 (SV40 transcriptional enhancer factor) 11p15.4
W93715
AA456323 Hs.271667 EH domain binding protein 1 2p15
AA495904 Hs.116471 Cadherin 11, type 2, OB-cadherin (osteoblast) 16q22.1
AA464139 Hs.250616 Isocitrate dehydrogenase 3 (NAD+) alpha 15q25.1-q25.2
R19310 Hs.132439 Reelin 7q22
T73794 Hs.508522 Similar to C219-reactive peptide 1p36.33
AA227982 Hs.493516 PC4 and SFRS1 interacting protein 1 9p22.3
R61518
A22
APPENDIX 6.1 Means* of Ratios for Realtime Results
ID qPCR ID HRPT2/18s CASR/18s MOX2/18s RALDH2/18s UCHL1/18s VCAM1/18s class
9A 1 0.504913152 2.995385765 0.470820549 0.027894518 0.004015725 0.054650414 Adenoma
14A 2 0.952934777 2.957635329 0.447129087 0.040804164 0.027352952 0.019368763 Adenoma
82A 3 0.811016537 3.419494221 4.638119676 1.197298597 0.038407387 0.011089078 Adenoma
100A 4 0.892820811 2.338560911 0.205945961 0.004581066 0.01500743 0.009986615 Adenoma
89A 5 0.859788227 4.319836237 7.626602098 0.040920017 0.067421672 0.008197167 Adenoma
99A 6 0.576011724 1.404462328 0.069402312 0.001758028 0.033677778 0.273381113 Adenoma
88A 7 0.668323781 1.724924695 0.075325466 0.023885873 0.006299215 0.034341028 Adenoma
93A 8 0.988840214 1.325117768 0.650619338 0.010311788 0.083969641 0.017729052 Adenoma
101A 9 0.740296879 2.330901158 0.514330464 0.216685904 0.08269908 0.011523725 Adenoma
78A 10 0.4195364 1.215115714 0.107348938 0.010992514 0.012345877 0.0125891 Adenoma
95A 11 0.680827689 1.351547693 1.292109536 1.663757441 0.00566977 0.153244615 Hyperplasia
1293G 12 0.866684029 2.120130563 2.864808843 0.050994558 0.026012896 0.100164934 Hyperplasia
2082G 13 0.521570881 1.181343481 1.061724721 0.604008714 0.024316382 0.087531217 Hyperplasia
1749G 14 1.073356454 1.944924564 0.864359898 1.179562708 0.156553135 0.092563146 Hyperplasia
866G 15 0.685130976 1.15101749 1.034321257 0.177007546 0.019416238 0.038846909 Hyperplasia
2358G 16 0.731999483 2.187344561 6.291362674 0.088543807 0.351420419 0.038096528 Hyperplasia
1363G 17 0.481349594 1.617328187 1.083258866 0.314808593 0.055224458 0.038294886 Hyperplasia
2636G 18 0.604986044 1.914006122 1.774471584 0.66787436 0.142571341 0.064476846 Hyperplasia
1417G 19 0.493001715 1.62711625 1.434763381 0.705690571 0.050294358 0.024113603 Hyperplasia
2356G 20 0.478006858 2.000437142 0.24098996 0.479418695 0.007072806 0.165129771 Hyperplasia
Normal 21 1.298442615 5.406056283 1.002555258 0.415602694 0.019506638 0.03846545 Normal
UHR 22 0.871126592 0.208394209 0.495561411 0.097529421 0.014750385 UHR
54A 23 1.524947607 1.263761113 0.299917243 1.454936399 3.363240527 3.946668277 HRPT2/carc
4A 24 0.780527062 0.499664768 0.505876058 0.279771198 1.032774892 0.876372192 HRPT2/carc
78G 26 0.628096493 0.18977864 0.491518381 0.02720413 1.735113345 0.174467605 HRPT2/carc
1765G 27 0.881232487 0.632689308 0.710919729 0.11847489 1.072314035 1.88166619 HRPT2/carc
1613G 28 0.780147792 0.5463078 0.159117544 0.377720299 2.431061189 1.021493664 HRPT2/carc
2077G 29 0.51996224 0.164588621 0.104933173 0.01079139 1.864155452 0.025334771 HRPT2/carc
2119G 30 0.714299311 0.290663511 0.055991505 0.007416585 0.755549388 1.445119312 HRPT2/carc
ID qPCR ID HRPT2/SSR3 CASR/SSR3 MOX2/SSR3 RALDH2/SSR3UCHL1/SSR3 VCAM1/SSR3 class
9A 1 0.331402775 1.966039406 0.309025891 0.018308734 0.002635745 0.035870127 Adenoma
14A 2 0.85785244 2.662527116 0.402515248 0.036732789 0.024623717 0.017436178 Adenoma
82A 3 0.468616181 1.975829406 2.679967461 0.691815112 0.022192301 0.006407417 Adenoma
100A 4 0.956875467 2.506338939 0.220721376 0.004909731 0.016084126 0.010703096 Adenoma
89A 5 0.501842887 2.521410528 4.451510143 0.023884276 0.039352814 0.004784538 Adenoma
99A 6 0.521509526 1.271572178 0.062835469 0.001591684 0.030491189 0.247513807 Adenoma
88A 7 1.078575416 2.783772508 0.121564125 0.038548254 0.010165998 0.055421324 Adenoma
93A 8 0.718588963 0.962961447 0.47280427 0.007493563 0.061020635 0.01288368 Adenoma
101A 9 0.456340806 1.436836143 0.31704845 0.133571575 0.05097815 0.007103564 Adenoma
78A 10 0.348110158 1.008241771 0.089072738 0.009121034 0.010243987 0.010445801 Adenoma
95A 11 0.734457934 1.458011979 1.393891752 1.794815154 0.00611639 0.165316019 Hyperplasia
1293G 12 0.588630119 1.439939661 1.945706525 0.034634229 0.017667308 0.068029518 Hyperplasia
2082G 13 0.440084167 0.996778349 0.895848017 0.50964247 0.020517355 0.07385593 Hyperplasia
1749G 14 0.766261168 1.388467142 0.617060085 0.842081021 0.111762116 0.06608014 Hyperplasia
866G 15 0.890678026 1.496335768 1.344629345 0.230111814 0.025241329 0.050501421 Hyperplasia
2358G 16 0.616800795 1.843110405 5.301257156 0.074609192 0.296115501 0.032101072 Hyperplasia
1363G 17 0.56627501 1.902676448 1.27438027 0.370350867 0.064967813 0.045051325 Hyperplasia
2636G 18 0.649132567 2.053673337 1.903956804 0.716609916 0.152974935 0.069181795 Hyperplasia
1417G 19 0.522911671 1.72583188 1.521809142 0.748504162 0.05334567 0.025576553 Hyperplasia
2356G 20 0.403504276 1.688647197 0.203429046 0.404696063 0.005970432 0.139392495 Hyperplasia
Normal 21 0.977430026 4.06952273 0.754694586 0.312853681 0.014684032 0.028955678 Normal
UHR 22 0.359333651 0.085961159 0.20441563 0.040230207 0.006084431 UHR
54A 23 0.542979643 0.449980415 0.106789871 0.51805114 1.197530414 1.405268299 HRPT2/carc
4A 24 0.590711719 0.378151955 0.382852729 0.211734011 0.781615734 0.663248399 HRPT2/carc
78G 26 0.571516027 0.172682916 0.447241205 0.024753516 1.578810098 0.158751137 HRPT2/carc
1765G 27 0.575414757 0.413124538 0.464206335 0.077360062 0.700184491 1.228663843 HRPT2/carc
1613G 28 1.265004349 0.885834389 0.258008018 0.6124709 3.941949213 1.656345042 HRPT2/carc
2077G 29 0.956119473 0.302649642 0.192953723 0.019843475 3.427855314 0.046586205 HRPT2/carc
2119G 30 0.793631652 0.32294552 0.062210099 0.008240294 0.839463093 1.605618834 HRPT2/carc
Legend: *Means of 3 runs, with each run performed duplicate. A23
APPENDIX 6.2 Group summaries of quantitative real-time PCR results
Results relative to 18s
Gene Groups N Mean Std. Deviation Std. Error Minimum Maximum
Lower Bound Upper Bound
HRPT2_18sAdenoma 10 0.759363 0.175643719 0.055543421 0.633715015 0.8850109 0.504913152 1.01222201
Adenoma (8)* 8 0.737236 0.190995791 0.067527209 0.577559469 0.8969124 0.504913152 1.01222201
Hyperplasia 10 0.643569 0.186241619 0.058894771 0.510339842 0.7767983 0.411798423 1.01065615
Normal 1 1.241924 . . . . 1.241924333 1.24192433
UHR 1 0.776971 . . . . 0.776970836 0.77697084
HRPT2/carc 7 0.83631 0.262922439 0.099375341 0.593146984 1.0794724 0.633326115 1.38991288
CASR_18s Adenoma 10 2.466981 0.937557135 0.296481598 1.796292748 3.1376687 1.325117769 4.27112904
Adenoma (8)* 8 2.122398 0.632341369 0.223566435 1.593747377 2.6510486 1.325117769 2.95763533
Hyperplasia 10 1.716657 0.312615633 0.098857743 1.493025069 1.9402886 1.273458378 2.17597106
Normal 1 5.170743 . . . . 5.170742829 5.17074283
UHR 0 . . . . . . .
HRPT2/carc 7 0.505482 0.33784796 0.127694526 0.193025164 0.8179397 0.184639083 1.15185455
MOX2_18s Adenoma 10 1.450753 2.464389238 0.779308303 -0.31216444 3.2136713 0.075049443 7.28026308
Adenoma (8)* 8 0.323644 0.224701642 0.079444027 0.135788652 0.5114992 0.075049443 0.65934252
Hyperplasia 10 1.807945 1.717767084 0.543205648 0.579128109 3.0367612 0.20761059 6.27623528
Normal 1 0.958916 . . . . 0.958916285 0.95891629
UHR 1 0.18587 . . . . 0.185869912 0.18586991
HRPT2/carc 7 0.334323 0.242659171 0.091716546 0.10990069 0.5587453 0.065277961 0.71091973
RALDH2_1 Adenoma 10 0.159584 0.370585436 0.117189405 -0.10551692 0.4246848 0.001939357 1.1972986
Adenoma (8)* 8 0.044184 0.075118451 0.026558383 -0.01861647 0.1069847 0.001939357 0.2274735
Hyperplasia 10 0.602404 0.529684651 0.167500994 0.223490922 0.9813181 0.054574196 1.78958766
Normal 1 0.414658 . . . . 0.414657544 0.41465754
UHR 1 0.416694 . . . . 0.416694309 0.41669431
HRPT2/carc 7 0.305207 0.470415807 0.177800463 -0.12985503 0.7402691 0.007749712 1.32610119
VCAM1_18 Adenoma 10 0.045184 0.083766529 0.026489302 -0.01473927 0.1051067 0.007556015 0.28100157
Adenoma (8)* 8 0.054149 0.092528132 0.032713635 -0.02320647 0.1315044 0.01010187 0.28100157
Hyperplasia 10 0.073217 0.03968817 0.012550501 0.044825784 0.1016082 0.022753694 0.13997999
Normal 1 0.035494 . . . . 0.035494496 0.0354945
UHR 1 0.012557 . . . . 0.012557497 0.0125575
HRPT2/carc 7 1.268843 1.188279581 0.449127466 0.169867841 2.3678185 0.029692087 3.54036182
UCHL1_18sAdenoma 10 0.037279 0.028836143 0.009118789 0.016651146 0.0579074 0.004208658 0.08366005
Adenoma (8)* 8 0.032939 0.029768958 0.010524916 0.008051809 0.0578268 0.004208658 0.08366005
Hyperplasia 10 0.084866 0.107950465 0.034136934 0.007643068 0.1620893 0.005674971 0.34776509
Normal 1 0.019282 . . . . 0.019281876 0.01928188
UHR 1 0.089552 . . . . 0.089552136 0.08955214
HRPT2/carc 7 1.820912 0.844271157 0.319104503 1.040091644 2.6017328 0.922162 3.06542421
Legend: * Adenoma (8) consists of the adenoma group, but with the outliers q3(82A) and q5(89A) removed.
95% Confidence Interval 
for Mean
A24 
APPENDIX 6.3 Group summaries of quantitative real-time PCR results
Results relative to SSR3
Gene Groups N Mean Std. Deviation Std. Error Minimum Maximum
Lower Bound Upper Bound
HRPT2_sAdenoma 10 0.620436 0.259597388 0.082091902 0.434730936 0.8061405 0.331402775 1.02352538
Adenoma (8)* 8 0.660646 0.278177955 0.098350759 0.428083739 0.8932089 0.331402775 1.02352538
Hyperplasia 10 0.595077 0.161168034 0.050965807 0.479784638 0.71037 0.411602769 0.92926097
Normal 1 0.883044 . . . . 0.883044326 0.88304433
UHR 1 0.34854 . . . . 0.34853993 0.34853993
HRPT2/carc 7 0.824509 0.232654482 0.087935129 0.609339903 1.0396789 0.553200412 1.23031073
CASR_ssAdenoma 10 1.891884 0.631326928 0.199643104 1.44026042 2.3435086 1.159393383 2.72314315
Adenoma (8)* 8 1.844604 0.700225903 0.247567242 1.259200519 2.4300075 1.159393383 2.72314315
Hyperplasia 10 1.564245 0.2635424 0.083339424 1.375718487 1.7527722 1.04851007 1.98987447
Normal 1 3.676549 . . . . 3.676548561 3.67654856
UHR 0 . . . . . . .
HRPT2/carc 7 0.461127 0.223702927 0.084551759 0.254236562 0.668018 0.172310097 0.86153977
MOX2_ssAdenoma 10 0.852649 1.291099778 0.408281598 -0.0709483 1.776246 0.055713626 3.8556772
Adenoma (8)* 8 0.261713 0.176018635 0.062231985 0.11455794 0.4088685 0.055713626 0.57688258
Hyperplasia 10 1.546823 1.230950305 0.389260665 0.666253723 2.4273913 0.207511949 4.7250504
Normal 1 0.681817 . . . . 0.681817372 0.68181737
UHR 1 0.083379 . . . . 0.083379045 0.08337905
HRPT2/carc 7 0.306509 0.188340145 0.071185884 0.132323263 0.4806944 0.075282197 0.5355426
RALDH2_Adenoma 10 0.09471 0.204421179 0.064643653 -0.05152432 0.2409439 0.001439699 0.66526203
Adenoma (8)* 8 0.032246 0.045245241 0.015996608 -0.00558002 0.0700719 0.001439699 0.13930042
Hyperplasia 10 0.571269 0.529229632 0.167357104 0.192681248 0.9498574 0.035514459 1.87550232
Normal 1 0.294834 . . . . 0.294833576 0.29483358
UHR 1 0.186924 . . . . 0.18692414 0.18692414
HRPT2/carc 7 0.234643 0.269425771 0.10183337 -0.01453404 0.4838205 0.008937401 0.64023152
VCAM1_sAdenoma 10 0.036058 0.062271989 0.019692132 -0.00848824 0.0806052 0.004001717 0.20860403
Adenoma (8)* 8 0.043803 0.068137424 0.024090217 -0.01316164 0.100767 0.006186192 0.20860403
Hyperplasia 10 0.067167 0.040148581 0.012696096 0.038446441 0.0958876 0.022280038 0.14670016
Normal 1 0.025238 . . . . 0.025237619 0.02523762
UHR 1 0.005633 . . . . 0.005633145 0.00563315
HRPT2/carc 7 1.048155 0.688785381 0.260336404 0.411134664 1.6851751 0.046859374 1.70925964
UCHL1_sAdenoma 10 0.052247 0.07791761 0.024639712 -0.00349145 0.1079864 0.002762378 0.26787207
Adenoma (8)* 8 0.060233 0.086239961 0.030490431 -0.01186546 0.1323314 0.002762378 0.26787207
Hyperplasia 10 0.072113 0.082388848 0.026053641 0.013175203 0.1310501 0.005947416 0.26181421
Normal 1 0.005708 . . . . 0.005708447 0.00570845
UHR 1 0.01371 . . . . 0.013709975 0.01370998
HRPT2/carc 7 1.802974 1.473485944 0.556925338 0.440227265 3.1657217 0.040172029 4.02618416
Legend: * Adenoma (8) consists of the adenoma group, but with the outliers q3(82A) and q5(89A) removed.
95% Confidence Interval 
for Mean
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